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ABSTRACT
Usher syndrome is an autosomal recessive disease, displaying pathology of 
the auditory and visual systems. The three clinical phenotypes are linked to 
eleven different loci, and differ in the severity and age of onset of 
sensorineural hearing loss, vestibular areflexia and Retinitis Pigmentosa. 
The expression pattern of U s h lc  which encodes a PDZ domain containing 
protein (Harmonin) has been established in the murine ear. This study 
examined the localisation of the protein in the murine eye, detecting U sh lc  
m RNA from E12.5 and localising the protein to the newborn photoreceptors 
from P2.
In the developed retina, harmonin was localised to the photoreceptor outer 
segments. Further immunoreactivity was noted in unfixed tissue, showing 
harmonin colocalising with the USH1B and 1D proteins to the photoreceptor 
inner segments and outer plexiform layer. The USH1B and USH1D proteins 
are known to interact with and be involved in the correct localisation of 
harmonin in the ear. Yet in the eye, harmonin localisation in fixed tissue was 
maintained in the outer segments in the absence of either USH1 protein.
To further examine the protein interactions of harmonin, a Yeast Two-Hybrid 
study was undertaken using a bovine retinal library. Six possible interacting 
proteins were identified and confirmed by yeast mating. Several of these 
positive interactors, although interacting with the whole harmonin protein, did 
not interact with any of its PDZ binding domains. One such protein was 
phosducin, a small acidic cytosolic protein. Its potential as a binding partner
for harmonin in the retina was confirmed by a pull down assay and 
immunolocalisation studies. Phosducin is known to interact with proteins 
associated with glutamate receptors at the photoreceptor ribbon synapses. 
Its interaction with harmonin would suggest a role for harmonin in the outer 
plexiform layer and more specifically at the ribbon synapses of the retina.
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DNA-BD DNA binding domain
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IVT In vitro translation
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PCR Polymerase Chain Reaction
PDE Phosphodiesterase
PDZ Protein-protein interaction domain named after the first three
proteins it was discovered in PSD-95/Dlg/ZO-1  
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PFA Paraformaldehyde
PM SF Phenylnisthyl-sulfonyl fluoride
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p-gal assay p -galactosidase assay
1 INTRODUCTION
1.1 Hearing loss, vision loss and combined sensory loss: 
Epidemiology
Hearing impairment can develop at any age with varying degrees of severity. 
Age-related hearing loss affects -25%  of people aged 65 to 75 and 70%- 
80% of those aged over 75 (http://www.nlm.nih.gov/medlineplus/). Hearing 
loss in children is rarer and has many causes: some are environmental (i.e. 
acoustic trauma, ototoxic drugs, certain infections in the mother during 
pregnancy, or infections in the newborn baby), and some are genetic. Of the 
disorders attributable to genetic causes, -30%  are syndromic, many of which 
have been documented and the genes in question identified. The remaining 
70% are classed as nonsyndromic with a variety of inheritance patterns 
involved -  autosomal recessive (DFNB loci), autosomal dominant (DFNA 
loci), X-linked and mitochondrial (reviewed in Resendes, B L et al, 2001). In 
each case, the hearing impairment is classified according to the degree of 
severity and by the site of the defect. Conductive hearing loss refers to 
defects of the external and/or middle ear, whilst sensorineural hearing loss 
commonly refers to the inner ear but also stretches to the cortical auditory 
centres of the brain. Approximately 840 babies are born each year in the UK 
with significant deafness (www.RNID.org.uk). It is estimated that 50% 
percent of deaf children in the USA have an hereditary form of hearing loss 
and of these, one third have a syndrome associated with their hearing loss 
(http://www.pediatric-ent.com/learning/problems/hearing_loss.htm).
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Hereditary retinal diseases are also characterized by the severity of vision 
loss. These diseases are further characterized by the age of onset of the 
disease, the topographic pattern of visual loss, rod verses cone involvement, 
ophthalmoscopic findings, and family history. In the developed world, the 
most common retinal diseases are diabetic retinopathy, glaucoma, and age- 
related macular degeneration (AMD), which together affect several percent of 
the population and have both genetic and non-genetic components. 
Monogenic Mendelian retinal diseases, for example Retinitis Pigmentosa 
(RP), affect -1 :  2000 people (Rattner, A et al, 1999). RP, like deafness can 
be inherited both as syndromes and as nonsyndromic RP, in an autosomal 
recessive mode (84% ), an autosomal dominant mode (10% ), or as an X- 
linked recessive disease (6% ) and in a few rare cases it is inherited in a 
digenic mode. The overall frequency of RP in the white US population was 
estimated at about 1 in 3,700, with no evidence for ethnic heterogeneity 
(Boughman, J A et al, 1980).
Currently in the UK, it is estimated that there are 23000 individuals affected 
with both types of defects (www.RNID.org.uk), either as isolated retina- 
cochlea disorders or associated with other organs in a multisystem disorder 
e.g. Bardet-Biedl syndrome.
1.1.1 Usher syndrome
Usher syndrome is an example of an isolated retina-cochlea disorder, named 
after the British ophthalmologist, Charles Usher and with an estimated 
prevalence of 2-6.2 per 100,000 (Keats, B J et al, 1999). This is an 
autosomal recessive disease, defined by bilateral sensorineural deafness
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combined with a progressive loss of vision due to RP and sometimes 
associated with vestibular dysfunction (Usher CH., 1914). It is estimated to 
account for 50% of deaf-blind individuals (Vernon, M, 1969), 18% of Retinitis 
Pigmentosa sufferers and 3-6% of children born with profound hearing loss 
(Boughman, J A et al, 1983).
Usher syndrome is both clinically and genetically heterogeneous, with three 
recognised clinical types (type 1-3) linked to eleven different genes. It is 
estimated that in the United States and Northern Europe the type 1 
phenotype (definitions of type 1-3 are found in section 1.3.1) accounts for 33- 
44% of all Usher syndrome patients and type 2 accounts for 56-67%. Type 
3, whilst accounting for only 2% of all Usher syndrome cases, accounts for 
40% of all Finnish Usher syndrome cases due to the presence of a founder 
mutation in the population (Plantinga, R F et al, 2005 and references therein). 
It is also thought to account for 20% of the Usher cases seen in Birmingham 
in the UK (Hope, C I et al, 1997) and for a large percentage of New York 
Ashkenazi Jewish subjects with Usher syndrome, who displayed a wide 
range of phenotypic severities, all of which were homozygous for a particular 
mutation (Ness, S L et al, 2003).
This study examines the role of USH1C  and its encoded protein in Usher 
syndrome.
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1.2 The vertebrate ear and eye
An understanding of normal ear and eye anatomy is necessary in order to 
discuss the clinical phenotype of Usher syndrome further.
1.2.1 The vertebrate ear
1.2.1.1 Anatomy of the ear
The human ear is made up of three compartments: the external ear, middle 
ear (Figure 1.1 A) and inner ear (Figure 1.1B). Genetic defects may affect 
any part of the system, but most genetic hearing impairment in the 
population affects the inner ear. The inner ear is a complex membranous 
labyrinth in a cavity of the temporal bone consisting of the cochlea which 
contains the auditory receptors (the hair cells), and the vestibular part 
containing the balance and gravity receptors. The cochlea consists of a bony 
tube spiralling around a central core which is divided along its length by the 
basilar membrane. Two types of hair cells run along the length of the basilar 
membrane: a single row of 3,500 inner hair cells (IHC) that act as the primary 
receptor cells, and a triple row of 15,000 outer hair cells (OHC) acting as 
motor cells to amplify the auditory stimulus, all in contact with the tectorial 
membrane (Figure 1.1B). Together, the hair cells and their supporting cells 
on the basilar membrane are called the organ of Corti. On the apical surface 
of each hair cell are 30-300 stereocilia, stiff actin-filled microvilli that act as 
the mechanoreceptive structure of the hair cell. The stereocilia are arranged 
into staircase arrays, where each stereociliar tip is connected to the next- 
taller stereocilium by a tip link, thus forming a characteristic “V” shape (Figure
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1.2A and Figure 1.22 wildtype) (Petit, C et al, 2001; Berne R.M. et al, 98; 
Martini, Alessandro et al, 96).
Figure 1.1 The structure of the vertebrate ear
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The vertebrate ear is divided into three sections: the external, middle and inner ear. The 
main structural features and functional elements of the external and middle ear are shown in 
(A) (http://www.neurophys.wisc.edu/www/aud/johc.html). The arrangement of the Organ of 
Corti of the inner ear is shown in (B) (http://www.vestibular.org/gallery.html), highlighting the 
two different kinds of auditory hair cells, topped by the tectorial membrane.
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1.2.1.2 Auditory transduction
The detection of sound results from channelling of the sound wave through the 
external and middle ear to the hair cells of the inner ear. The action of the sound 
wave on the ossicles and tympanic membrane of the middle ear causes 
displacement of the perilymph within the cochlea. This in turn results in wave 
movements of the basilar membrane which supports the organ of Corti in the 
inner ear. This motion leads to deflection of the hair cell stereocilia against the 
tectorial membrane (Petit, C et al, 2001; Berne R.M. et al, 98; Martini, 
Alessandro et al, 96).
There is a large potential difference across the tops of the hair cells, between 
the positive endolymph into which the stereocilia project (a fluid high in K+ ions 
and low in Na+ ions) and the negative potential maintained inside the hair cells. 
This large potential gradient, generated by ion pumps in the lateral wall of the 
cochlear duct, is essential for normal hair cell function. A  few nanometers 
deflection of a stereocilia bundle, through an angle that can be less than 1°, 
opens mechanically-gated ion channels within the hair cell, allowing an influx of 
potassium ions from the endolymph (Figure 1.2B). This causes depolarization 
of the hair cell which in turn opens voltage-sensitive C a2+ channels that allow 
entry of C a2+into the cell. The organ of Corti is penetrated by afferent nerve 
fibres, with a synapse at each hair cell base that links the hair cells to the 
bipolar neurones at the centre of the cochlea (Figure 1.2A). An increase in 
Ca2+ concentration triggers neurotransmitter release at the hair cell synapses 
(Figure 1.2B), thereby converting sound to an electrical stimulus for 
transmission through the central nervous system (CNS) (Friedman, T  et al, 
2000).
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Signal transduction in the auditory system is different to that of other sensory 
systems e.g. the visual and olfactory systems, as it does not use a second 
messenger cascade system to amplify and transmit the signal (Martini, 
Alessandro et al, 96). Instead it employs direct gating of the transducer 
channel since it requires responses up to 100 kHz or more, too fast for a 
second messenger cascade to function. An adaptation motor in the stereocilia 
regulates the ion channel through a gating-spring which, together with the 
adaptation motor, controls the tension on the transduction channel. Little is 
known about the molecular basis of hair cell transduction or the identity of the 
proteins that form this spring or motor. However there is some evidence that a 
myosin plays a role in long term adjustment of the tension of links between the 
stereocilia which are thought to be involved in modulation of the steoreocilia 
bundle as a whole. The stereocilia of hair cells in the vestibular system also 
function by deflection, this time involving the otolithic membrane, similar to 
the tectorial membrane, which moves in response to changes in gravity as 
the head moves (reviewed in Friedman, T et al, 2000; Willems, P J, 2000).
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Figure 1.2 Hair cell structure and auditory transduction
(A) The structure of a vertebrate hair cell, showing the actin-rich stereocilia on its apical 
surface, the ion channels controlling intracellular ion concentrations and the synaptic 
vesicles of the ribbon synapses at its base. (B) The auditory transduction reaction. Deflection 
of the stereocilia in response to sound alters intracellular K+ and Ca2+ levels, leading to 
neurotransmitter release at the hair cell synapse.
(Figure adapted from (A) Willems, P J, 2000 and (B) Friedman, T et al, 2000)
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1.2.2 The vertebrate eye
1.2.2 .1 Anatomy of the eye
The mature vertebrate eye is a composite structure, composed of three 
concentric layers (Figure 1.3). The outermost layer or fibrous coat consists 
of the transparent cornea, the conjunctiva and the opaque sclera. The 
middle layer (vascular coat) consists of the choroid, containing the blood 
vessels that supply the fibrous coat of the eye, and the retina. The middle 
layer also consists of the iris with its radial and circular smooth muscles. The 
innermost layer is the neural retina (Figure 1.7), containing the 
photoreceptors that are essential for sight (Rattner, A et al, 1999; Berne R.M. 
et al, 98).
Figure 1.3 The anatomy of the vertebrate eye
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The main structural features of the vertebrate eye are shown above, with a more detailed 
illustration of the inner layer, the retina, in Figure 1.7.
(Figure adapted from National Eye Institute, National Institutes of Health).
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The photoreceptors are the visual equivalent of the auditory hair cells. There  
are two types of photoreceptor cells (Figure 1.4A), 95%  of human 
photoreceptors are rods (97.2%  in mice) and 5%  are cones (2.8%  in mice) 
(Jeon, C J et al, 1998). Three types of cone photoreceptor exist in humans, 
dependent upon which of the light-sensing visual pigments (opsins) is 
present (red, blue or green). Cones are found throughout the retina but are 
most concentrated within a small central region, the fovea, where they 
mediate colour vision and high visual acuity. Rods have low thresholds for 
detecting light, thus operating well under conditions of reduced lighting. They  
do not contribute to providing well-defined images or colour vision. Rods 
also have greater pigment content, accounting for their greater sensitivity to 
light and thus their role in night vision and in sensitivity to brightness.
Each photoreceptor cell is composed of a synaptic terminal, a cell body, an 
inner segment (IS), followed by the connecting cilium leading to the highly 
membranous outer segment (OS). The OS of rods are longer than those of 
cones and the discs are free floating, whilst cone discs consist of infoldings of 
the surface membrane (Figure 1.4A) (Rattner, A et al, 1999; Berne R.M. et al, 
98).
Transport between the IS and the OS occurs through the connecting cilium. 
Like all other cilia, the connecting cilium has a microtubule based 
cytoskeleton, the axoneme, which originates at the basal body in the IS. In 
the region of the connecting cilium, the axoneme consists of nine pairs of 
microtubules (each composed of an a and p tubule) but lacks the two central 
pairs of microtubules, that are often seen in other nonmotile primary cilium
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e.g. kidney tubule epithelium (Schwartz, E A et al, 1997). Beyond the 
connecting cilium itself, the axoneme loses this organization. However the 
microtubules clearly extend for some distance into the OS (Figure 1.4B).
Since the photoreceptor appears to contain several similar proteins to those 
used by green algae for intraflagellar transport, it has been postulated that 
this or a similar transport system is employed in the photoreceptors. This 
postulate is further supported by the abnormal OS assembly (followed by cell 
death), phenotype seen in retinas of mice with mutations in the gene 
encoding IFT88 (a protein of the intraflagellar transport system). The cargo 
carried by this transport system is not well known, but thought to include 
components of the axoneme, opsins and proteins responsible for OS disc 
morphogenesis including Peripherin and ROM1 (Besharse, J C et al, 2003). 
Rhodopsin is directly transported up the connecting cilium using a 
cytoplasmic dynein that traverses the microtubule network. Also during its 
passage through the connecting cilium, rhodopsin colocalises with myosin 
VIIA. Myosin VIIA employs the actin cytoskeleton for movement through the 
connecting cilium (Wolfrum, U et al, 2000), suggesting that multiple transport 
systems may exist in the connecting cilium.
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Figure 1.4 Specialised features of the vertebrate photoreceptor
(Ai) A schematic of the general features of rod and cone photoreceptors (adapted 
from http://www.fz-juelich.de/ibi/ibi-1/datapool/page/24/Figure2.jpg). (Aii) A more 
detailed examination of the photoreceptor outer segments (adapted from Berne 
R.M. et al, 98).
(B) An electron micrograph of the connecting cilium of a human photoreceptor in 
longitudinal section (figure adapted from Barrong, S D et al, 1992).
O, outer segment. B, basal body, mt ciliary microtubules. Single arrow, a 
tubulovesiculer structure within the cilium. Original magnification x 65 006. The 
insert is a cross section of the connecting cilium showing the 9 peripheral 
microtubule doublets (arrowhead) interconnected by a nexin link and joined to the 
surface membrane by Y shaped linker proteins (*)
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The synaptic terminals of the photoreceptors form chemical synapses with 
the retinal interneurons/second order neurons in the OPL. Synapses consist 
of a presynaptic active zone, a synaptic cleft and a postsynaptic density. The 
presynaptic active zone is filled with vesicles containing neurotransmitter, 
that are released from the presynaptic active zone to dock with the ion 
channel-rich postsynaptic density membrane, that then passes on the 
stimulatory signal through the cell layers (Garner, C C et al, 2000). Synapses 
where exocytosis is evoked by graded depolarization and where signalling 
requires a high rate of sustained neurotransmitter release, use specialized 
ribbons for vesicle release.
Ribbon Synapses
Ribbon synapses are organelles common to the vertebrate photoreceptors, 
bipolar cells and the auditory and vestibular hair cells. Photoreceptor and hair 
cell ribbons vary in structure. The photoreceptor ribbon is a plate ~30 nm 
thick that extends perpendicular to the plasma membrane and juts -2 0 0  nm 
into the cytoplasm. It is anchored along its base to an electron-dense 
structure (arciform density) that is itself anchored to the presynaptic 
membrane. Hair cells lack an arciform density, and the ribbons are more 
spherical in shape. The ribbon is still anchored, but the identity of the anchor 
and how it functions is not yet known, since it is not visible by standard TEM  
procedures (Figure 1.6). The ribbon is studded with small particles ~5nm in 
diameter, along its surface, which tether the synaptic vesicles into dense but 
not touching clusters, via several fine filaments. Those vesicles tethered 
along the base of the ribbon make direct contact with the presynaptic 
membrane and are classed as ‘docked’ vesicles. There are approximately
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5:1, tethered: docked vesicles for plate-like ribbons and 10:1 for spherical 
ones. The space between spherical ribbons and the membrane is occupied 
by docked synaptic vesicles which may be the sphere’s anchoring element 
(Sterling, P et al, 2005).
Ribbon synapses vary in their postsynaptic configurations but all the 
synapses invariably employ glutamate as the primary neurotransmitter. In 
hair cells, each ribbon supplies a single postsynaptic process (also known as 
a bouton) across a 20 nm cleft. One released vesicle can depolarize the 
bouton sufficiently to evoke an action potential, but often there is 
multivesicular release from a single ribbon onto a single bouton, possibly to 
enhance signal reliability (Glowatzki, E et al, 2002). The postsynaptic region 
of the cone photoreceptor ribbon synapses is a triad, formed from the lateral 
processes of two horizontal cells and the central processes of a bipolar cell. 
In the rod photoreceptor, the postsynaptic region is only a dyad, formed from 
the two horizontal cells. In this case, each ribbon supplies glutamate to 
multiple postsynaptic processes, each expressing a different and 
characteristic type of glutamate receptor that is located at different distances 
from the release sites. On average, each vesicle released from a cone 
synaptic ribbon contributes glutamate to postsynaptic processes at five, 
progressively more distant locations.
Exocytosis at the ribbon synapses involves the opening of C a2+ channels to 
release all the vesicles promptly across the ribbon. The level of free Ca2+ 
required for vesicle release varies between ribbon synapses. Hair cells 
exhibit a steep dependence on Ca2+ concentration, whilst exocytosis at
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photoreceptor synapses is less steeply dependent on Ca2+ levels and is 
stimulated by much lower levels of free Ca2+ (Sterling, P et al, 2005).
Figure 1.5 A schematic showing the differences in structure of the hair cell 
and photoreceptor ribbon synapses
At the basal pole of the hair cell, the spherical ribbons (red) tether the vesicles 
(white -  free vesicles; yellow -  docked vesicles) near the presynaptic membrane. 
Each ribbon supplies one postsynaptic process with 10-20 ribbons per hair cell. In 
photoreceptors, the ribbons (red) are located at the apex of an invagination formed 
with three postsynaptic processes (two horizontal cells, H and one bipolar dendrite, 
B). Each cone forms -20-50 triads (figure adapted from Sterling, P et al, 2005).
BB
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1.2.2.2 Development of the eye
The mature vertebrate eye arises from two different and independent types of 
primordial cells (Figure 1.6). The neural plate folds to give the optic sulcus 
which enlarges into the optic vesicle, whilst the lens placode originates from 
the surface ectoderm of the head. The two types of cells are brought 
together to form the optic cup, with the innermost layer of the optic vesicle 
(facing the lens placode) containing neural progenitor cells that will become 
the neural retina. The surrounding tissue differentiates into the pigmented 
epithelium and the stalk of the optic vesicle develops into the optic nerve. 
The neural retina regulates the development and orientation of the lens, 
whilst the neural crest migrates to form the sclera. The multipotent cells of 
the optic cup further develop into the iris and the ciliary body, with a vitreous 
cavity forming between lens and the retina. The pupil then forms, followed by 
the eyelids from folds in surface ectoderm and its associated mesenchyme 
(Larsen, William J., 2001), whilst the cells of the retina differentiate into their 
specific layers and types (Traboulsi, Elias. 1 ,1999).
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Figure 1.6 Development of the human eye
A timeline showing the main stages of eye development in the human embryo (adapted from 
Larsen, William J., 2001).
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This pattern of development is very similar for most vertebrates, including 
mice. However, humans and mice do differ in the timing of the final stages of 
retinal differentiation, occurring in utero in humans and postnatally (P) in 
mice. This makes mice an excellent model for investigating the final stages of 
retinal development.
The different cellular layers of the mature neural retina are shown in Figure 
1.7, alongside their function. In normal mice, the ganglion cell layer (GCL) 
and inner plexiform layer (IPL) have differentiated by P2, with the inner 
nuclear layer (INL) differentiating by P4. The outer retina at this time consists 
of progenitor cells. The uppermost layer of these cells are the newborn 
photoreceptors. Between P6-P8, the cell bodies of the newborn 
photoreceptors have formed a discreet layer as the outer nuclear layer 
(ONL), and the inner segments (IS) have become visible by light microscopy. 
They have passed the outer limiting membrane (OLM ) and are budding in 
order to form the membranous disks of the outer segments (OS). Also over 
this period, the ribbon synapses start to form in the outer plexiform layer 
(OPL), initially as dyads and then forming triads to be fully functional by P12- 
P14. Thus by P12, differentiation of the retina into its final layers is complete 
(Bowes, C et al, 1988 and Grun, G, 1982).
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Figure 1.7 The neural retina
(A) A semithin section of an adult murine retina (scale bar 50pm), aligned to the relevant layers in a schematic showing the individual cells of the neural retina (figure 
adapted from Fiore, Mariano et al, 74). (B) A table listing the main features and functions of the retinal layers (Rattner, A et al, 1999; Berne R.M. et al, 98).
Layer Function
1 Retinal Pigmented 
Epithelium (RPE)
A central nervous system (CNS) derivative that daily digests the tip of 
the OS and ‘recycles’ rhodopsin (a photopigment)
2 Photoreceptor outer 
segments (OS)
Stacks of membranous discs into which the photopigments are 
embedded. Disks are constantly renewed by new synthesis and 
assembly at its base, with shedding of older material from its tip
3 Photoreceptor inner 
segments (IS)
Contains a number of organelles, including numerous mitochondria and 
is the site of phototransduction protein and OS disk synthesis
4 Outer limiting membrane 
(OLM)
Formed by tight junctions between the photoreceptor IS and Muller cells 
that help maintain the specific photoreceptor geometry
5 Outer nuclear layer (ONL) Contains the cell bodies of photoreceptors and outer processes of 
Muller cells.
6 Outer plexiform layer 
(OPL)
Contains bipolar cells and horizontal cells (retinal interneurons) that form 
synaptic connections with the photoreceptors. This layer also contains 
the synaptic regions amacrine cells that process visual information in 
inner retina
7 Inner nuclear layer (INL) Contains the cell bodies of various retinal interneurons and Muller cells
8 Inner plexiform layer (IPL) Site of synapse formation between retinal interneurons and the ganglion 
cells
9 Ganglion cell layer (GCL) Consist of the cell bodies of the ganglion cells
10 Nerve fibre layer (NFL) Axons of the retinal ganglion cells run along the vitreous surface of the 
retina, avoiding the macula. They come together at the optic disk and 
leave the eye via the optic nerve.
11 Inner limiting membrane 
(ILM)
The innermost layer of the eye formed similarly to the OLM by 
projections of the Muller cells
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5 0 N L Muller cell
Cone 
4
Photoreceptor
nuclei
6 OPL
7 INL
8 IPL
9  GCL
9
10 NFL
11 ILM
Choroid 
1 RPE
Amacrine cell
4^
1.2.2.3 Phototransduction
Phototransduction starts when light is absorbed by the photoreceptor OS 
photopigment e.g. rhodopsin. The photopigment undergoes a conformational 
change that enables it to activate a photoreceptor G-protein called Transducin. 
Transducin activates phosphodiesterase (PDE), which in turn catalyses the 
hydrolysis of cGMP to GMP (Figure 1.8). This causes the closure of cGMP 
dependent ion channels in the plasma membrane of photoreceptor OS, meaning 
that Ca2+ ions are only being pumped out through the Na+/Ca2+ channel and not 
being replaced. This results in the stimulation of recoverin and guanylate cyclase 
activities to increase cGMP production. As a result, there is hyperpolarization of the 
membrane, leading to a graded attenuation in neurotransmitter release. This drop 
in Ca2+ levels activates a negative feedback loop that mediates light adaptation in 
cases of a sustained stimulus, or restores the cell to its normal state in cases of 
transient stimulus.
The recovery phase of phototransduction involves inactivation and recycling of the 
components of the transduction pathway, so that cGMP-dependent channels in the 
OS membranes start to open and neurotransmitter is again tonically released (Dark 
Current). In rod photoreceptors, rhodopsin is regenerated in the RPE. Cone 
photopigments are thought to be recycled within the retina itself and employ a 
different proteins to those used in the rod photopigment recycling system.
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Figure 1.8 Phototransduction and photopigment recycling0
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Photoactivated rhodopsin (R) molecules stimulate transducin (T), which in turn activates cGMP 
phosphodiesterase (PDE -> PDE*), leading to reduced cytoplasmic cGMP concentrations and 
hence closure of cGMP-gated channels. This means that Ca2+ ions are only being pumped out 
through the Na+/Ca2+ channel and not being replaced, resulting in stimulation of recoverin and 
guanylate cyclase activities to increase cGMP production. The rod cell is returned to the "unexcited” 
state, with the ‘used’ disk recycled in the RPE (although the recovery reaction is shown here in the 
OS) (Humphries, P et al, 1992).
°Figure reprinted (abstracted/excerpted) with permission from Humphries, P., Kenna, P., and Farrar, 
G. J. (1992) On the molecular genetics of retinitis pigmentosa. Science.256, 804-8. Copyright 1992 
AAAS.
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1.3 Usher syndrome
1.3.1 The clinical phenotype
1.3.1.1 The auditory phenotype: sensorineural hearing loss
Of the three clinical subtypes, type 1 is the severest form of Usher syndrome. It is 
defined by profound bilateral hearing loss from birth. These children do not develop 
speech in the absence of intervention, nor do they benefit significantly from the use 
of hearing aids. They also suffer from vestibular areflexia, the symptoms of which 
include a difficulty in lifting the head during infancy, delayed motor skill 
development, an inability to sense gravity and absence of nystagmus in response 
to ice-water caloric stimulation (Smith, R J et al, 1994). In contrast, individuals with 
type 2 have normal vestibular activity, and the congenital hearing loss is 
predominantly in the higher frequencies, with speech development benefiting from 
hearing aids and speech therapy (Smith, R J et al, 1994).
Usher syndrome type 3 displays the most range in phenotype. Patients show a 
highly variable type and degree of progressive sensorineural hearing loss, which 
also varies in age of onset. Hearing loss can range from normal, to USH2-like 
hearing impairment at younger ages, to profound or even USH1-like hearing 
impairment at more advanced ages (Ness, S L et al, 2003). Patients also show 
wide variability in vestibular function, ranging from normal to decreased but 
function is never absent (reviewed by Gorlin, R J et al, 1979).
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1.3.1.2 The visual phenotype: Retinitis Pigmentosa
The progressive bilateral retinal degeneration displayed in Usher syndrome is 
caused by Retinitis Pigmentosa, a condition which can be inherited as an isolated 
disorder or as part of a syndromic condition. At the cellular level, the progression of 
RP starts with the degeneration of the photoreceptor layer (Figure 1.9). This is 
thought to occur by apoptosis, with diseased or dying photoreceptor cells inducing 
cell death in adjacent photoreceptor cells. The actual mechanism involved is as yet 
unknown but photoreceptor degeneration spreads through the rods of the 
midperiphery, to the cones in the midperiphery and then onto the photoreceptors of 
the fovea (Dryja, T P, 2001). Patients initially experience normal vision, with the 
development of night blindness as the rod photoreceptors die. This is followed by a 
constriction of the visual fields and tunnel vision, as photoreceptor loss continues in 
the peripheral retina and onto the central photoreceptors. As the rest of the retinal 
layers degenerate, impairment in visual acuity increases and rapidly progresses to 
clinical blindness, although some patients maintain some residual but highly 
restricted vision (Smith, R J et al, 1994).
In all Usher patients, children are born with normal vision. In type 1 (USH1) 
patients, retinal degeneration starts in childhood/adolescence, whilst in USH2 
patients degeneration occurs slightly later, in adolescence or in early adulthood 
(Smith, R J et al, 1994). The onset of RP in USH3 patients is also in early 
adulthood. It had previously been thought that hearing loss occurred prior to retinal 
degeneration in Usher syndrome but in some type 3 cases, onset of retinal
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degeneration was prior to the onset of hearing loss (reviewed by Gorlin, R J et al, 
1979).
Figure 1.9 The pattern of cell death during the progression of retinitis pigmentosa.
Early stages of End stages of 
Normal retinal retinitis
degeneration pigmentosa
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retina
(A) The layers of the neural retina are clearly discernable in the healthy eye. (B) In the early stages 
of RP, the photoreceptor layer is reduced in thickness where the photoreceptors have lost their 
outer segments and the number of photoreceptor nuclei is reduced. (C) In end-stage RP, there are 
no recognisable cell layers and the retina is reduced in both overall thickness and cell number 
(figure adapted from Dryja, T P, 2001).
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Figure 1.10 Features of retinitis pigmentosa seen by fundus examination
A Normal control patient b  RP patient
Aside from ERG abnormalities, patients with Usher syndrome or retinitis pigmentosa also develop 
fundus abnormalities. A normal healthy fundus (A) is compared to that of a retinitis pigmentosa 
patient (B) (National Eye Institute, National Institutes of Health). The fovea is located in the centre 
of each image (F). As the disease progresses, patients develop abnormal pigment deposits around 
the mid-periphery of the retina (block arrow). The optic-disk appears paler (*) and the retinal blood 
vessels are attenuated (->).
1.3.1.3 Atypical Usher syndrome
Atypical forms of Usher syndrome also exists, where the clinical phenotype does 
not correspond to the genetic diagnosis (Bolz, H et al, 2001). For example, a 
patient may have a mutation in an USH1 gene but displays a phenotype 
resembling USH3. Furthermore, cases of USH1D have been found where patients 
display the characteristic visual and auditory phenotype but have normal vestibular 
function (Otterstedde, C R et al, 2001).
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1.3.1.4 Additional associated clinical characteristics
Other clinical features thought to be associated with Usher syndrome but seen in 
only a handful or a single isolated case are listed in Table 1.1. The cilia anomalies 
seen in some Usher syndrome sufferers, led to the suggestion that Usher 
syndrome type 1 could be a primary cilia disorder (Hunter, D G et al, 1986).
Table 1.1 Additional clinical features thought to be associated with the Usher
syndrome phenotype
Clinical phenotype References
Olfactory loss due to structural abnormalities of the nasal cilia
Marietta, J et al, 
1997
Decreased sperm motility and reduced fertility
Hunter, D G et al, 
1986
Abnormal axonemes of the retinal photoreceptor cells
Hunter, D G et al, 
1986
Abnormal connecting cilia of the retinal photoreceptor cells
Hunter, D G et al, 
1986
Profound hearing loss similar to USH1 individuals, but with normal peripheral 
vestibular function
Otterstedde, C R et 
al, 2001
Degeneration or atrophy of both the organ of Corti and the stria vascularis, 
accompanied by loss of the spiral ganglion in all USH types
Takasaki, K et al, 
2000
Widespread loss of supporting cell elements of the organ of Corti and 
damage to the cochlea nerve in USH3 patients
Takasaki, K et al, 
2000
Association with bronchiectasis
Bonneau, D et al, 
1993
A drop in long chain polyunsaturated fatty acid levels in USH1 patients
Maude, M B et al, 
1998
Adnexal tumours found on the lips
Began, D M et al, 
2001
Decrease in intracranial volume and in the size of the brain and cerebellum
Keats, B J et al, 
1999
Associated mental instability and/or learning defects = Hallgren’s syndrome 
(connection between Usher and Hallgren’s not yet known)
Gilbert, P., 0000
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1.3.2 The genetics of Usher syndrome
The three clinical forms of Usher syndrome have been linked to eleven different 
loci (Table 1.2). Type I has been mapped to seven loci so far, labelled A-G, type 2 
to three loci, A-C, and type 3 to one locus. At present, nine of the Usher genes 
have been cloned (M Y07A, USH1C, CDH23, PCDH15, USH1G, USH2A, USH2B, 
USH2C  & USH3A), and it has been suggested that their USHI proteins are 
involved in the same signalling pathway or multi protein complex (section 1.3.4.1 & 
Adato, A et al, 2005b, Boeda, B et al, 2002, Petit, C, 2001). It is thought that 
mutations in M Y07A  are responsible for 29-60 % of the cases of USH1, whilst 
mutations in USH2A account for 41-80% of patients suffering from USH2 
(Maubaret, C et al, 2005 and references therein).
Some genes underlying nonsyndromic hearing loss have been shown to be allelic 
with genes causing Usher syndrome e.g. USHIB/DFNB2/DFNA11 (Weil, D et al, 
1997); USHIC/DFNB18; USHID/DFNB12 and USHIF/DFNB23 (Ahmed, Z M et al, 
2002). Research suggests a genotype-phenotype correlation for some of the Usher 
genes e.g. USH1C  and CDH23. In these cases, hypomorphic alleles are 
associated with nonsyndromic hearing loss, whilst more severe mutations result in 
Usher syndrome. This would suggest that residual function associated with some 
missense allele products is sufficient for normal vision but not for hearing (Ouyang, 
X M et al, 2002; Ahmed, Z M et al, 2002; Ahmed, Z M et al, 2003). Meanwhile, 
mutations in USH2A have been associated with nonsyndromic RP but not with 
isolated hearing loss. Mutations in this gene are thought to account for 70% of all
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Usher type 2 patients and about 4.5% of nonsyndromic autosomal recessive RP 
(Seyedahmadi, B J et al, 2004).
Cases of digenic inheritance have been proven for PCDH15  & CDH23 (Zheng, Q 
Y et al, 2005) and suggested by linkage analysis for USH3A & M Y07A  (Adato, A et 
al, 1999). This further highlights the genetically heterogenous nature of Usher 
syndrome and suggests that the Usher proteins may directly interact.
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Table 1.2 Usher syndrome
Chromosomal location of the different Usher regions, the gene symbols, encoded protein and 
corresponding mouse model. Further references are given in the text of sections 1.3.3 and 1.3.5.
Usher
type
Gene Location Protein Mouse model
USH1A USH1A
(Kaplan, J et al, 1992)
14q32
USH1B MY07A
(Kimberling, W J et al, 
1992; Smith, R J et al, 
1992)
11q13.5 Myosin VIIA Shaker-1
(Gibson, F et al, 1995; Self, T 
et al, 1998; Kros, C J et al, 
2002; Liu, X et al, 1999; Liu, 
X et al, 1998; Libby, R T et 
al, 2001)
USH1C USH1C
(Smith, R J et al, 1992; 
Saouda, M et al, 1998; 
Bitner-Glindzicz, M et al, 
2000; Verpy, E et al, 
2000)
11 p15.1 Harmonin 
(Kobayashi, I 
et al, 1999; 
Scanlan, M J 
et al, 1999)
Deaf circler
(Johnson, K R et al, 2003)
USH1D CDH23
(Bork, J Met al, 2001)
10q22.1 Cadherin 23 Waltzer
(Di Palma, F et al, 20011a; 
Libby, R T et al, 2003)
USH1E USH1E
(Chaib, H et al, 1997)
21q21
USH1F PCDH15
(Ahmed, Z M et al, 2001)
10q21.1 Protocadherin
15
Ames Waltzer
(Alagramam, K N et al, 
2001a; Ball, S Let al, 2003)
USH1G USH1G
(Mustapha, M et al, 2002)
17q24-25 Sans Jackson shaker
(Kikkawa, Y et al, 2003)
USH2A USH2A
(Eudy, J D et al, 1998a; 
Weston, M D et al, 2000; 
Van Wijk, E et al, 2004)
1q41 Usherin
USH2B PROPOSED GENE - 
USH2B
3p23-24.2 NBC3 Slc4ar-
(Bok, D et al, 2003)
USH2C USH2C
(Pieke-Dahl, S et al, 
2000; Weston, M D et al, 
2004)
5q14.3-
21.3
Vlgrlb VIgr1"
(Johnson, K R et al, 2005; 
McMillan, D R et al, 2004; 
Weston, M D et al, 2004); 
Johnson, K R et al, 2005)
USH3 USH3A
(Joensuu, T et al, 2001; 
Fields, R R et al, 2002)
3q25.1 Clarin-1
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1.3.3 Usher syndrome proteins: their structure and localisation within the normal 
ear and eye
1.3.3.1 Myosin VIIA
The USH1B protein of 2215 amino acids (Weil, D et al, 1996) is an unconventional 
myosin. Myosins consist of both heavy and light chain polypeptides, although the 
light chains of unconventional myosins are normally substituted for calmodulin 
molecules (Redowicz, M J, 2002 and references therein). The structure of the 
heavy chain of Myosin VIIA is shown in Figure 1.11. Studies have shown that 
mutations in the conserved IQ motifs disrupt interactions between myosin VIIAa 
and calmodulin (Bolz, H et al, 2004). Analysis of the effects of different mutations 
on the structure/function of the other Usher proteins is limited.
IQ M F
Figure 1.11 The structure of myosin VIIA
Myosin VIIA heavy chain consists of a motor domain typical to most myosins, followed by a neck 
region of five IQ motifs (IQ). These motifs normally bind the light chain. This is followed by a short 
coiled coil region which would suggest that myosin VIIA may function as a dimer. The protein ends 
with a tail region consisting of two large repeats, each comprising a MyTH4 (myosin tail homology) 
(M) domain and a FERM domain (band 4.1/ezrin/radixin/moesin-homology) (F) (Weil, D et al, 1996).
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Myosin VIIA is expressed in the olfactory receptor sensory neurons (Weil, D et al,
1996), in the cochlea, photoreceptors, RPE cells, testes and kidney (interestingly, 
no kidney phenotype is seen in Usher syndrome patients) (Hasson, T et al, 1995). 
Within the cochlea the protein was localised to the hair cell stereocilia (first E12, 
Sahly, I et al, 1997), cuticular plate and cytoplasm of both inner and outer hair cells 
of guinea pig cochlea, and in the sensory epithelium of the bullfrog vestibular 
system (Hasson, T et al, 1995; Figure 1.12). The protein localisation data and the 
phenotype of the myosin VIIA null mice (shaker-1), led to the postulate that myosin 
VIIA may be responsible for organising the developing array of haircell stereocilia 
(Wolfrum, U et al, 1998). This postulate was supported by the null rat model 
tornado (Smits, B M et al, 2005) and the Drosophila model (Todi, S V  et al, 2005), 
which showed similar auditory phenotypes and disorganization of the stereocilia of 
the hair cells (Johnston’s Organ in the fly).
Studies on the retina proved more complex, with some groups claiming isolated 
enrichment of the protein to the RPE (Hasson, T et al, 1995), whilst others 
localised it to the RPE during development but showed that it was confined to the 
photoreceptor cells in the mature eye (Weil, D et al, 1996). Furthermore, some 
claimed that myosin VIIA was restricted to the RPE in mice but was seen in both 
the RPE and photoreceptor cells in humans (El-Amraoui, A et al, 1996). It was 
thought that this difference between rodents and humans would account for the 
observed difference in retinal phenotypes between Usher type 1B and the shaker-1 
mouse model (section 1.3.5). Finally it was confirmed that the protein was localised 
to the RPE and the connecting cilia of photoreceptor cells in both humans and
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rodents (Figure 1.13), where it was thought to be involved in the transport of newly 
synthesised OS proteins to the site of disk membrane assembly (Liu, X  et al,
1997). The difference in previous staining results of Hasson, T et al, 1995, Weil, D 
et al, 1996 and El-Amraoui, A et al, 1996, was explained through different tissue 
preparations and the use of different antibodies.
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Figure 1.12 Localisation patterns of the Usher proteins within the normal ear
A schematic comparing and summarizing the localisation of the Usher proteins discussed in section 
1.3.3 (all relevant references are included therein). The Usher proteins are thought to be involved in 
the different kinds of links that interlink the stereocilia or connect the stereocilia to the cytoskeleton. 
These different types of links are denoted by different kinds of arrows on the schematic. Coloured 
boxes around regions of the haircell highlights situations where expression of the Usher gene has 
been shown by in situ hybridisation. The exact pattern of protein localisation in these cases has yet 
to be confirmed. Localisation of the Usher proteins in addition to or other regions than the hair cells 
are denoted by numbers.
Myosin VHA Harmonin Cadherin Protocadherin Sans Usherin Nbc3 V lgrlb  Clarin 1 
23 15
STEREOCILIA
CUTICULAR
PLATE
SPIRAL
GANGLION
1 3
(1) Cadherin 23 is also localised to the Kinocilium, centrosomes and Reisners membrane. (2) 
Usherin is localised to the strial capillary basement membranes of the cochlea. (3) NBC3 is 
localised to the spiral ligament, beneath the stria vascularis, beneath the spiral prominence and in 
the suprastrial region of the cochlea. The exact subcellular localisations of V lgrlb  and Clarin-1 have 
not been confirmed but in situ hybridization has shown gene expression of both in the hair cells.
Tip link, ( (T b  curved arrow). Stereocilia-stereocilia links ( £) wide arrow head). Stereocilia- 
cytoskeletal links ( O  double ended arrow). Internal cytoskeletal links four way arrow).
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Figure 1.13 Localisation patterns of the Usher proteins within the normal eye
A schematic comparing and summarizing the localisation patterns of the Usher proteins in the eye, 
at the start/early stages of this research (section 1.3.3, all relevant references are included therein). 
Coloured boxes around regions of the photoreceptor highlights situations where expression of the 
Usher gene has been shown by in situ hybridisation. The exact pattern of protein localisation in 
these cases has yet to be confirmed. Localisation of the Usher proteins in addition to or other 
regions than the photoreceptor are denoted by numbers.
Myosin Harmonin Cadherin Protocadherin Sans Usherin Nbc3
VELA 23 15
RPE
OS
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IS
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OPL
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3
Clarin 1
(1) The exact pattern of protocadherin 15 localisation in the photoreceptor has yet to be confirmed 
(section 1.3.3.4). (2) Usherin is localised to the Bruch’s membrane adjacent to the RPE. (3) Vlgrlb  
mRNA has been detected in neural retina, RPE and hair cell progenitors.
2ryN, retinal interneurons. OPL, outer plexiform layer. ONL, outer nuclear layer. IS, photoreceptor 
inner segments. CC, connecting cilium. OS, photoreceptor outer segments. RPE, retinal pigmented 
epithelium.
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1.3.3.2 Harmonin -  the USH1C protein
Three isoform classes of harmonin (a, b, c) exist (Figure 1.14) produced by 
alternative splicing of 8 of the 28 exons of the USH1C. RT-PCR of various human 
foetal tissues of gestation age range 10-13 weeks, showed expression of USH1C  
transcript ‘a ’ in all foetal tissue examined including the ear, eye, gut, kidney, 
adrenal, muscle and heart. The shorter transcript species ‘c’, was detected in the 
gut, kidney and faintly in the foetal ear and eye (Scanlan, M J et al, 1999). 
Immunostaining of foetal human eyes showed low levels of harmonin in the 
outermost aspect of the developing outer neuroblastic layer of the retina (the cells 
destined to become photoreceptors) (section 1.2.2.2; Bitner-Glindzicz, M et al,
2000). Isoform ‘b’ was hypothesized to be restricted to the ear (Verpy, E et al,
2000), and shown to localise along the length of the emerging stereocilia during 
development but was absent in the developed hair cell. In contrast, isoforms ‘a’ 
and ‘c’ were localised to the cuticular plate and stereocilia during development, and 
in the mature hair cell (Figure 1.12; Boeda, B et al, 2002).
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Figure 1.14 The structure of the three isoform classes of harmonin
Isoform class ‘a’ consists of 3 PDZ domains (PDZ) with 1 coiled coil (CC) region and corresponds to 
AIE75/PDZ-73. Class ‘b’ proteins have 3 PDZ domains, 2 coiled coil regions and a PST domain 
(rich in proline 27%, serine 13% & threonine 8%) (PST). Class ‘c’ isoforms have 2 PDZ domains 
and 1 coiled coil region.
All three harmonin isoform classes contain protein-protein recognition modules, 
known as PDZ domains (PSD-95/Dlg/ZO-1). These global folds form a pocket that 
specifically recognises short C terminal peptide motifs in their ligands, but can also 
recognise internal sequences within their binding partners, known as PBIs (PDZ 
binding interface), which structurally mimic the C terminus. The four C terminal 
amino acids of the ligand that make up the binding motif have different preferences 
for particular classes of amino acid, particularly P0, and P.2> and can be divided into 
three classes based on these specificities (Table 1.3). PDZ domains are commonly 
seen in proteins involved in transporting and targeting appropriate proteins to sites 
of cellular signaling, in proteins that organise multiprotein signalling complexes, in 
proteins affecting the establishment and maintenance of cell polarity, in proteins 
that organize polar sites of cell-cell communication or in protein receptors and their
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downstream effectors (Hung, A Y et al, 2002;Harris, B Z et al, 2001a; Harris, B Z et 
al, 2001b; Huber, A, 2001; Sheng, M eta l, 2001).
Table 1.3 PDZ domain classes
The three main PDZ domain classes and the respective amino acid sequences of their binding 
partners.
X, unspecified amino acid O, hydrophobic amino acid
PDZ domain classification Preferred amino acid sequence 
Of P.3, P-2, P-1, Po
I -X -S/T- X- O
II -X- 0 -  X- 0
III -X -D /E - X- 0
1.3.3.3 Cadherin 23
CDH23  encodes a novel cadherin-like protein of 3354 amino acids (Bolz, H et al,
2001), expressed in the heart, brain, liver, lung, kidney, ear and eye (Bolz et al
2001). It consists of an N-terminal signal peptide, followed by an extracellular 
domain of 27 cadherin repeat (CAD) domains, a single transmembrane region (TM 
and cytoplasmic tail that showed no homology to any known protein (Figure 1.15; 
Bolz, H et al, 2001). Within the retina, cadherin 23 is localised to two distinct 
compartments of the photoreceptor cells, at the OPL and IS, where it may have a 
role within the ribbon synapses (Figure 1.13). Numerous cadherins localise to 
synapses and N-cadherin has been shown to be required for axonal outgrowth and
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guidance in the retina, suggesting a role for cadherin 23 in synapse plasticity 
and/or modulation of synapse activity (Bolz, H et al, 2002).
TM
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Figure 1.15 The structure of cadherin 23
CAD, cadherin repeat domains. TM, transmembrane region
In the ear two splice forms of CDH23 exist (now known as isoform ‘a’), with and 
without exon 68 as part of the mature mRNA. The + exon 68 transcript is prominent 
in the cochlear hair cell bundle but absent from other tissues (Siemens, J et al,
2002), whilst the -  exon 68 species is detected in Reisners membrane and the 
developing hair bundle in immature hair cells. In the developed hair cells, cadherin 
23 is restricted to the stereocilia tips in both cochlear and vestibular hair cells, 
where there are ongoing arguments as to its presence as a component of the tip 
link (Figure 1.12; Siemens, J et al, 2004; Lagziel, A et al, 2005). The tip link 
controls opening of mechanotransduction channels in the hair cell upon deflection 
of the stereocilia. Myosin-1 C is the only known component of the 
mechanotransduction apparatus so far and has been shown to interact with the 
cytoplasmic domain of both isoforms of cadherin 23. Cadherin 23 was also seen to 
form links between the tallest stereocilia and the kinocilium during development 
(Siemens, J et al, 2004 and references therein).
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A further two isoforms of cadherin 23 (isoforms ‘b’ and ‘c’) have recently been 
shown to be expressed in the murine retina and inner ear. The finding of cadherin 
23 in the cochlea and vestibular apparatus of the null (nonsense mutation) 
waltzer mice, would suggest that not all isoforms of Cdh23 are affected by this 
mutation. It would appear that isoform ‘a ’ is coupled to the waltzer phenotype and 
is vital for correct hair bundle organization during development, whilst alternative 
roles for isoforms ‘b’ and ‘c’ exist (Lagziel, A et al, 2005).
1.3.3.4 Protcadherin 15
In the ear, protocadherin 15 (Figure 1.16) was localised to the IHC and OHC  
stereocilia, concentrated at the cuticular plate level but also found along the length 
of the stereocilia. Protein levels along the stereocilia varied between bundles and 
between stereocilia of the same bundle (Figure 1.12). A similar pattern of staining 
was seen in the vestibular apparatus (Ahmed, Z M et al, 2003). Protein localisation 
data and the disorganization of hair cell stereocilia in protocadherin 15 mutant 
mice, led to the postulate that protocadherin 15 played a role in the maintenance of 
the links between the stereocilia to correctly organise the bundle (Ahmed, Z M et 
al, 2003).
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Figure 1.16 The structure of protocadherin 15
The 1955 amino acid protocadherin 15 protein, has an N terminal signal peptide, 11 extracellular 
calcium binding domains (CAD), a transmembrane domain (TM) and a unique cytoplasmic domain 
(Ahmed, Z Met al, 2001).
Localisation of protocadherin 15 in the eye is disputed, with one group localizing 
the protein to the IPL, OPL and NFL in adult and foetal retinas (Alagramam, K N et 
al, 2001b) and another to the photoreceptor OS, with strongest immunoreactivity in 
the cones (Figure 1.13) (Ahmed, Z M et al, 2003). In the USH1F zebrafish model, 
orbiter, there are two closely related Pcdh15 genes ‘a’ and ’b' that are differentially 
expressed in the ear and eye respectively. Pcdh15a morphants display a similar 
auditory phenotype to the mouse models but no retinal phenotype. Meanwhile the 
Pcdh15b morphants showed a decrease in b-wave ERG amplitude (although the a- 
wave was present, it could not easily be measured), with a reduction in correctly 
positioned melanosomes and a tilting of the photoreceptor OS, but no auditory 
phenotype. Protocadherin 15 was therefore postulated to be essential in OS 
alignment and interdigitation with the RPE (Seiler, C et al, 2005).
1.3.3.5 Sans
The USH1G protein, sans (Figure 1.17), was localised to the hair cells, where it did 
not directly interact with either actin, microtubules or immediate filaments (Weil, D
65
et al, 2003). Sans, unlike the other USH1 proteins, is not found along the length of 
the stereocilia but from P1, was detected underneath the cuticular plate of the 
developing hair cells as well as in some of the supporting cells (Adato, A et al, 
2005b) (Figure 1.12). High levels of Sans immunoreactivity were also seen in 
cochlea ribbon synapses (Adato, A et al, 2005b). Gene expression has been seen 
in the eye but the pattern of protein localisation has not yet been determined (Weil, 
Det al, 2003).
AK SAM
Figure 1.17 The structure of sans
Sans is a novel 460 amino acid protein that contains three ankyrin-like domains (AK) involved in 
protein-protein interactions) at the N terminal end, a central region, a SAM (sterile alpha motif) 
domain (thought to be involved in homo- or heterodimerisation) (SAM) and has a PDZ binding motif 
at its C terminus.
1.3.3.6 Usherin
The USH2A gene encodes two protein isoforms of Usherin (Figure 1.18), both of 
which are expressed in the foetal cochlea, eye, brain, kidney, and in adult retina, 
brain, lung, bone marrow, adrenal gland, trachea, spinal cord, and thyroid gland 
(Eudy, J D et al, 1998b). Semi quantitative RT-PCR showed that transcription 
levels were low in all tissues except the eye (Van Wijk, E et al, 2004), where the 
short protein isoform was localised to virtually every basement membrane in the 
cochlea (Figure 1.12), and to the lens capsule and the Bruch’s layer (found 
between the RPE and the choroids) in the eye (Bhattacharya, G et al, 2002; Figure 
1.13). The long isoform has been localised to the base of the differentiating
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cochlea and vestibular hair cell stereocilia (possibly acting as a component of the 
ankle links between stereocilia), but is only maintained in the stereocilia of mature 
vestibular hair cells (Adato, A et al, 2005a).
T
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Figure 1.18 The structure of usherin
The long isoform of usherin is 5202 amino acids, containing the following: a domain homologous to 
a thrombospondin N-terminal-like domain (T), a laminin G-like domain (LGL), a pentaxin (X) 
domain, a laminin N-terminal (LT) domain, 10 laminin-type EGF-like repeats, four fibronectin type 3 
(F3) repeats, 2 laminin G (LG), 28 F3 repeats, a transmembrane domain (TM) and a C terminal
class 1 PBI. Between F3 repeats 13 and 14 there is a partial F3 domain and a stretch of -350  
amino acids with no significant homology to any known domain (Van Wijk, E et al, 2004).
1.3.3.7 NBC3
NBC3 is proposed to be the protein involved in Usher type 2B, although no 
mutations in the gene in humans have been detected to date. The visual and 
auditory systems have a special requirement for H+ disposal during sensory 
transduction, mediated by the sodium bicarbonate cotransporter, NBC3 (SLC4A7) 
(Figure 1.19). In wildtype mice the transporter is localised to the photoreceptor 
synaptic terminals of the OPL (Figure 1.13). The plasma membrane ATPase - Ca2+ 
transporters found at the photoreceptor synaptic terminals, extrude Ca2+ in 
exchange for H+. It is postulated that NBC3-mediated bicarbonate flux in the
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maintaining normal rates of Ca2+ efflux. In the cochlea it is localised to the spiral 
ligament and to fibrocytes beneath the stria vascularis, spiral prominence and in 
the suprastrial region (Figure 1.12). These findings suggested that in the ear, the 
fibrocytes themselves may be involved in cochlear fluid homeostasis, which is 
essential for maintaining hair cell morphology in normal auditory function (Bok, D et 
al, 2003).
LOOP TM
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Figure 1.19 The structure of NBC3
This 12 transmembrane domain (TM) protein has A/-linked glycosylation sites on two of its 
extracellular loops (LOOP); protein kinases A and C, casein kinase II, and ATP/GTP-binding 
consensus phosphorylation sites and potential sites for myristylation and amidation on other loops. 
Both its N and C termini are cytoplasmic and it has a C terminal PBI (Pushkin, A et al, 1999).
1.3.3.8 Very large G-coupled receptor protein b (Vlgrlb)
Multiple isoforms of Vlgrl exist (a-c, Weston, M D et al, 2004; McMillan, D R et al, 
2002 and d-e, Yagi, H et al, 2005) that vary in structure, showing different 
expression patterns within species and between species. All the mutations 
associated with Usher syndrome have been found in VLGRIb, expressed by 
neural retinal precursors and by cells destined to become the RPE (Figure 1.13). 
Transcript expression continues at low levels in adulthood, implying a function for 
the protein (Figure 1.20) in neural development and/or maintenance (McMillan, D R 
et al, 2002; Schwartz, S B et al, 2005). The EPTP domain has been postulated to 
be an epilepsy-associated repeat that when mutated, results in autosomal
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dominant lateral temporal lobe epilepsy which increases susceptibility to 
audiogenic seizures in mice. This postulate is supported by the finding that frings 
mice that express a truncated Vlgrlb protein (lacks the EPTP repeat) experience 
audiogenic seizures. Other proteins that possess Calx-/? domains have been 
shown to act as calcium dependent aggregating molecules. Therefore it has been 
postulated that isoform ‘b’ acts as a calcium ion receptor whilst isoforms ‘d’ and ‘e’ 
are secreted as extracellular proteins whose function is related to extracellular Ca2+ 
distribution (Yagi, H et al, 2005).
CAL LAM E A R /E P T
G P S TM
Figure 1.20 The structure of V lgrlb
The 6300 amino acids of VLGRIb produce: a large ectodomain of 35 CalX-J5 domains (CAL) 
(portions of which bind calcium ions and other cations), 1 LamG/TspN/PTX homology domain 
(LAM), 7 EAR/EPTP repeats forming a putative ^-propeller folding domain (a protein interaction 
domain that acts as a highly specific receptor (EAR/EPT), with possible ligands including 
extracellular or cell adhesion proteins), a GPS (G-protein coupled proteolysis site) (GPS), a B-family 
7 transmembrane region (TM), a putative intracellular tail with potential serine phosphorylation sites, 
and a C terminal class 1 PBI (Weston, M D et al, 2004).
Vlgrlb shows similar localisation in the inner ear, to the long isoform of Usherin. It 
too is localised at the base of the stereocilia in developing vestibular and cochlea 
hair cells but is absent in the stereocilia of mature cochlea hair cells (Adato, A et al, 
2005a; figure 1.12).
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1.3.3.9 Clarin-1
The USH3A protein, Clarin-1 (Fields, R R et al, 2002) (Figure 1.21), belongs to a 
large family of small integral membrane glycoproteins. PCR amplification showed 
USH3A transcripts in the human retina, inner ear, testes, skeletal muscle and 
olfactory epithelium (Joensuu, T et al, 2001). In situ hybridisation showed gene 
expression in the IHC and OHC of the organ of Corti and in the spiral ganglion cells 
(Figure 1.12; Adato, A et al, 2002). Immunohistochemistry labelled Clarin-1 in the 
horizontal cells and the Muller cells of the inner retina, but this was not 
reproducible in either the rat or human (Geller, S.F. et al 2004; Figure 1.13).
TM
Figure 1.21 The structure of Clarin-1
Clarin-1 consists of 204 amino acids forming four transmembrane domains (TM) (Fields, R R et al, 
2002).
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1.3.4 Usher syndrome proteins: their interactions in the normal ear and eye
1.3.4.1 Usher protein complexes formed in the normal ear
Yeast two-hybrid and other interaction studies on the Usher proteins, initially 
discovered novel or non-Usher protein binding partners for harmonin, including 
M CC2 (Ishikawa, S et al, 2001); p-catenin (Johnston, A  M et al, 2004); PP2AC-a, 
PP2AC-P or PPP6C (Hirai, A et al, 2004) and Harp (Johnston, A M et al, 2004). Yet 
because of the similar phenotypes of all the USH1 patients and USH1 mouse 
models, it was hypothesised that all the type 1 proteins interacted, forming a multi­
protein functional complex. The absence of any one of the USH1 proteins would 
therefore result in the same deafness-blindness phenotype (Boeda, B et al, 2002).
Harmonin has the ability to form dimers or long chains of protein, through 
interaction of its own PDZ1 and C terminus (Siemens, J et al, 2002). It is also able 
to interact with the actin cytoskeleton, using the C terminus of isoform ‘b’ (Boeda, B 
et al, 2002). Siemens et al (2002) and Boeda et al (2002) went onto show that 
myosin V IIA  which does not have the classic C terminal sequences usually 
required for PDZ interactions, binds PDZ1 of harmonin isoform ‘b’ and that 
cadherin 23 interacts with PDZ2 of the same isoform. The fact that harmonin 
isoform ‘b’ was seen along the entire length of the developing stereocilia and that it 
was mislocalised in the shaker-1 mice, suggested that in the ear, myosin VIIA  
functions to convey harmonin isoform ‘b’ to its site of action in the stereocilia. The  
distribution of isoform ‘b’ in the stereocilia overlaps with that of cadherin 23, which 
is thought to interlink the stereocilia and organize the stereocilia bundle until it
reaches maturity. Therefore harmonin isoform ‘b \ once correctly localised by 
myosin VIIA, may function to link cadherin 23 to the actin filaments of the growing 
stereocilia, during hair cell bundle development (Boeda, B et al, 2002). Whether 
this complex is found in adults is not yet certain due to the argument surrounding 
the localisation of cadherin 23 to the stereocilia tip links (section 1.3.3.3).
Siemens et al (2002) also noted that cadherin 23 had two PBIs: the C terminal PBI 
interacts with PDZ2 of harmonin, whilst an internal PBI interacts with PDZ1. The 
presence of exon 68 in the ear isoform of cadherin 23, perturbs the internal PBI 
resulting in harmonin-cadherin 23 interactions through PDZ2 only. In the eye using 
the -68 cadherin 23 isoforms, there is the possibility that one harmonin molecule is 
able to interact with two cadherin 23 molecules at the same time, through both 
PDZ1 and PDZ2 (Siemens, J et al, 2002). This raises questions as to whether 
myosin VIIA is necessary to correctly localise harmonin within the eye and whether 
it competes with cadherin 23 for interaction with PDZ1. Different kinds of 
mutations in these genes may alter the proteins binding ability, giving one of the 
proteins a greater binding advantage over the other. This may explain why 
particular mutations affect the ears only, giving nonsyndromic deafness 
phenotypes rather than Usher syndrome. Another theory is that the alternatively 
spliced isoforms for both cadherin 23 and harmonin that are differentially 
expressed between the retina and cochlea, and could result in differing USH1 
protein complexes forming in the two organs.
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1.3.4.2 Postulated Usher protein complexes formed in the normal eye
Very little is known about the interactions of harmonin or any of the Usher proteins 
in the eye. It has been suggested that the USH1 proteins form a similar complex in 
the retina, as in the ear as discussed previously. Yet the fact that the USH1 
patients have normal vision at birth would suggest that if this complex did form, it 
has a different function to that seen in the ear where it is essential for correctly 
organising the developing hair cell bundle and therefore for hearing at birth.
1.3.5 Mouse models of Usher syndrome
All the USH1 mouse models display similar degrees of hyperactivity, head tossing, 
circling and profound deafness (references listed in Table 1.2). This is thought to 
be caused by disorganization or degeneration of auditory and vestibular hair cell 
stereocilia (Figure 1.22). In contrast, the USH1 mutants show little, if any, retinal 
abnormalities and certainly nothing comparable to the human phenotype.
The shaker-1 (USH1B) and waltzer (USH1D) mice models used in this research, 
have normal vision throughout their lifespan and show only minor reductions in 
ERG a- and/or b- wave amplitudes (Libby, R T et al, 2001; Libby, R T et al, 2003). 
The deaf circler (USH1C) mouse has a normal ERG, with only a slight 
degeneration in peripheral region of the retina seen in a small sample of mice 
(Johnson, K R et al, 2003).
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Figure 1.22 Scanning electron microscope images comparing the organisation of hair cell
stereocilia in the USH1 mutant model mice
Wildtype Shaker-1 Deaf circler Waltzer Ames waltzer
The auditory hair cells are arranged in a single row of IHC and a triple row of OHC. On the apical 
surface of each hair cell, the stereocilia are arranged in a characteristic “V” shape, with each 
stereociliar tip connected to its taller neighbour. This organized formation is seen in the wildtype 
mouse but is lost in all the null mouse models for USH1.
Figure adapted from: wildtype, Johnson, K R et al, 2003. shaker-1, Self, T et al, 1998. deaf circler, 
Johnson, K R et al, 2003. waltzer, Di Palma, F et al, 2001. ames waltzer, Alagramam, K N et al, 
2001a.
The reason for the differences in retinal phenotypes between humans and mice is 
as yet unknown. It has been suggested that genetic background may be a cause, 
or that mutations found in humans resulting in Usher may be different from those 
found in mice, or that there is a degree of redundancy in mice not seen in humans. 
A further hypothesis is that there are just intrinsic differences between the two 
species, one of the main differences being that the first sign of retinal degeneration 
in human patients generally occurs after several years of age, well beyond the 
lifespan of a mouse. Several mutant mouse strains e.g. the model for Oguchi 
disease (Chen, J et al, 1999), developed retinal degeneration after a certain 
amount of exposure to light. So it has been suggested that the retinas of Usher
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mutant mice do not degenerate because they have not been exposed to light in the 
same way as their human counterparts (Libby, R T et al, 2001). Yet it has been 
argued, for the waltzer mice in particular, that the decreases in implicit time in the 
murine ERG could be an important observation of the very early retinal pathology 
of USH1 (Libby, R T et al, 2003; Seeliger, M W  et al, 2001).
1.4 Research aims
Mutations in USH1C  are known to cause Usher syndrome and its function in the 
ear has been postulated. However very little was known about harmonin’s 
localisation and function in the eye. Therefore the aims of this research were to:
• Determine the temporal and spatial expression of U shlc  and harmonin 
within the normal murine eye.
■ Investigate potential harmonin-interacting proteins within the normal eye.
■ Infer possible pathogenic mechanisms in Usher syndrome.
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1.5 Background to research methodology
1.5.1 Methods for determining gene expression and protein localization patterns 
Gene expression can be analysed on a small scale using the reverse transcription 
polymerase chain reaction technique, or on a larger scale with cDNA microarrays. 
Gene expression patterns on tissue sections can be analysed by in-situ 
hybridization, whilst protein localisation is examined by immunostaining 
techniques.
1.5.1.1 Reverse Transcription Polymerase Chain Reaction (RT-PCR)
RT-PCR-based assays are the most common method for characterising or 
confirming gene expression patterns and comparing mRNA levels in different 
sample populations. As RNA cannot serve as a template for PCR, the first step in 
an RT-PCR assay is the reverse transcription of the RNA template into cDNA, 
followed by its amplification in a PCR reaction. Gene expression levels can be 
compared in a semi-quantitative fashion if housekeeping genes e.g. 3-phosphate- 
dehydrogenase (GAPDH), are amplified simultaneously with the target, to act as 
an internal reference against which other RNA values can be normalised. Real­
time RT-PCR is a fully quantitative approach that uses fluorescent reporter 
molecules to monitor the production of amplification products during each cycle of 
the PCR reaction (reviewed in Bustin, S A, 2000).
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1.5.1.2 Immunostaining
Protein localization by immunostaining, involves the binding of antibodies to target 
proteins which may be detected directly or indirectly. Direct detection systems, use 
an antibody that is directly labelled with a reporter molecule e.g. a flurophore. 
Alternatively there is the indirect system, which uses the primary antibody as an 
intermediate unlabelled molecule, which once bound to its target, is in turn 
detected and bound by a secondary reagent (e.g. a secondary antibody). This 
secondary molecule is conjugated to a reporter which may be a flurophore or an 
enzyme (e.g. alkaline phosphatase). This system allows for amplification of low 
level signals through the use of multiple specific antibodies and the use of readily 
available commercial affinity-purified secondary antibodies. The secondary labelling 
can be varied to allow for investigation of a single protein under different conditions 
whilst using only the single primary antibody e.g. immunofluorescence and Western 
blotting. It also allows for double labelling of cells and tissue for more than one 
protein at a time.
The difficulties associated with the use of antibodies in experiments, include the fact 
that their immunoreactivity can be affected by the fixation conditions required to 
maintain tissue architecture. Furthermore, the use of secondary antibodies can result 
in high levels of non-specific background labeling. This can be reduced using the 
direct labeling system but this has the disadvantage that a large variety of primary 
antibodies need to be produced and this is expensive. There are also issues of
77
cross reactivity between species, where an antibody raised to a mouse protein may 
detect a different protein in rabbits, giving false positives (Strachan, T et al, 1999).
1.5.1.2.1 Synthesis of antibodies
1.5.1.2.1.1 Selection of epitopes
Traditionally, antibodies have been isolated by immunising suitable animals (e.g. 
rodents, rabbits, goats, etc.) with a suitable immunogen/antigen. Two types of 
immunogen are commonly used:
■ Synthetic peptides. A synthetic peptide of 12-50 amino acids long is chosen 
from the amino acid sequence and conjugated to a suitable carrier molecule 
(e.g. keyhole limpet hemocyanin (KLH)), allowing the peptide to adopt a 
conformation that resembles that of its native state. Although technically simple, 
the success of this approach is limited due to the reduced number of amino 
acids with which to form an epitope. Furthermore the use of a short peptide 
increases the chance of finding homology with other proteins, resulting in cross­
reactivity.
a Fusion proteins. A cDNA sequence is cloned into an appropriate expression 
cloning vector for expression in bacteria. The expression vector can confer 
properties such as the ability to be secreted into the extracellular medium or 
protection from degradation. This method has a higher success rate as the 
fusion protein contains most/all of the desired amino acid sequence (Strachan, 
T et al, 1999).
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If immunization is successful, the animal's immune system secretes the protein- 
specific antibodies into the serum. The serum also contains antibodies to the 
carrier protein and any other antigens to which the animal had been exposed. Thus 
the serum is a heterogeneous mixture of antibodies, each produced by a different 
B lymphocyte. Different antibodies recognize different epitopes of the immunogen, 
and so the serum is classed as a polyclonal antibody source. Monoclonal 
antibodies are produced by propagating a clone of cells from a single immortalized 
B lymphocyte (Strachan, T et al, 1999).
Whether using synthetic peptides or fusion proteins to generate an antibody, it is 
important that the peptide is hydrophobic. There are two main scales for examining 
the hydrophobic nature of a peptide: the Kyte-Doolittle scale and the Hopp-Woods 
scale (http://arbl.cvmbs.colostate.edu/molkit/hydropathy/). With the Kyte-Doolittle 
scale, peptide regions with values above 0 are said to be hydrophobic in character. 
For the Hopp-Woods scale, values greater than 0 are said to be hydrophilic. Both 
scales employ window sizes, referring to the number of amino acids examined at 
the time, when calculating antigen hydrophobicity. Window sizes can vary from 5 to 
25 and should be of a magnitude appropriate for the expected size of the structural 
motif under investigation:
• Window size of 5-7 is good for determining hydrophilic regions.
• Window size of 19-21 makes hydrophobic, membrane-spanning domains 
stand out clearly (typically > 1.6 on the Kyte-Doolittle scale).
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1.5.1.2.1.2 Polvclonal antisera production protocol
The polyclonal antisera production protocol is a multi-step process that in rabbits 
takes 77 days. On day zero a pre-bleed was taken from the animal, prior to 
injection with the antigenic peptide. The primary immune response results in low 
level production of predominantly IgM antibodies. A booster antigen innoculation 
was performed on day 14 and then again on day 28, with a test bleed/blood 
sample taken from the animal on day 35. The secondary immune response is 
much quicker, producing IgGs at a far greater level and for a longer period than 
that seen for the primary response (Roitt, I et al, 2001). Further booster antigen 
injections were given to the animal on days 42, 56 and 70 with test bleed recovery 
on days 49, 63, and the final harvest bleed on day 77. The antibody was not 
initially purified from the sera sample as this process can damage the antibody.
1.5.1.2.2 Techniques for the validation of synthesised antibodies
•  ELISA analysis
Unconjugated peptides are bound to ELISA plates and the preimmune bleed, 
individual test bleeds and harvest bleed are analysed at a variety of dilutions, to 
see if IgGs to the antigenic peptides have been produced.
•  Ouchterlony test
To detect whether any IgGs are produced during the synthesis protocol, antigenic 
proteins/immunoglobulins are placed in wells radial to the central antibody well, 
and allowed to diffuse through agarose and come into physical contact. If the
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antibody serum contains IgGs to an antigen in one of the radial wells, a visible 
precipitate is formed.
•  Immunolabelling and Western blotting 
In order to determine whether the antibody can detect and is specific for the protein 
it was raised against, tissue sections can be immunolabelled and protein extracts 
blotted.
1.5.2 Techniques for investigating protein interactions
Protein interactions techniques that use libraries or large numbers of candidate 
interacting-proteins, include mass spectroscopy, phage display and the yeast two- 
hybrid system. Individual possible interactions between proteins can then be 
further analysed using FRET (Fluorescence Resonance Energy Transfer), yeast 
mating and co-immunoprecipitation.
1.5.2.1 The yeast two-hybrid system
The yeast two-hybrid system employs yeast transcriptional activators, such as 
GAL4, that contain two distinct functional domains: a DNA-BD (binding domain) that 
binds to an upstream activation site (UAS) of the yeast genes and a transcriptional 
activation domain (AD) to drive the gene’s transcription. Yeast, unlike bacteria, can 
support the propagation of more than one plasmid having the same replication
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origin, i.e. there is no plasmid incompatibility issue in yeast. Therefore when these 
domains are expressed as spatially distinct fusions with candidate interacting 
proteins in yeast, these subunits may be brought into sufficiently close proximity to 
reconstitute normal function. This interaction can be measured as the activation of 
expression of specific reporter genes (Figure 1.23; Toby, G G et al, 2001). Since 
the test interaction happens within the nucleus of S.cerevisiae, it may produce 
some false positives for nuclear or membrane proteins, so any candidate positive 
interactors must be confirmed by alternative methods.
Figure 1.23 A schematic showing the basic steps involved in a yeast two-hybrid reaction.
(Figure adapted from Strachan, T et al, 1999)
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The yeast two-hybrid system is subject to a number of false positives and false 
negatives which must be detected during the screening process.
False Positives
■ Autoactivation of nutritional selective reporter genes by the untransformed 
yeast strains.
In the MATCHMAKER two-hybrid system, the bait and prey vectors carry 
nutritional reporter genes TRP1 and LEU2 respectively. The yeast strains 
themselves contain the reporter genes HIS3  and ADE2  which are only expressed 
when a protein-protein interaction occurs. LacZ a colourmetric reporter gene is also 
only expressed when a protein-protein interaction occurs. Prior to transformation 
and screening, the phenotypes of the yeast strains are examined under different 
growth conditions to ensure that none of the reporter genes can be expressed 
inappropriately.
■ Autoactivation of nutritional selective and colourimetric reporter genes by yeast 
transformed with the bait construct.
The phenotype of the yeast strain transformed with the bait is also examined under 
different growth conditions to ensure none of the reporter genes can be expressed 
inappropriately. It is understood that the HIS3  yeast promoters can be~‘leaky’ but 
this can be compensated for in transformed yeast, by the addition of the His3p 
inhibitory compound, 3-amino-1,2,4-triazole (3-AT) to the growth media.
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■ Inappropriate yeast mating
Yeast mating is the process by which multiple plasmids are introduced into a single 
yeast cell. One yeast strain of cassette type MATa expressing one plasmid, is 
incubated with a MATa cassette strain containing the other plasmid. At this point, 
one strain transfers its DNA to the other strain, allowing expression of both 
plasmids in one cell. Yeast mating control experiments are set up using the empty 
MATCHMAKER III vectors to ensure that the reporter genes will only express if an 
interaction occurs between bait and prey.
False Negatives
■ Incorrect production of bait fusion proteins
Interactions can be missed or false interactions found (false positives), if the fusion 
protein produced in the yeast is not the desired bait protein. Therefore the bait 
construct is sequenced before and after transformation into yeast, and yeast 
protein extracts on western blots are probed with tag-specific and bait protein- 
specific antibodies. The use of yeast protein extracts and/or certain antibodies can 
result in high background levels on western blots. In such cases, an in vitro 
translated (IVT) bait protein using the inbuilt T7 promoter in the bait vector, can be 
used as the bait protein source to try and minimise background levels.
■ Bait proteins are toxic to the host yeast cells
The growth rates of yeast transformed with the bait is compared to that of yeast 
transformed with the empty MATCHAKER III vectors. A reduction in growth rate
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would suggest that the bait fusion protein is toxic to the yeast and therefore 
inappropriate for screening.
■ Failure of yeast mating reactions
Yeast mating control experiments are set up using positive controls/known 
interactors to ensure that the reporter genes will express if an interaction does 
occur.
■ Non-representative amplification of prey library cDNA
The prey library to be screened must contain at least 106 independent clones to 
maximise the number of different protein interactions examined. Amplification of 
aliquots with insufficient volume must be representational, such that the same 
range and proportion of transcripts in the original cDNA library aliquot are 
maintained. Libraries in the pACT2 vector (Appendix 15), are known to be poor 
amplifiers in comparison to other GAL4 libraries (expected yields of plasmid DNA 
per 1 x 106 cfu: pACT2 Libraries = -0 .2 5  mg; all other MATCHMAKER GAL4 
Libraries = ~1 mg, (Y2H Protocols, Clontech)) and require maximum efficiency 
cells for transformation. The library titre (the number of independent clones per ml) 
is determined after amplification and must be >108 cfu/ml for plasmid libraries to 
ensure continued representation during screening.
■ Reduced transformation efficiency during bait generation and library screening. 
Library screening by co-transformation, can be accomplished either through the 
simultaneous transformation of both bait and prey plasmids into one cell, or
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through sequential transformation. Simultaneous co-transformation is generally 
preferred because it is simpler than sequential transformation. There is also the 
risk that expression of proteins encoded by the first plasmid may be toxic to the 
cells, thus should spontaneous deletion mutants arise that have a growth 
advantage, they will accumulate at the expense of true clones containing intact 
plasmids. On the other hand, if there is no selective disadvantage to cells 
expressing the first cloned protein, then sequential transformation may be 
preferred because it uses significantly less plasmid DNA than simultaneous co­
transformation.
The overall transformation efficiency for transformation with a single plasmid and 
for sequential co-transformations should be at least 1x104 cfu/pg. Simultaneous co­
transformation usually results in an efficiency an order of magnitude lower, due to 
the lower probability that a particular yeast cell will take up both plasmids. A low 
transformation efficiency would suggest that the bait construct is not optimal and 
during co-transformation, can reduce the number of library proteins screened and 
so possible interactions may be missed. Reduced transformation efficiency may be 
due to suboptimal carrier DNA; suboptimal yeast competent cells; a contaminant in 
the water that can affect transformation efficiency and/or cell growth; and 
suboptimal plasmid preparation (Yeast Protocols Handbook, Clontech). ~
■ Species incompatibility
Possible interactions may be missed if the prey library is screened with a bait 
protein of a different species. Alternatively this may lead to false positives.
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Therefore any possible interactions must be assessed further, using additional 
techniques.
1.5.2.2 Confirmation and further characterization of positive interactors
1.5.2.2.1 Sequencing of candidate interacting proteins
Once identified by the activation of the reporter genes, the identity of the preys 
must be determined by sequencing and database homology searches. PCR  
products can be produced using the yeast colony directly as template, extracting 
the yeast plasmid DNA first for use as PCR template or by transforming the 
plasmid in E.coli and using this amplified product as template.
Transformation of yeast plasmid DNA into bacteria can be problematic since the 
plasmid may be toxic to E. co//; may have integrated into the yeast genome and is 
therefore unable to replicate autonomously; or plasmid DNA may be absent from 
the extracted yeast DNA aliquot and may be contaminated with yeast 
chromosomal DNA. Furthermore there may have been insufficient lysis of the yeast 
cell during plasmid preparation or the yeast may have cannibalized their plasmids 
due to inhibitory growth pressures i.e. lack of aeration.
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1.5.2.2.2 Yeast mating
One of the main features of the yeast two-hybrid assay, aside from the fact that 
yeast are able to take up more than one plasmid at a time, is that each colony is 
able to shed plasmids that are not selected for. In order to confirm the protein- 
protein interactions in vivo by yeast mating, prey plasmids (-leu/+amp) can be 
segregated from the bait plasmids (-trp/+kan) in AH 109 cells. The interactions are 
then confirmed through mating analysis.
1.5.2.2.3 Co-im mu noprecipitation (CO-IP)
Immunoprecipitation is an in vitro technique that can be used to confirm and further 
characterize the nature of the interaction between suspected binding partners. An 
antigen is isolated from a sample e.g. cell lysate, through the formation of an 
immune complex with an antigen-specific antibody. The immune complex is then 
captured/precipitated on a solid support e.g. Protein A (a system that binds the 
antibody but not the antigen). Both of the components of the bound immune 
complex are then eluted from the support and analyzed by SDS-PAGE and 
Western blotting to identify the antigen. Co-immunoprecipitation is conducted in 
essentially the same manner as immunoprecipitation, however in this case the 
target antigen precipitated by the antibody “co-precipitates” a binding 
partner/protein complex from the lysate.
Problems associated with immunoprecipitations most commonly involve 
interference from antibody bands in gel analysis. In those cases where several 
proteins may be co-precipitated with the target, presence of the co-eluted antibody 
heavy and light chains (25 and 50 kDa bands in reducing SDS-PAGE gel) in the 
preparation can obscure the results. The use of fusion tags incorporated into the 
primary target protein for immobilization of the protein complex or for Western 
blotting purposes is thought to help minimise this background
(http://www.piercenet.com/).
The following chapters use the techniques discussed in section 1.5 to investigate 
harmonin localisation and interactions in the retina, in order to infer possible protein 
functions in the normal eye, and pathogenic mechanisms in Usher syndrome.
2 METHODOLOGY
The methods and techniques discussed in this chapter are adaptations of standard 
protocols used within this laboratory unless otherwise stated. Yeast two-hybrid 
techniques are adapted from the Yeast Protocols Handbook and Y2H 
MATCHMAKER III Protocols from Clontech. The pull down assay was adapted 
from methods supplied with the Pro-Found kit (Pierce).
2.1 Materials: Solutions
Detailed information on suppliers, solution recipes and strains used in this work 
can be found in the relevant appendices (Table 2.1).
Table 2.1 Index to Materials: Solutions data
Suppliers Appendix 1
Media Appendix 2
Buffers and solutions Appendix 3
Fixatives and cryopreservation buffers Appendix 4
Antibodies and cell labeling solutions Appendix 5
Agarose and SDS-PAGE gels Appendix 6
Escherichia coli (E.coli) strains Appendix 7
Yeast (Saccharomyces cerevisiae) 
strains
Appendix 8
Plasmids Appendix 9
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2.2 Materials: Technical
Detailed information on technical resources used can be found in the relevant 
appendices (Table 2.2).
Table 2.2 Index to Materials: Technical data
Equipment Appendix 10
Software Appendix 11
2.3 Determination of the temporal and spatial expression of Ushlc and 
harmonin within the normal murine eye
2.3.1 Methodology: Identification of the pattern of protein localisation of harmonin in 
the adult murine retina
2.3.1.1 Tissue preparation
2.3.1.1.1 Tissue collection
CD1, SV129, shaker-1 and waltzer mice were culled by cervical dislocation. Whole 
eyes from fetal, postnatal and adult mice were removed immediately after death 
and transferred to cold Phosphate Buffered Saline (PBS). Tissue for 
immunofluorescence studies was either embedding directly in Optimal Cutting 
Temperature compound (OCT) (Raymond A Lamb) on dry ice, or was fixed and 
cryoprotected prior to embedding (section 2.3.1.1.2). The lens was removed from 
tissue designated for Western blot analysis (section 2.4.4.2 - 2.4.4.3) or semithin
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sectioning (section 2.3.1.1.6). Fetal eyes were frozen in TRIZOL (Invitrogen) 
(0.5ml/10mg tissue) at -70°C overnight prior to use (section 2.3.3.2.1). All research 
involving animal tissue was carried out in accordance with EC directives and the
Institute of Child Health Research Ethics Committee.
2.3.1.1.2 Tissue fixation and crvopreservation
Tissue was dissected and fixed in fresh 4% paraformaldehyde (Appendix 5) at 4° 
overnight. Tissue was washed in Phosphate Buffered Saline (PBS) for 5 minutes, 
and then transferred to the cryoprotectant sucrose solution for overnight incubation 
or storage for up to one month at 4°C. Tissue was washed in PBS prior to 
positioning in the cryomould (L.I.P equipment services), covered in OCT and quick
frozen on dry ice and isopentane. Tissue was then stored at -80°C.
2.3.1.1.3 TESPA coating of slides
Coating of slides was carried out in a fume hood. Superfrost glass slides (BDH) 
were loaded into glass holders, then each was dipped for a minimum of 30 
seconds into successive 400ml glass troughs, containing 10%HCI/70% ethanol, 
diethylpyrocarbonate (DEPC)-water and 95% ethanol. Slides were then covered 
and dried in an oven overnight at 65°C. Holders were then dipped into glass 
troughs containing cold 2%TESPA (3-aminopropyltriethoxysilane) in acetone 
(BDH), acetone wash one, aceton^wash two and finally in DEPC-water, each for
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30 seconds. Slides were covered again and dried in a 45°C oven overnight. 
Coated slides were stored covered at room temperature.
2.3.1.1.4 Crvosectionina sectioning
Tissue was removed from the cryomold and affixed to the specimen holder of the 
OFT Cryostat with a 5040 microtome (Bright) using OCT. The blade and cryostat 
were precooled to -15 and -20°C respectively, with a knife angle of 15°. 10pm 
sections were cut and placed on TESPA coated superfrost slides (2.3.1.1.3). 
Sections were allowed to dry overnight at room temperature and then frozen at -  
80°C.
2.3.1.1.5 Processing and UV light curing of LR gold resin
Freshly dissected eyes minus the lens (section 2.3.1.1.1), were fixed in 2% PFA in 
PBS for 1 hr at room temperature. Tissue underwent three, 5 minute washes, in 
PBS and then was dehydrated for 10 minutes periods in graded alcohols of 30%, 
50%, 70%, 95%, and 100%. Tissue was transferred to 50% London Resin (LR) 
gold (Agar Scientific): 50% absolute alcohol for 1hour, then to 100% LR gold for a 
further 1 hour. Tissue was incubated over night in 100% LR gold + 0.2% Benzoin 
methyl ether (which acts as an initiator for the polymerization reaction), then 
transferred to gelatin capsules fully filled with resin mixture and polymerized in the 
freeze substitution polymerization apparatus (RMC) at -30 °C  by overnight UV 
irradiation.
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2.3.1.1.6 Semithin sectioning
The tissue specimen, embedded in the polymerized resin, was locked into the 
specimen holder and locked in the upright horizontal position of an ultracut E 
microtome (Reichert). Thin layers of resin were removed manually using a scalpel 
until the tissue was reached. The specimen holder was returned to its original 
stand and positioned parallel to the fresh glass knife surface (produced by user). A  
wax boat was added to the knife, sealed with wax and filled with water. Semithin 
sections of 1pm were cut until the surface of the specimen was flat and the 
sections produced, even and complete. A fresh ribbon of semithin sections was 
then cut and retrieved from the boat using human eyelashes (provided by user). 
Sections were mounted on uncoated glass slides (BDH) using water, dried on a hot 
plate for 30 secs and then stained using a 2% methyl blue solution in borax.
2.3.1.2 Harmonin localisation in the adult murine retina
In all immunostaining experiments, the slides were removed from storage at -80°C  
and thawed at room temperature. Boundaries around each section were 
established using a PAP PEN (The Binding Site) to minimize the volume of 
antibody used per slide. The slides were washed in PBS for 2 minutes to remove 
the OCT, prior to immunolabelling.
All sections immunostained in sections 2.3.1.2, 2.3.1.3 and 2.3.2 were analysed 
using an epifluorescent microscope (Axioplan 2, Zeiss), and images captured using 
Openlab software (Improvision), before transfer to Adobe Photoshop.
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2.3.1.2.1 Single antibody staining of fixed tissues
Fixed adult CD1 retinal cryosections were blocked with 4% goat serum (Santa 
Cruz Biotechnology Inc.) + 1% Tween 20 in PBS for 2 hours at room temperature. 
Sections were gently washed in PBS and then incubated at 4°C overnight, with the 
anti-harmonin rabbit polyclonal antibody (Kobayashi et al 1999) diluted 1:100 in 
PBS and 1% goat serum (Santa Cruz Biotechnology Inc.). After washing, 
sections were incubated in the dark with FITC (Fluorescein isothiocyanate) 
conjugated anti-rabbit IgGs antibody (Vector Laboratories) diluted to 1:50 in PBS 
and 1% goat serum, for 2 hours at room temperature. A nuclear counter stain was 
provided by 30 minutes incubation with Hoechst at 1:200 in PBS, at room 
temperature in the dark. Internal retina structures containing F-actin were 
visualized on alternative retinal sections by incubation with 1:50 Rhodamine 
conjugated Phalloidin (Molecular Probes) at room temperature for 20 minutes. 
Sections were washed and slides partly air dried before mounting with Citifluor 
(Citifluor Ltd) mounting media. Stained sections were stored at 4°C.
Negative control sections substituted the anti-harmonin antibody for PBS or rabbit 
IgGs (data not shown), but were visualized and counter stained as previously 
described.
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2.3.1.2.2 Double antibody staining of fixed tissues
Double immunostaining with the polyclonal anti-harmonin antibody, and the 
photoreceptor outer segment labelling anti-rhodopsin antibody (Santa Cruz), used 
a 4%  horse serum (Vector Laboratories) solution supplemented with 1% TWEEN  
20 as blocking solution. Tissues were incubated with blocking solution at room 
temperature for two hours before washing and then incubating with the primary 
antibodies overnight at 4°C. All antibodies were diluted in blocking serum. The 
polyclonal anti-harmonin antibody was diluted 1:100 and the anti-rhodopsin at 1:50. 
The anti-harmonin antibody was detected using a biotinylated anti-rabbit IgGs 
antibody (1:100) (KPL) that was pre-conjugated to an avidin D- rhodamine antibody 
(Vector Laboratories) (1:100) at 37°C for one hour. The anti-rhodopsin antibody 
was detected using an anti-goat IgGs antibody conjugated to FITC (Jackson 
Laboratories) which was incubated at room temperature for four hours at 1:50. 
After immunolabelling; the cell nuclei were labelled using Hoechst nuclear stain 
(section 2.3.1.2.1), prior to air drying and mounting using Citifluor.
Negative control sections substituted the anti-harmonin and anti-rhodopsin 
antibodies for PBS.
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2.3.1.3 Methodology: Investigation into the effects of fixation upon harmonin 
localisation
Unfixed adult CD1 retinal sections were collected and cryosectioned (section 
2.3.1.1.1, 2.3.1.1.3 and 2.3.1.1.4). Sections were immunostained as described by 
Reiners, J et al, 2003, using polyclonal anti-harmonin (1:50), anti-myosin VIIA  
(1:50) (Affinity BioReagents) and anti-cadherin 23 (1:50) (Bolz, H et al, 2002). 
Negative controls substituted the primary antibodies for PBS. After 
immunolabelling; the cell nuclei were labelled using Hoechst nuclear stain (section 
2.3.1.2.1), prior to air drying and mounting using Citifluor.
2.3 .2Methodology: Examination of the protein localisation of harmonin in the 
absence of myosin VIIA and cadherin 23
Shaker-1 and waltzer eyes were collected and sectioned (section 2.3.1.1), then 
immunostained with the polyclonal anti-harmonin antibody (section 2.3.1.2.1). 
Negative control sections substituted the anti-harmonin antibody for PBS.
2.3.3 Methodology: Determination of the age of onset of Ush 1c gene expression
2.3.3.1 Harmonin localisation in the postnatal murine retina
The retinas from P2, P4, P8 & P12 CD1 mouse pups were collected, sectioned 
(section 2.3.1.1) and immunostained with polyclonal anti-harmonin antibody 
(section 2.3.1.2.1) to study the onset of harmonin expression during development.
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Negative control sections substituted the anti-harmonin antibody for PBS or rabbit 
IgGs (data not shown). Semithin sections (2.3.1.1.5 - 2.3.1.1.6) were also collected 
to study the structure of the developing retina during this time period.
Immunolabelled sections were analysed using a laser scanning confocal 
microscope (SP2 Leica), with projection images gathered at 0.3pm throughout the 
whole section, using Leica Confocal Software (version 2.5), before transfer to 
Adobe Photoshop. Semithin sections were analysed using a light microscope 
(Axioplan 2, Zeiss), and images captured using Openlab software (Improvision).
2.3.3.2 U shlc  expression in the prenatal murine retina
2.3.3.2.1 Isolation of total RNA
All RNA isolation techniques used RNase free solutions (including DEPC H2O 
(Appendix 3) and equipment. Freshly dissected tissue (section 2.3.1.1.1) was 
incubated overnight at -20°C/-70°C in 0.5ml TRIZOL per 10mg tissue. Once 
thawed, tissue was homogenized in a falcon tube using a hand-held homogeniser 
(Kontes). A further 0.5ml TRIZOL/10mg tissue was added, before incubation at 
room temperature for 5 minutes. 0.2ml chloroform/1 ml TRIZOL was then added to 
the tissue sample and mixed by shaking the tubes by hand for 15 seconds, before 
incubation at 15-30°C for a further 2-3 minutes. Tubes were centrifuged in a bench 
top centrifuge (Jencons PLC) at 12000g/10000rpm for 30 minutes at 4°C to 
separate the coloured organic layer containing DNA and protein, from the upper 
colourless layer containing the RNA. The aqueous phase was added to another
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RNase free tube and another chloroform separation was performed as previously 
described, using 0.2ml chloroform/1 ml TRIZOL. The aqueous layer was again 
removed to a new tube and 0.5ml isopropyl alcohol/1 ml TRIZOL was added, 
vortexed and then the RNA was precipitated out of solution overnight at -20°C. 
Tubes were centrifuged at 12000g/10000rpm for 10 minutes at 4°C, then the 
supernatant was removed and the RNA pellet washed with cold 75% ethanol,
1 ml/1 ml TRIZOL. The tube was again vortexed and centrifuged at 7500g/6000rpm  
for 5 minutes at 4°C. The pellet was partially air dried and then re-dissolved in 
RNase free water by incubating the tube at 55-60°C for 10 minutes. Total RNA 
concentration was measured by UV spectroscopy (section 2.5.1.2.3) and the RNA 
stored at -20°C.
2.3.3.2.2 Two-step Reverse Transcription Polymerase Chain Reaction (RT-PCR)
To produce cDNA, 1pg of total RNA was incubated with 1 pi DNase 1 enzyme, 1pl 
10x buffer and RNase free ddiH20  to a total volume of 13pl at room temperature 
for 15 minutes. DNase 1 was deactivated by the addition of 2.5pl 25mM EDTA 
(pH8), and then incubated for 10 minutes at 65°C. 1pl of both an oligo dT primer 
and a random nonamer primer were added and the solution incubated for a further 
10 minutes at 70°C. The tube was rapidly chilled on ice, then 4pl 5x First Strand 
Buffer, 1pl 0.1M DTT, 2pl 10mM dNTP (deoxyribonucleotide triphosphates) and 1pl 
RNase Inhibitor were added, pulse spun on a bench top centrifuge, and heated for
2 minutes at 42°C. After which, 1pl Superscript III RT enzyme was added and the 
enzyme mixture incubated for 5 minutes at 25°C and then for 50 minutes at 42°C.
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The enzymes were deactivated by heating for 15 minutes at 70°C and the resulting 
cDNA stored at -20°C. The quality of the cDNA was examined by Touchdown 
PCR (section 2.5.1.2.6) for a total of 35 cycles, using primers to the housekeeping 
gene Gapdh (Appendix 13).
The age of onset of U shlc  expression was examined in the second stage of the 
RT-PCR reaction, using U shlc  specific primers (Appendix 13). A standard 25pl 
PCR reaction using Hot star taq (Qiagen) instead of Bioline taq, with a Touchdown 
thermocycler program of 40 cycles was used to produce an amplimer at all ages 
tested (section 2.5.1.2.6). To compare USH1 gene expression the PCR  
amplification step must be semi-quantitative, meaning that readings must be taken 
using the cycle number which first shows product production. An aliquot of PCR  
reaction mix was removed after cycle 25 and after each subsequent cycle. Aliquots 
were electrophoresed on 2% agarose gels (section 2.3.3.2.2.1), to determine the 
cycle number required to first detect the appearance of the PCR product. The 
same PCR reaction mix was used with the following thermocycler program 
(95°C/20 secs, 52°C20 secs; 72°C/30 secs) and primer pairs to Myo7a, Cdh23, 
Pcdh15 and U shlc  (Appendix 13). Gapdh first appeared at 28 cycles and the 
USH1 genes at 35 cycles.
Products were electrophoresed on 2% agarose gels and images captured on the 
transilluminator using the same imaging conditions for each gene. The product 
band intensity/mm2 was calculated for each primer pair at each developmental
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stage, and normalized to Gapdh expression. PCR amplification reactions were 
carried out in triplicate, using multiple cDNA preparations.
2.3.3.2.2.1 Aaarose ael electrophoresis
Ultra pure agarose powder (Invitrogen) was mixed with 1XTBE buffer at a w/v 
concentration to produce the desired percentage gel (Appendix 6). The resulting 
suspension was heated in a microwave oven until the agarose was dissolved. On 
cooling, Ethidium bromide (0.5pl/ml) was added and the gel poured into a Hybaid 
gel tray with the appropriate well forming comb. Once set, 10pl of PCR product 
was diluted with 5pl of loading buffer (Appendix 3), loaded onto the gel and the gel 
electrophoresed at 75 amps for 20-40 minutes. The gel was transilluminated and 
photographed under UV light using the Bio-Rad Transgenomic™ Chemidoc 
system. The size of the amplified product was compared to DNA standards 
(various ladders from Invitrogen, see specific figure legends), loaded at the same 
time as the PCR product.
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2.4 Generation of polyclonal antibodies to harmonin isoforms
2.4.1 Selection of the antigenic peptides for anti-harmonin antibody synthesis
The sequences of the peptides used to raise the isoform-specific anti-harmonin 
antibodies and their locations relative to the 3 PDZ domains of murine isoform ‘a \  
is show in Figure 2.1 A. Peptide 1 could be used to detect all three isoform classes 
of harmonin, whilst peptide 2 would detect only isoform classes ‘a’ and ‘b’. 
Differences between the immunostaining data obtained for each antibody would 
highlight the specific pattern of localisation of the class ‘c’ isoform.
A comparison of the murine and human sequences of both peptides (Figure 2.1B) 
would suggest that antibodies raised to peptide 1 would be suitable for 
immunostaining murine or human tissue, whereas antibodies raised against 
peptide 2 would be more effective on murine tissue only.
102
Figure 2.1 Selection of Peptide 1 and 2
(A) The complete amino acid sequence of human harmonin isoform ‘a’ (NCBI AAG12457). The 
three PDZ domains are highlighted in red and the chosen peptides are underlined within the 
sequence. (B) A comparison of the human and murine amino acid sequence of the two peptides 
chosen by Sigma-Genosys for antibody production. The cysteine residues enclosed in square 
brackets are not part of the murine harmonin sequence but were added by Sigma-Genosys to 
enable conjugation to the carrier protein.
A
MDRKVAREFRHKVDFLIENDAEKDYLYDVLRMYHQTMDVAVLVGDLKLVINEPNRLPLFDAIRPLIP
LKHQVEYDQLTPRRSRKLKEVRLDRLHPEGLGLSVRGGLEFGCGLFISHLIKGGQADSVGLQVGDE
IVRINGYSISSCTHEEVINLIRTKKTVSIKVRHIGLIPVKSSPEESLKWQYVDQFVSESGGVRGGLGSP
GNRTTKEKKVFISLVGSRGLGCSISSGPIQKPGIFVSHVKPGSLSAEVGLETGDQIVEVNGIDFTNLD
HKEAVNVLKSSRSLTISIVAGAGRELFMTDRERLEEARQRELQRQELLMQKRLAMESNKILQEQQE
MERQRRKEIAQKAAEENERYRKEMEQISEEEEKFKKQWEEDWGSKEQLILPKTITAEVHPVPLRKP
KYDQGVEPADHLDGSTEEQRQQDFRKYEEGFDPYSMFSPEQIAGKDVRLLRIKKEGSLDLALEGG
VDSPVGKWVSAVYEGGAAERHGGVVKGDEIMAINGKIVTDYTLAEAEAALQKAWNQGGDWIDLV
VAVCPPKEYDDELTFF
B
Mouse sequence Human sequence
Peptide 1 LTPRRSRKLKEVRLD[C] LTPRRSRKLKEVRLD
Peptide 2 [C]PADHLDGSTEEQRQQ PADDLDGGTEEQGEQ
2.4.2 Methodology: Analysis of the anti-harmonin antibodies by ELISA 
Peptide 1 was diluted to 20/vg/ml in PBS. 50//I of this was added to enough wells 
of a flat bottom 96-well plate (Nunc), to allow for examination of a variety of 
antibody sera concentrations for each bleed and also to allow for blank controls. 
The plate was sealed with a transparent plate sealer (ABgene) and incubated at 
4°C overnight. The plate was then washed four times, each time adding 300/vl of 
PBS to each well and completely emptying the wells each time before the next 
wash. The wells were blocked using 300/vl of 5% non-fat powdered milk (Marvel) 
as blocking buffer, and incubated, shaking (200rpm) at room temperature for 2
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hours. The plate was then washed a further four times, as above in PBS. 50pl of 
serum from each of the LTPR bleeds was diluted in blocking buffer (in the range of 
1:100 -  1:10000) and added to the blocked wells. Controls substituted PBS for 
serum. The plate was incubated, shaking at room temperature for a further 2 
hours, after which it was washed four times in PBS as previously described. 50pl of 
anti-rabbit IgG antibody conjugated to horse-radish-peroxidase (HRP) (Amersham 
Pharmacia) was diluted in blocking buffer, added to the wells and then incubated 
shaking at room temperature for 2 hours. The plate was washed again as 
previously described before development of the ELISA. 50pl of PNPP substrate 
solution (p-Nitrophenyl phosphate), was added per well and incubated stationary at 
room temperature for 40 minutes. On addition of the substrate, positive results 
(where peptide 1 -  anti-LTPR antibody complexes have formed) turn yellow and 
the absorbance of the well can be read at 405nm on a Multifunction Microplate 
Reader (Genois, TECAN) with XFIuor4 software (TECAN). The ELISA reading 
must be 0.3 units greater that the background reading (bound antigen and buffer 
only) to be valid.
The same ELISA protocol was repeated for peptide 2 using the PADH bleeds.
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2.4.3 Methodology: Analysis of the anti-harmonin antibodies by immunolabelling of 
murine retinas
P10 CD1 murine eyes were collected, fixed and cryosectioned (section 2.3.1.1). 
Sections were blocked with 4% goat serum + 1% Tween 20 in PBS for 2 hours at 
room temperature. Sections were gently washed in PBS and then incubated at 
4°C overnight; with the anti-harmonin rabbit polyclonal antibody (positive control) 
diluted 1:100 in PBS and 1% goat serum. After washing, sections were incubated 
with FITC conjugated anti-rabbit IgG secondary antibody diluted to 1:100 in PBS 
and 1% goat serum, for 4 hours at room temperature in the dark. Rabbit serum 
(Santa Cruz Biotechnology Inc.) at 1:100 was substituted for the primary antibody 
as a negative control, and visualized with FITC conjugated anti-rabbit IgG 
secondary antibody as above.
Sections were incubated with anti-LTPR or anti-PADH unpurified sera at 1:2, 1:5, 
1:10, and 1:20 dilutions then incubated with FITC conjugated anti-rabbit IgG as 
previously described. Sections were washed in the dark, then further incubated 
with an anti-FITC antibody (Rockland) at 1:100 for 1 hour at room temperature to 
further amplify any signal. This and the following incubations were carried out in 
the dark. Sections were washed and then incubated again for a further 1 hour at 
room temperature, with anti-goat IgGs antibody conjugated to Cy5 (1:50) 
(Rockland) for visualization by confocal microscopy. Sections were washed, air 
dried and then mounted with Citifluor.
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Control sections were visualized using an epifluorescent microscope (Axioplan 2), 
and images captured using Openlab software (Improvision). Anti-LTPR and anti- 
PADH labelled sections were analysed using a laser scanning confocal microscope 
(SP2 Leica) and single images captured using Leica Confocal Software (version 
2.5), before transfer to Adobe Photoshop.
2.4.4 Methodology: Analysis of the anti-harmonin antibodies by immunoblotting 
analysis
2.4.4.1 Preparation of protein samples
2.4.4.1.1 Protein extraction from cells
Prior to protein extraction, cell lines had to be recovered from cryostorage, grown 
to confluence and then harvested (2.4.4.1.1.1 - 2.4.4.1.1.2). R28 is an adherent 
retinal precursor cell line derived from postnatal day 6 Sprague-Dawley rat retina 
immortalized with the 12S E1A gene of an adenovirus (Sun, W  et al, 2002). Caco2 
is also an adherent cell line, derived from an isolated primary human colonic tumor 
(www.sigmaaldrich.com).
2.4.4.1.1.1 Crvostoraae and recovery of mammalian cell lines
R28 adherent cells were frozen in liquid nitrogen for long term storage purposes. 
Cells at 95%-100% confluence were harvested from the flask surface, as described 
for trypsinisation (section 2.4.4.1.3) Cells were pelleted by centrifugation at 41 Og, at
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room temperature for 5 minutes (Pattemson Scientific, EBA 12). Cells were 
resuspended in 3mls 20% fetal calf serum supplemented with 10% dimethyl 
sulfoxide (DMSO) (added very slowly) as a cryoprotectant. 1ml aliquots of cell 
suspension were added to cryogenic vials (Nalgene). All vials were placed in a 
polystyrene container packed with cotton wool and frozen at -80°C for 16-24 hours 
before transferring to the liquid nitrogen cell bank for long-term storage.
After removal from liquid nitrogen, cells were rapidly defrosted by incubation at 
room temperature for 1 minute and then transferred to a 37°C water bath for 1-2 
minutes until thawed. The cells were immediately transferred into 12mls prewarmed 
growth medium and incubated under normal conditions for 16-18 hours (section 
2.4.4.1.3). Growth medium was changed on the next day to remove any remaining 
DMSO.
2.4.4.1.1.2 Maintenance of R28 cells and trypsinisation
Cells were grown in vented medium culture flasks (Corning Incorporated) in 
DMEM+L-glutamine, supplemented with 10% fetal calf serum (PAA), 1% MEM  
vitamins (Gibco), 1% MEM non-essential amino acids (Gibco) and 0.125%  
Gentamicin (from an 80mg/ml stock). Cells were fed with prewarmed ~12mls 
media and incubate in a 37°C, 5% C 0 2 incubator (Heraeus). Cells were fed or 
trypsinized/passaged every 2-3 days.
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Media was removed from confluent flasks needing to be passaged, and cells were 
washed with sterile PBS, which was in turn removed. 1.5mls of prewarmed trypsin 
was washed over the cells and then the flask placed back in the 37°C incubator 
until the cells were no longer adhered to the flask surface. 10mls of medium was 
added to the flask to block the action of the trypsin and cell clumps were separated 
by pipetting. 2mls of trypsinised cells were added to 10mls of media in a fresh 
flask and re-incubated to maintain the cell line.
2.4.4.1.1.3 Protein extraction from cells
Media was removed from confluent cells, which were washed twice with 5mls 
aliquots of cold sterile PBS. Wash buffer was completely removed and then 100- 
300pl of freshly prepared ice cold RIPA buffer (Appendix 3) with 2pl 50x protease 
inhibitor cocktail (Appendix 3) per 100pl RIPA buffer was added. Flasks were 
incubated on ice for 5mins, and then cells were scrapped from the flask surface 
and collected in ice cold eppendorfs. Cell membranes were completely lysed 
through passage of the cell suspension through a 21G needle a few times and then 
centrifuged for 30mins at 13,000g. The supernatant was transferred to a fresh tube 
and stored at -70°C.
2.4.4.1.2 Protein extraction from tissue
The hand-held homogenizer was washed with 10mls of ddiH20. Fresh ice cold RIPA 
buffer was prepared (1ml required per 50-1 OOmg tissue) (Appendix 3) 
supplemented with 2pl 50x protease inhibitor cocktail (Appendix 3) per 100pl RIPA
108
buffer. Tissue was collected (section 2.3.1.1.1) and homogenized in the 
supplemented RIPA buffer in a round bottom falcon tube on ice for 2 minutes. The 
homogenizer was cleaned in 40mls of ddihfeO whilst the supernatant from the 
homogenized tissue sample was transferred to another eppendorf and passed through 
a 21G needle a few times to completely lyse cell membranes. The sample was 
incubated on a rotator (Stuart Scientific) at 4°C for 30mins and then centrifuged at 
13000rpm at 4°C for 20mins (Jencons PLC). The supernatant was transferred to a 
fresh eppendorf, supplemented with lOpI of PMSF (Phenylnisthyl-sulfonyl fluoride) and 
stored at -80°C.
2.4.4.1.3 Calculation of protein concentration by the Bradford method
Two sets of BSA protein standards, concentrations 1 mg/ml, 0.5mg/ml, 0.25mg/ml, 
0.125mg/ml, 0.0625mg/ml, were prepared and kept on ice alongside a ddihfeO control. 
A range of dilutions of the experimental protein samples was set up and added to the 
ice. The dye (BioRad) for the Bradford assay was diluted 1:5 with ddihfeO and filtered 
through filter paper. 5pl of dye was added to 100pl of protein standard/sample, 
vortexed and then incubated at room temperature for 5mins - 1  hour. The absorbance 
of samples was measured at 595nm. The standards were used to create a calibration 
curve (Excel, Microsoft) from which to calculate the protein concentration of the 
experimental samples.
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2.4A .2  SDS-PAGE and electrotransfer of proteins onto nitrocellulose membranes
SDS-PAGE (Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis) mini­
protein gel plates (BioRad) were cleaned with detergent and ethanol (Hayman). 
~10mls resolving gel of the appropriate % (Appendix 6, Table 2.3) was poured 
between the plates, leaving room for ~2mls stacking gel and the exposed gel 
surface covered with N-butanol. Once the resolving gel had polymerized, the N- 
butanol was removed and the gel surface washed with ddiH20 . The ddiH20  was 
removed and the stacking gel layer pipetted on top of the resolving gel. A 10 or 15 
well comb was added and the gel left to polymerize at room temperature. When 
both gels were set, the comb was removed and the wells washed out with running 
buffer (1xTGS). The gel was loaded into the gel tank (Mini-PROTEAN II cell, 
BioRad) and running buffer added according to the manufacturer’s instructions 
(BioRad).
Protein samples were denatured for 20mins at 60°C in the appropriate volume of 
6x Lamelli loading buffer (Appendix 6). Denatured protein samples were kept on 
ice until ready to load on the SDS-PAGE protein gel alongside 10pl of a pre­
stained protein ladder (BioRad & Fermentas). The gel was electrophoresed at 
200V for~45-75 minutes (Power Pac 200, BioRad).
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Table 2.3 Separation ranges of proteins in different percentages of denaturing SDS- 
PAGE Gels (Sambrook, J. et al, 1989)
Protein range to be detected (kDa) % denaturing SDS-PAGE
>250 4-5
250-120 7.5
120-50 10
70-30 13
<40 15
Whilst the gel was running, the Bio-Ice cooling unit (BioRad) was filled with ddihfeO 
and frozen at -70°C. Transfer filter papers (Whatman) and fiber pads (BioRad) 
were equilibrated in Transfer buffer (Appendix 3) for 30mins at 4°C. Once 
electrophoresis was complete, the layer of stacking gel was cut from the SDS- 
PAGE gel. This was placed in the transfer sandwich as follows: fiber pad, 2x filter 
papers, SDS-PAGE gel, nitrocellulose membrane (Hybond ECL, Amersham), 2x 
filter papers and a fiber pad. The sandwich was positioned in the Electrode 
module of the Mini Trans-Blot® Electrophoretic Transfer Cell (BioRad) in order to 
transfer the protein from the gel to the membrane using electric current. The 
electrode module was placed within the transfer cell according to the 
manufacturer’s instructions, the frozen Bio-Ice cooling unit added, and then the cell 
filled with cold transfer buffer and electrophoresed at 100V for 1 hr.
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Once transfer was complete as witnessed by the transfer of the pre-stained protein 
standards from the gel to the membrane, the membrane was removed from the 
sandwich and washed in PBS (Appendix 3), keeping the protein side, face up. Any 
excess membrane was removed and the top left-hand corner marked to determine 
orientation.
2.4.4.3 Western blotting with monoclonal and polyclonal anti-harmonin
~100mg R28 cell lysate (-2 4  mg/ml), ~80mg Caco2 cell lysate (-2 2  mg/ml) (kindly 
donated to this work by Dr Blaydon of this lab), ~100mg whole eye homogenate 
(-2 5  mg/ml) and 2pL USH1C IVT (section 2.5.6.1.1) using a PDZ 73 construct with 
a Sp6 promoter (kindly donated to this work by Dr Blaydon of this lab) as template 
with the Sp6 TNT® IVT Kit), were run on a 15% SDS-PAGE gel (Appendix 6) and 
electrotransferred (section 2.4.4.2J. The membrane was blocked for 1 hour at room 
temperature on a rotator (Stuart Scientific), in 5% Marvel milk + 0.1% TW EEN 20 in 
PBS to minimize non-specific binding of antibodies used to visualize proteins on 
the membrane. The membrane was then washed (3x 5mins and 1x 15mins 
rotating incubation with PBS-T (Appendix 6)). In a fresh falcon tube, one half of the 
membrane was incubated with monoclonal anti-harmonin diluted to 1:1000 in PBS- 
T, overnight at 4° C. After which it was washed again as above, before incubating 
for one hour at room temperature with biotinylated anti mouse IgGs (KPL) diluted 
to 1:500, washed and finally, with Streptavidin conjugated to alkaline phosphatase 
(AP) (Promega) diluted to 1:2500, at room temperature for a further one hour. The 
other half of the membrane was incubated with polyclonal anti-harmonin at 4° over
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night, diluted to 1:500. After which it was washed, incubated for one hour at room 
temperature with biotinylated anti rabbit IgGs (KPL) at 1:750, washed again and 
then with incubated for a further 1 hour at room temperature with the streptavidin- 
AP antibody, diluted to 1:2500. Membranes were washed 2x 1min in PBS and then 
1x 2min in ddihhO. Western blots were developed using the ProtoBlot® Western 
Blue® Stabalised Substrate (Promega) at room temperature until the required 
colour developed. The reaction was stopped by washing in tap water.
2.4.4.4 Western blotting with anti-LTPR serum
2pL USH1C IVT and ~100mg whole eye homogenate were run on a 15% SDS- 
PAGE gel and electrotransferred (section 2.4.4.2). Immunoblotting on one half of 
the membrane was carried out exactly as described in section 2.4.4.2, with the 
polyclonal anti-harmonin antibody as a control. The other half of the membrane 
was immunoblotted using the following antibodies: anti-LTPR sera diluted to 1:100 
and incubated overnight at 4° C, followed by biotinylated anti rabbit IgGs diluted to 
1: 1000 for one hour at room temperature, and finally with streptavidin-AP diluted 
to 1:2500 at room temperature for a further one hour.
2.4.4.5 Protein purification from serum
2.4.4.5.1 Isolation of immunoglobulins from serum
Immunoglobulins (IgGs) were isolated from anti-LTPR whole serum according to 
the manufacturer’s instructions (KPL) as summarized below. 40ml of
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Wash/Binding Buffer (final 1x concentration, 0.1M Sodium Phosphate, 0.15M NaCI, 
pH 7.4) was diluted to 1x in ddiH20 . A minimum buffer volume of 30x the quantity 
of agarose used for purification was required. Elution Buffer (final 1x concentration, 
0.2M Glycine, pH 3± 1.85) was diluted to 1x in ddiH20 , to achieve a final volume of 
4x the quantity of agarose used. The column was prepared according to the 
manufacturers instructions, using 20% ethanol to force all air from the frit that was 
inserted into the bottom of the column barrel. The end of the column was clipped 
to allow liquid to flow through, and the frit was washed five times using a column 
volume (CV) of 1x Wash/Binding Buffer per wash. The column volume was 
calculated according to the amount of resin used in the purification process (1ml 
resin = 1ml CV). 1ml of resin per 500pl serum was suspended in 1x Wash/Binding 
Buffer at a 1:1 ratio. The slurry was poured into the column and buffer allowed to 
flow out by gravity. The resin was equilibrated with ten CV of the 1x wash/binding 
buffer. The absorbance of the eluate at 280nm was measured to calculate the 
background level.
5Q0pl of serum was diluted 1:1 with binding buffer to insure proper ionic strength 
and pH for optimal binding to the beads. Any particulate matter was removed by 
filtration through a 0.8pm filter. The sample was layered onto the top of the resin, 
without disturbing the bed surface itself. The column was washed with ton CV of 1x 
Wash/Binding buffer (or until the absorbance of the eluate at 280nm approached 
the background level). Eight eppendorfs were set up to catch the eluted IgGs in 
500pl aliquots. 120pl 5X Wash/Binding Buffer was first added to each collection 
tube. Then the anti-LTPR IgGs were eluted using 1ml of 1x Elution buffer at a time,
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collecting the flow-through until a total of four CV passed through the column. 
Elution of bound IgGs was monitored by absorbance at 280nm.
2.4.4.5.2 Column regeneration
Once the sample had been eluted, the column was regenerated according to the 
manufacturer’s instructions. The resin was washed with two CV of Elution buffer, 
then re-equilibrated with at least ten CV of 1x Wash/Binding Buffer. To confirm that 
equilibration was successful, the pH of both eluate and Wash/Binding Buffer were 
taken and found to be the same. The resin was stored in storage buffer in the 
sealed column at 2-8°C.
2.4.4.6 Western blotting with purified anti-LTPR IgGs and unpurified anti-LTPR 
serum
2pL USH1C IVT, ~100mg R28 cell lysate (~24 mg/ml) and ~80mg Caco2 cell 
lysate (-2 2  mg/ml) were run on a 15% SDS-PAGE gel and electrotransferred 
(section 2.4.4.2). Immunoblotting on one third of the membrane was carried out 
exactly as described in section 2.4.4.3, with the monoclonal anti-harmonin antibody 
as a control. The next third of the membrane was immunoblotted using the 
following antibodies: unpurified anti-LTPR serum diluted to 1:100 and-incubated 
overnight at 4° C, followed by biotinylated anti rabbit IgGs diluted to 1: 1000 for one 
hour at room temperature, and finally with streptavidin-AP diluted to 1:2500 at 
room temperature for a further one hour. The last third used purified anti-LTPR
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IgG (aliquot 2) diluted to 1:100 and incubated overnight at 4° C, followed by 
biotinylated anti rabbit IgGs diluted to 1:1000 for one hour at room temperature, 
and finally with streptavidin-AP diluted to 1:2500 at room temperature for a further 
one hour.
2.4.4.7 Western blotting with pre-absorbed purified anti-LTPR IgGs and unpurified 
anti-LTPR serum
To ensure that any bands seen on the blot are specific for harmonin, aliquots of the 
unpurified and purified anti LTPR antibody were incubated with an excess of 
peptide 1 (1 mg/ml), at room temperature for 1 hour. Peptide 1 acts to pre­
absorbed the antibody and therefore when incubated with the blots, it prevents the 
antibody from complexing with the harmonin protein. Therefore if identical 
experiments were performed using the standard development methods, harmonin 
should be detected on the standard blot but the band should be missing on the pre­
absorbed blot if anti LTPR is truly detecting the harmonin protein. 2pL USH1C IVT, 
~100mg whole eye homogenate and ~80mg Caco2 cell lysate ( -2 2  mg/ml) were 
run on a 15% SDS-PAGE gel and electrotransferred (section 2.4.3). Sections of 
membrane were probed with normal anti-LTPR serum (section 2.4.4.4), pre­
absorbed anti-LTPR serum (section 2.4.4.6), normal anti-LTPR IgGs (section 
2.4.4.6) and pre-absorbed anti-LTPR IgGs (section 2.4.4.6).
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2.4 .5Methodology: Analysis of antigenic peptide hydrophobicity
Kyte-Doolittle plots were issued for each peptide using a window size of 7. The 
complete harmonin protein was also examined, using both hydrophilicity scales 
and a window size of 20.
2.4 .6Methodology: Investigation into the presence of anti-harmonin IgGs in the 
anti-LTPR antibody sera
Antigenic proteins/immunoglobulins are able to diffuse in a 360° formation through 
agarose. If the antigen and antibody come into physical contact under these 
conditions, they will form a visible precipitate arc equidistant between the two wells. 
This principle was used in an Ouchterlony test, to examine whether the serum from 
the rabbits used to make the polyclonal antibodies against harmonin, actually does 
contain IgGs and whether they are against harmonin.
1% agarose was poured into a petri dish and six wells holding 20pl of solution 
each, were bored at a 1cm radius around a larger central well (holding 50pl), using 
the ‘wrong’ end of a 20pl pipette tip for the peripheral ring of wells and the ‘wrong’ 
end of a 1000pl pipette tip for the larger central well. An initial control Quchterlony 
plate was set up, with the central well filled with neat anti-LTPR serum, whilst each 
surrounding well was filled with varying dilutions of anti-rabbit IgGs solutions (made 
in goat), with PBS buffer and undiluted anti-goat IgGs solution (made in donkey) as
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negative controls. The plate was sealed and incubated face up at room 
temperature in a humid environment for 120 hours.
An experimental plate was then set up, using 0.5% agarose and with the wells 
spaced closer together to reduce the incubation time required to form a precipitate. 
The central well was filled with neat anti-LTPR serum, whilst each surrounding well 
contained undiluted anti-rabbit IgGs antibody as a positive control, PBS buffer as a 
negative control and a variety of different sources of harmonin protein, including 
the IVT USH1C protein (section 2.5.6.1.1; diluted 1:10), whole eye homogenate 
(~80mg/ml) and the R28 cell line (~80mg/ml). The remaining well contained a 
solution of peptide 1 of the same concentration used in the ELISA reaction 
(20mg/ml). Plates were then sealed and incubated face up at room temperature in 
a humid environment, for 24-48 hours. Precipitates could be visualized by eye and 
images captured using the gel imaging system (Chemidoc, BioRad).
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2.5 Investigation into candidate harmonin-interacting proteins within 
the normai eye
2.5.1 Methodology: A Yeast Two-hybrid screen of a bovine retinal library to find 
harmonin-interacting proteins
2.5.1.1 Confirmation of yeast strain phenotypes
2.5.1.1.1 Long term storage of veast
An isolated colony was scraped from the agar plate to inoculate 200-500pl of 
Yeast Peptone Difco agar supplemented with adenine (YPDA) medium (or the 
appropriate synthetic dropout (SD) medium (Clontech; Appendix 2). The tube was 
vortexed vigorously to thoroughly disperse the cells. Sterile glycerol was added to 
give a final concentration of 25%. The tube was vortexed to spread the cells 
evenly in the tube, and stored at -80°C.
2.5.1.1.2 Recovery of veast from frozen stocks
Yeast from frozen stocks was streaked onto YPDA (or appropriate SD) agar plates 
using a sterile inoculating loop stick. The plate was incubated at 30°C until the 
yeast colonies reached 2 mm in diameter and then sealed with parafilm. Both Y187 
and AH 109 can produce pink colonies of >2mm diameter under conditions of 
limited adenine which are useable in later reactions. Small white colonies also 
formed as a result of spontaneous mutations and were avoided for all techniques
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used in the yeast two-hybrid screen. The plate was stored at 4°C for up to two 
months.
2.5.1.1.3 Preparation of liquid veast cultures
YPDA (or appropriate SD) medium was inoculated with a single colony (less than 2 
months old) from the working stock plate (section 2.5.1.1.2) and vigorously vortexed 
for 1 minute to thoroughly disperse the cells. The culture was incubated at 30°C for 
16-18 hours with shaking at 230 rpm. For most strains, this yields a stationary phase 
culture, with ODeoo >1-5
If a mid-log phase culture was needed, sufficient stationary phase culture was 
transferred into fresh YPD A (or appropriate SD) to produce an O D6oo between 0.2- 
0.3. The medium was incubated at 30°C for 3-5 hours with constant shaking at 230 
rpm or until the O D 6oo was between 0.4 and 0.6.
2.5.1.1.4 Confirmation of the phenotype of the veast strains
Eight large pink colonies from working stock plates of AH109 and Y187 (section 
2.5.1.1.2; kindly donated by Drs J. Achermann & L. Lin) were individually streaked 
onto SD selective plates (SD/-Ade; SD/-His; SD/-Leu; SD/-Trp; SD/-Met; SD/-Ura; 
YPD and YPDA) to simulate a range of nutritional selections. The plates were 
incubated at 30°C for 3-5 days. Colonies which expressed the correct phenotype
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were made into frozen stocks (2.5.1.1.1) and used for subsequent yeast two-hybrid 
steps.
2.5.1.2 Generation of bait and control fusion proteins
DNA cloning: construction of veast two-hvbrid fusion proteins 
All enzymes used in the following sections were from New England Biolabs, with 
specific storage, activation and deactivation protocols (see appropriate 
accompanying information provided by the manufacturer).
2.5.1.2.1 Digestion of DNA with restriction endonucleases 
Sfi1 and Xma1 sites were within the multiple cloning site (MCS) of both bait and 
prey vectors (Appendix 15). Sfi1 and Xma1 sites were added to the 5’ and 3’ ends 
respectively, of the bait and control insert sequences (PDZ1, PDZ2, PDZ3, C- 
terminus of cadherin 23, and the complete sequence of USH1C  minus the first 
seven codons [due to primer requirements/secondary structure]) in the primers 
used for PCR amplification (Appendix 13). PCR amplification was performed for 35 
cycles (95°C/20secs; 61°C/20secs; 72°C/2.5mins) using taq (Bioline) in a standard 
25pl PCR reaction (section 2.5.1.2.6) with 0.017ug of template. The template used 
for the bait inserts was a pGEX4T-1-USH1C #12 clone donated by Dr-D Blaydon 
(Blaydon, D 2004) whilst foetal ear cDNA was used to generate the control prey 
insert. The fidelity of the PCR was confirmed by the absence of bands in the
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control lanes. PCR products were resolved by 2% agarose gel electrophoresis 
(section 2.3.3.2.2.1)
The insert DNA was purified from the components of the PCR reaction by gel 
extraction (section 2.5.1.2.2) and the resulting concentrations calculated (section
2.5.1.2.3). Full length USH1C  (~10pg), PDZ1 (~4.5pg), PDZ2 (~4.5pg), PDZ3 
(~7.5pg), pGBKT7 (~0.3pg), cdh23 (~10pg) and pACT2 (~10pg) were each 
incubated with 1pl Sfi1, 1pl Xma1 2pl 10X NEB buffer 4, 0.2pl 100X NEB BSA and 
12.8pl ddiH20, at 37°C for 1 hour to activate Xma1 and then at 50°C to deactivate 
Xma1 and S/77 activate. Samples were run on 1% agarose (Appendix 6, section
2.3.3.2.2.1) to deactivate S/77 and then gel purified (section 2.5.1.2.2). Samples 
were stored at -20°C .
2.5.1.2.2 Isolation of DNA from agarose gels
Under low intensity UV illumination, agarose gel slices containing the DNA product 
of interest were excised using a sterile scalpel. Slices were weighed and purified 
using a QIAquick Gel Extraction kit (Qiagen), according to the manufacturer’s 
instructions.
Three volumes of Buffer QG was added to one volume of gel (100mg=H00pl) in an 
eppendorf. This was incubated at 50°C for 10min in a water bath, with intermittent 
vortexing, until the gel slice had completely dissolved. Once dissolved, one gel 
volume of isopropanol was added to the sample to increase the yield of DNA
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fragments <500 bp and >4 kb. This step was omitted for DNA fragments outside 
this range. To isolate the DNA fragment, the sample was loaded onto a QIAquick 
spin column in a collecting tube and centrifuged at 13,000 rpm (~ 17,900 x g) in a 
table-top microcentrifuge (Biofuge PICO, Jencons PLC) for 60secs. The flow­
through was discarded and the sample washed with 0.5ml of Buffer QG, with 
centrifugation as before. The flow-through was discarded and the sample washed 
again with 0.75ml of Buffer PE followed by centrifugation. The flow-through was 
again discarded and the column centrifuged again as previously to remove all 
traces of ethanol. The purified DNA was eluted from the column into a new 1.5ml 
eppendorf by incubating the column with 30-50pl of ddiH20 , followed by 
centrifugation. The eluate was stored at -20°C.
2.5.1.2.3 Spectrophotometric quantification of DNA concentration
DNA concentration was calculated using an ultraviolet (UV) spectrophotometer 
(BioPhotomter, Eppendorf) to measure a solutions absorbance at 260nm (A26o), 
with A26o = 1 being equivalent to 50pg/ml of double stranded DNA or 40pg/ml of 
RNA. DNA purity was calculated using the ratio of A26o/A28o, where pure DNA has a 
ratio >1.7 (Sambrook, J. et al, 1989).
2.5.1.2.4 Ligation of DNA into plasmid vectors
The DNA concentration of each insert and vector aliquot was measured (section
2.5.1.2.3). It was decided to carry out at 2:1 and 5:1, insert:vector ratio ligation.
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The amount of each insert and vector for each ligation was calculated (Equation
2.1) and the DNA quantities listed in Table 2.4. Vector and insert were incubated 
with ddiH20  to a total final volume of 10|jl, for 5 min at 45°C. The separate ligation 
reactions were incubated on ice, then 1pl T4 DNA ligase and 1pl of 10x ligation 
buffer were added and the reactions incubated for 1 hr at 25°C. Ligations were 
stored at -20°C .
Equation 2.1 Calculation of the appropriate concentrations of insert and vector DNA required 
for ‘sticky ended’ ligation reactions.
x ng insert = a (bp of insert) X (v na linearised vector)
bp of vector
Where or represents the ratio of insert:vector i.e. for a 2:1 ratio, a = 2.
Table 2.4 Calculation of the ng of vector and insert DNA required for a 2:1 and 5:1 
insert:vector ligation reaction
The ~ng of insert DNA (x) were calculated using Equation 2.1 with y=100ng for both pGBKT7 
(8000bp) and pACT2 (8100bp).
x  (ng) of insert required 
when a  = 2
x  (ng) of insert 
required when a  = 5
USH1C (2060bp) 56 140
PDZ1 (390bp) 10 26
PDZ2 (255bp) 7 16.5
PDZ3 (300bp) 8 20
Cadherin 23 (800bp) 23 40
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2.5.1.2.5 Transformation of DNA into bacterial cells
The bait and control prey constructs were transformed into TOP10-One shot cells 
(Invitrogen), whilst the vectors themselves were amplified using 1pl of plasmid 
DNA in the TOP10-One shot cells only.
2.5.1.2.5.1 Preparation of liquid cultures
A single E.coli colony (less than 1 month old) from a working stock plate was used 
to inoculate appropriate medium (LB broth with/without selective antibiotics for 
plasmid selection; Appendix 2 & 4) and the culture was incubated at 37°C for 16-18 
hours with shaking at 230 rpm (Stuart Scientific). For most strains, this yielded a 
stationary phase culture.
2.5.1.2.5.2 Long term storage of E.coli and recovery of frozen stocks
400pl of 30% glycerol was added to 600pl of stationary phase culture to produce a 
glycerol stock. The culture was frozen immediately and stored at -80°C. Cells were 
recovered by scraping the surface of the frozen stock with an inoculating loop 
(NUNC), and restreaking on a LB agar plate supplemented with the appropriate 
antibiotic. The plate was incubated upside down at 37°C for 16-18 hours and sealed 
with parafilm. The plate was stored at 4°C for up to one month.
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2.5.1.2.5.3 Preparation of chemically competent E.coli
DH5a E.coli were recovered on LB agar at 37°C overnight. A single colony was used 
to inoculate 10ml of LB broth and was incubated at 37°C overnight, in a shaking 
incubator at 225rpm. This culture was then used to inoculate 200ml pre-warmed LB 
broth which was then incubated at 37°C 225rpm, until the absorbance reached 0.45 
at 550nm. Pipette tips and eppendorfs were prechilled and the following steps were 
carried out at 4°C. The culture was divided into four 50ml Falcon tubes and 
incubated on ice for 5mins, before pelleting at 2500rpm for 15 min at 4°C in a Legend 
RT centrifuge (Sorval). Cells were gently resuspended in 2ml TFB1 (Appendix 3), then a 
further 10ml of TFB1 was added and the cells left on ice for 15mins. The cells were 
pelleted as previously at 2500rpm for 15 min at 4°C. The pellet was resuspended in 
1.6ml TFB2 (Appendix 3) and left on ice for 15mins. Competent cells were then divided 
into 200pl aliquots for immediate use or storage at -70°C. The transformation efficiency 
was examined through transformation with the control plasmid pUC19 (Appendix 
10).
2.5.1.2.5.4 Transformation of plasmid DNA into chemically competent E.coli
The following method used to transform Max Efficiency DH5a (Invitrogen), One 
Shot® TOP 10 Chemically Competent Cells, KC8 cells (Clontech) and the DH5a 
cells created (section 2.5.1.2.5.3) was modified from that provided by the 
manufacturer. Appendix 8 lists the genotype data for each bacterial strain
126
Chemically competent cells were thawed on ice and 4pl of a ligation reaction was 
added to 50pl, mixed by flicking and incubated on ice for 20min. Cells were then 
heat shocked in a 42°C water bath for 45secs, then returned to the ice for a further 
2mins. 250pl of sterile pre-warmed SOC (37°C) was added to each tube and then 
the cells were allowed to recover at 37°C for 1 hr in a shaking incubator at 200rpm. 
100-200pl of cells were plated out at dilutions 1:10, 1:100 and 1:1000 on pre-dried 
LB-amp plates for pACT2-cdh23 or on LB-kan plates for the remaining four bait 
constructs (section 2.5.1.2.1) at 37°C overnight.
2.5.1.2.6 Polymerase Chain Reaction (PCR)
The standard PCR employed throughout the following chapters uses Bioline Taq 
and its provided buffers, in a 25pl total reaction volume (Table 2.5). Reactions were 
prepared on ice and added to a pre-heated PCR Thermocycler block 
(Mastercycler, Eppendorf) at 95°C. Oligonucleotide primers were designed using 
Primer 3 (Appendix 12) and synthesized by MWG. A negative control reaction, 
minus the DNA template, was included for every PCR reaction to monitor fidelity. 
The standard thermocycler program employed throughout these chapters unless 
otherwise stated is listed in Table 2.5.
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Table 2.5 Definitions of the PCR reaction and thermocycler program used in PCR 
reactions throughout the following chapters.
Standard Bioline PCR reaction 
components
Standard Thermocycler program
Primer (100pmol/pl) 0.1 pi of each 95°C 2 mins
Buffer (10x) 2.5pl 95°C 30 secs
dNTPs 2.5pl Annealina temD. 10 secs
Mg2+ (50mM) 0.75pl 72°C 20 secs
Taq 0.1 pi Repeat steps for 35 cycles
Template Xpl 72°C 10 mins
H20 18.95pl -  Xpl End
In reactions where Bioline Taq is substituted for Hot Star Taq (Qiagen), the following 25pl 
PCR reaction mix was used:
Standard Hot Star PCR reaction 
components
Standard Thermocycler program
Primer (1 OOpmol/pl) 0.1 pi of each
Buffer (1 Ox) 2.5pl
dNTPs 2.5pl
Taq 0.1 pi
Template Xpl
H20 19.7pl -  Xpl
95°C 5 mins 
95°C 30 secs 
Annealina temD. 10 secs 
72°C 20 secs 
Repeat steps for 35 cycles 
72°C 10 mins 
End
Single samples of the four DNA bases (Bioline) were combined to form a stock 2mM dNTP 
(Deoxyribonucleotide triphosphates) solution.
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2.5.1.2.6.1 Identification of positive recombinants
Positive recombinants were identified through PCR amplification performed directly 
on individual bacterial colonies, using primers to the flanking regions of the MCS 
(multiple cloning site; pACT2FB & R for control, T7 & pGBKT7R for bait vector 
primers; Appendix 13). Single colonies were picked and dipped in the PCR mix to 
act as template and then dipped in 5ml of LB-antibody broth. PCR amplification 
was carried out (section 2.5.1.2.6) with the following thermocycler programs: 
(pACT2FB & R) 95°C/15secs; 57°C/15secs; 72°C/2.5min for 35 cycles and (T7 & 
pGBKT7R) 95°C/20secs; 61°C/20secs; 72°C/1.5min for 35 cycles. Products were 
analysed on a 1% agarose gel (section 2.3.3.2.2.1). Those colonies containing 
plasmids with insert were grown overnight in the 5ml broth at 37°C 200rpm (section
2.5.1.2.5.1), with glycerol stocks created from the overnight cultures (section
2.5.1.2.5.2). At least five recombinants were selected for each bait construct and 
the construct DNA purified using Qiagen Miniprep kits (section 2.5.1.2.8.1).
2.5.1.2.7 DNA sequencing
Prior to sequencing, PCR products were cleaned to remove ssDNA and free 
dNTPs. For PCR with volumes of up to 25pl; 1pl Exonucleasel, 2pl Shrimp 
Alkaline Phosphatase (SAP] USB), 0.5pl SAP Dilution Buffer and 1.5pl ddihfeO was 
added to each PCR reaction and incubated for 30mins at 37°C. The enzymes 
were deactivated by heating at 80°C for 15 mins and the solution stored at 4°C.
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Sequencing of the cleaned PCR products was carried out in two ways (Table 2.6). 
The Big Dye (PE) protocol adapted from the manufacture’s instructions was used 
throughout the following chapters. The DYEnamic ET terminator protocol was used 
to try and increase sequence data yields in section 5.1.5.
Table 2.6 A comparison of the sequencing reaction components and thermocycler 
programs employed by the Big Dye and DYEnamic ET terminator sequencing 
systems.
Big Dye v3.1 DYEnamic ET terminator
For a 20pl sequencing reaction:
Single Primer (5pmol/pl) 1.3pl 
BigDyev3.1 2.7pl 
5x Seq Buffer 2.7pl 
Template (~50-100ng) Xpl 
ddiH20 13.3-Xpl
For a 20pl sequencing reaction: 
Single Primer (5pmol/pl) 1.3pl 
DYEnamic ET terminator 8pl 
Template (0.15pmol) Xpl 
ddiH20 9.3-Xpl
Thermocycler Program 
95°C 2mins 
95°C 20secs 
50°C 1Osecs 
60°C 3mins 
Repeat steps for 35 cycles 
Store at 4°C
Thermocycler Program 
95°C 1mins 
95°C 20secs 
50°C 15secs 
60°C 1mins 
Repeat steps for 25 cycles 
Store at 4°C
Sequencing reactions were cleaned using Sephadex G50 (Sigma) and run on a 
MegaBase 1000 DNA Analysis system (Amersham Bioscience) (Injection time: 3kV 
for 40sec, Run conditions: 9kV 100min) by Ms K Pearce (in-house sequencing 
service). Sequences were analysed using CHROMAS (Appendix 12).
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2.5.1.2.7.1 Sequencing of positive recombinants
The success of the cloning was further verified by DNA sequencing of PCR  
products (generated in 2.5.1.2.6.1) but using the extracted DNA as template 
(sequencing primers: T7, pGBKT7R, pGBKT7-PDZ1 F/R, pGBKT7-PDZ2 F/R and 
pGBKT7-PDZ3 F/R). PCR products were cleaned (section 2.5.1.2.7) and ~80ng of 
the product was sequenced using Big Dye v3.1 (ABI; section 2.5.1.2.7) with the T7 
primer (Appendix 13).
2.5.1.2.8 Isolation and purification of plasmid DNA
DNA was purified from overnight cultures of E. coil in LB broth using Qiagen 
Miniprep kits for cultures of 1-5ml with an expected yield of 20pg of plasmid DNA, 
and Qiagen Maxiprep kits (QIAGEN-tip 500 columns) for cultures of 100-500ml 
with an expected yield of 300-500pg plasmid DNA. The Qiagen purification 
protocols are summarized in sections 2.5.1.2.8.1 & 2.5.1.2.8.2 (Appendix 3).
2.5.1.2.8.1 Small scale plasmid purification
The overnight culture was centrifuged at 13000rpm for 10mins and the supernatant 
discarded. The bacterial pellet was resuspended in 250pl Resuspension Buffer P1 
and transfer to an eppendorf tube. To this, 250pl of Lysis Buffer P2 -was added 
and inverted 4-6 times to mix. The lysis reaction was allowed to continue for up to 
5mins until the solution became viscous and slightly clear. 350pl of Precipitation 
Buffer N3 was added and the tube immediately inverted 4-6 times, followed by
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centrifugation for 10min at 13000rpm in a tabletop microcentrifuge (Jencons PLC). 
The supernatant was applied to the QIAprep column and the white pellet 
discarded. The column was centrifuged at 13000rpm for 60secs and the flow­
through discarded. The column was washed with 0.5 ml Wash Buffer PB followed 
by centrifugation as above. The flow-through was discarded and the column 
washed again with 0.75 ml Buffer PE, followed by centrifugation as above. The 
flow-through was discarded and the column centrifuged again as previously, to 
remove residual wash buffer. DNA was eluted by incubation of the column with 30- 
50pl of ddiH20  for 1min and then centrifuged as previously. The eluate was stored 
at -20°C.
2.5.1.2.8.2 Large scale plasmid purification
Bacterial cells were harvested by centrifugation at 6000g for 15 min at 4°C using a 
6K15 Laboratory Centrifuge (Philip Harris). The supernatant was removed and the 
pellet resuspended in 10ml of Buffer P1 with vortexing to remove all cell clumps. 
10ml of Buffer P2 was added, mixed gently by inverting 4-6 times and incubated at 
room temperature for 5mins. 10ml of pre-chilled Buffer P3 was mixed immediately 
upon addition to the resuspended cells by inverting the tube 4-6 times, and then 
incubated on ice for 20mins to precipitate out the genomic DNA, proteins, cell 
debris, and detergents. The tubes were centrifuged at >20,000g/12,000 rpm for 
30min at 4°C and the supernatant moved to a new tube. The supernatant was 
centrifuged again at >20,000 x g for 15 min at 4°C and the new supernatant 
collected. A QIAGEN-tip 500 was equilibrated by applying 10ml Buffer QBT, and
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the column emptied by gravity flow. The supernatant was added to the top of the 
drained column and allowed to enter the resin by gravity flow. The QIAGEN-tip was 
washed with 2 x 30ml Buffer QC by gravity flow. The DNA was eluted using 15ml 
Buffer QF to which 10.5ml of room-temperature isopropanol was added to 
precipitate out the DNA. Eluate was centrifuged immediately at >15,000g for 
30mins at 4°C. The supernatant was discarded and the pellet washed with 5ml of 
room-temperature 70% ethanol, and centrifuged at > 15,000g for 10mins. The 
supernatant was again discarded and the pellet air-dried for 5-10min, then 
redissolved in ddiH20.
2.5.1.2.9 Transformation of veast cells with cloned DNA plasmid
A 50ml stationary phase culture for each yeast strain to be transformed was grown, 
and used to produce a 300ml mid-log phase culture (section 2.5.1.1.3). The mid­
log phase culture was aliquoted into 50ml falcons and centrifuged at 1,000 xg for 
5min at room temperature. The supernatants were discarded and the pellet 
resuspended in sterile 1x TE. Cells were pooled for each strain separately, to give 
a final volume of 25-50m l. The cells were pelleted as above, the supernatant 
discarded and the pellet resuspended in 1.5ml of fresh sterile 1x TE: 1x LiAc 
(Appendix 3).
0.1 pg of plasmid DNA to be transformed and 0.1 mg of herring testes carrier DNA 
(provided with MATCHMAKER system, Clontech) was denatured in a boiling water 
bath for 20mins. 0.1ml of yeast competent cells was added to each denatured
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plasmid/carrier DNA mix to be transformed and mixed well by vortexing. 0.6ml of 
sterile PEG/LiAc solution (Appendix 3) was added to each cell suspension and 
vortexed at high speed for 10sec. Cells were incubated at 30°C for 30min, shaking 
at 200 rpm. 70pl of DMSO was then added and mixed carefully by inversion 
before heat shocking the cells at 42°C for 15mins in a water bath. Tubes were 
chilled on ice for 2mins, and then centrifuged for 5sec at 14,000rpm at room 
temperature. The pellet was resuspended in 0.5 ml of sterile 1x TE buffer and 
100pl aliquots at several dilutions was plated on the appropriate SD agar plate that 
selected for the desired transformants. Plates were incubated upside down, at 
30°C for 4 days, sealed with parafilm and stored at 4°C for up to one month.
2.5.2 Validation of bait and control proteins
2.5.2.1 Plasmid extraction from yeast
A single yeast colony was spread over ~2cm2 patch of the appropriate SD agar 
medium and the plate incubated at 30°C for 3 -4  days. A portion of the patch 
(~1cm2) was scraped up using an inoculating loop and resuspended in 50pl of 
sterile 1X TE in a 1.5-ml eppendorf. 10pl of lyticase solution (5units/ml in 1X TE 
buffer) was added to the yeast suspension and vortexed. Tubes were incubated at 
37°C for 30-60min with shaking at 200-250 rpm, before 10pl of 20% SDS was 
added and tubes were vortexed again. Samples were put through one freeze/thaw  
cycle (at -20°C ) and vortexed again to ensure complete lysis of the cells. The 
entire contents of the tube was poured onto a prespun CHROMA SPIN-1000
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Column (Clontech) and centrifuged for 5min at 700g according to the 
manufacturer’s instructions, to elute the purified plasmid DNA.
Alternatively, plasmid DNA was purified by phenol: chloroform extraction. After the 
freeze-thaw cycle, sample volumes were brought up to 200pl with 1x TE, to which 
200pl of phenol:chloroform:isoamyl alcohol (25:24:1) was added. Samples were 
vortexed at the highest speed for 5mins and then centrifuged at 14,000 rpm for 
10mins. The upper aqueous phase was transferred to a new eppendorf to which 
an equal volume of chloroform:isoamyl alcohol (24:1) was added. Samples were 
vortexed and centrifuged as above and then the new aqueous layer underwent 
another chloroform:isoamyl alcohol extraction step. The new aqueous phase was 
transferred to a fresh tube, 8pl of 10 M ammonium acetate and 500pl of 95-100%  
ethanol was added. Samples were incubated at -70 °C  for 1 hr, then centrifuge at 
14,000rpm for 10mins. The supernatant was discarded and the pellet air dried, 
then resuspended in 20pl of ddihfeO. Samples were stored at -20°C .
2.5.2.1.1 Bait sequence analysis
3pl of plasmid DNA extracted from pGBKT7-USH1C, pGBKT7-PDZ1, pGBKT7- 
PDZ2, pGBKT7-PDZ3 and pACT2-cdh23 transformed yeast was used as template 
in a PCR amplification (section 2.5.1.2.6) for sequencing (section 2 .5 .12 .7 ). PCR 
products were produced with the primers from section 2.5.1.2.1. The same primers 
were used for sequencing, with the PDZ domain construct primers (Appendix 13) 
used to sequence the centre of pGBKT7-USH1C.
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2.5.2.2 Protein extraction from yeast
For each transformed yeast strain from which protein was required, a 5ml overnight 
culture in appropriate SD selection medium, was prepared using a single isolated 
colony 1-2m m  in diameter and no more than 4 days old. A 10ml culture of an 
untransformed yeast colony in YPD was also prepared as a negative control for 
Western blotting analysis. The entire overnight culture was used to inoculate 50ml 
aliquots of YPD medium, which were then incubated at 30°C with shaking (2 2 0 -  
250 rpm) until they reached mid-log phase (section 2.5.1.1.3). The O D 6oo reading 
for 1ml of culture at this point, was multiplied by the culture volume to obtain the 
total number of ODeoo units e.g. 0.6 x 55 ml = 33 total OD600 units. The culture was 
quickly chilled in two pre-chilled 50ml falcon tubes per sample, with the tubes half 
full with ice. These were immediately centrifuged in a pre-chilled rotor (Legend RT, 
Sorval) at 1000xg for 5min at 4°C. The supernatant was discarded and the pellet 
resuspended in 50ml of ice-cold ddiH20 . The pellet was recovered by 
centrifugation at 1000 xg for 5min at 4°C.
Each cell pellet was resuspended in 100pl of ice-cold TCA buffer (Appendix 3), per
7.5 ODeoo units of cells on ice, and then transferred to 1.5ml screw-top eppendorfs 
containing glass beads (425-600pm ) and ice-cold 20% TCA, (100pl of beads and 
100pl of 20% TCA per 7.5 O D6oo units of cells). Tubes were vortexecLvigorously 
for 4 x 1min, to disrupt the cells, with incubation on ice for 30sec in between each 
vortexing. The supernatant above the settled glass beads was transferred to 
another tube also on ice. The glass beads were washed with 500 pi of ice-cold 1:1
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20% TCA:TCA buffer and vortexed as above. The liquid above the beads was 
added to the previously isolated aliquot of supernatant on ice. Any carryover glass 
beads in the combined supernatant extracts were allowed to settle and then the 
liquid above these beads was transferred to another eppendorf and the protein 
pelleted at 14,000rpm for 10min at 4°C. The supernatant was discarded and the 
pellet resuspended in TCA-Laemmli loading buffer (Appendix 3), using 10pl of 
loading buffer per ODeoo unit of cells. The protein samples were denatured by 
boiling in a water bath for 10min before centrifugation at 14,000rpm for 10min at 
room temperature. The supernatant was collected and loaded directly onto SDS- 
PAGE gels (Appendix 6; section 2.4.4.2) or stored at -70°C .
2.5.2.2.1 Confirmation of fusion protein identity
The total protein content of [AH109]pGBKT7-USH1C (7&12), [AH109]pGBKT7- 
PDZ1, [AH109]pGBKT7-PDZ2, [AH109]pGBKT7-PDZ3 and [Y187]pACT2-CDH23, 
with [AH109]pGBKT7, [Y187]pACT2, AH109 and Y187 (used as positive and 
negative controls respectively) were isolated (section 2.5.2.2). 15pl aliquots from 
the PDZ domain fusion proteins, [Y187]pACT2 and controls underwent 
electrophoresis on a 15% SDS-PAGE gel, whilst [AH109]pGBKT7-USH1C (7&12) 
and AH 109 were run on a 10% SDS-PAGE gel (Appendix 6; section 2.4.4.2). 
Separated proteins were transferred to membranes and immunoblotted (section
2.4.4.3) using the following antibodies:
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■ pGBKT7 based constructs expressing the c-Myc tag were visualised using 
monoclonal anti c-Myc primary antibody (1:500 dilution, Invitrogen) overnight at 
4°C, followed by biotinylated anti-mouse IgG secondary antibody (1:500 
dilution, KPL) for 1 hour at room temperature and a Streptavidin-AP antibody 
(1:2500 dilution) for a further hour at room temperature.
■ pACT2 based constructs expressing the influenza hemaglutinin (HA) tag were 
visualised using a mouse monoclonal anti HA primary antibody (1:200 dilution, 
Santa Cruz Biotechnology) overnight at 4°C, followed by the same biotinylated 
anti-mouse IgG secondary antibody as above (1:200 dilution) for 1 hour at room 
temperature and a Streptavidin-AP antibody (1:2500 dilution) for a further hour 
at room temperature.
To further confirm that the main bait fusion protein was actually harmonin, not just 
a protein of a similar size, pGBKT7-USH1C(12) underwent In Vitro Translation 
(IVT) (section 2.5.6.1.1). The c-Myc/USH1C tagged product was run on a 12% 
SDS-PAGE gel alongside a ‘No DNA’ lysate control. The membrane was divided 
and immunoblotted (section 2.4.4.3), with either anti c-Myc-AP (1:400 dilution 
incubated overnight at 4°C, Invitrogen); monoclonal anti-harmonin (1:400 dilution) 
followed by biotinylated anti-mouse IgG secondary antibody (1:1000 dilution for 1 
hour at room temperature) and the Streptavidin-AP antibody (1:2500 dilution); or 
polyclonal anti-harmonin (1:400 dilution) with biotinylated anti rabbit IgGs-AP 
(1:1000 dilution for 1 hour at room temperature, KPL) and a Streptavidin-AP 
antibody (1:2500 dilution).
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2.5.2.3 Toxicity effects of the fusion proteins on the host yeast cells
To investigate the effects of the bait fusion proteins on yeast growth, their rate of 
growth was compared to that of yeast transformed with the ‘empty’ vectors for the 
GAL4-BD or GAL4-AD proteins alone. Growth rates were also compared to the 
Clontech control fusion proteins. Isolated yeast colonies were added to single DO 
(drop out) SD liquid media to be incubated to mid log phase (section 2.5.1.1.3).
2.5.2.4 Autonomous activation of the reporter genes
As yeast two-hybrid selection is based on the nutritional and colourmetric selection 
of the reporter genes (ability to grow on SD/-His/-Ade and positive for p- 
galactosidase), it is important to know that none of the baits or controls are capable 
of activating the transcription and expression of the reporter genes.
2.5.2.4.1 Nutritional reporter gene activation
Eight colonies from the transformation plates (section 2.5.1.2.9) were streaked on 
SD media lacking various combinations of amino acids (SD/-Ade; SD/-His; SD/- 
Leu; SD/-Trp; SD/-Met; SD/-Ura; YPD and YPDA). Transformants able to 
autoactivate HIS3  were re-streaked on SD-Trp supplemented with the His3p 
inhibitor, 3-amino-1,2,4-triazole (3-AT). Colonies were grown on 5mM, 10mM, 
15mM, 50mM, 100mM and 500mM 3-AT supplemented plates.
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2.5.2A.2 B-qalactosidase assay
Lac Z  activation was examined by Colony Filter Lift assay as it is relatively 
sensitive, especially for cells that contain one or only a few copies of the lac Z  
reporter gene. It is convenient for large-scale experiments and inexpensive but is 
only qualitative.
Z buffer/X-gal solution was prepared (Appendix 3). For each plate of transformants 
to be assayed, a #5 filter paper (Whatman) was saturated with Z buffer/X-gal 
solution and placed in a clean empty Petri dish. A clean dry #5 filter paper was 
placed over fresh colonies 1-3mm in diameter grown on the appropriate SD 
selection medium appropriate for the system and plasmids. Filters were pressed 
down to ensure that colonies clung to the paper, which was orientated with respect 
to the original agar plate by poking holes in the agar at three asymmetric points. 
The filter was quickly snatched from the agar plate using forceps and submerged 
colony face up in liquid nitrogen for 10secs. Filters were allowed to thaw and then 
submerged in liquid nitrogen again to permeabilise the thick yeast cell walls. Once 
thawed, this filter was placed colony face up on the Z buffer/X-gal pre-wetted filter, 
bubbles between them eliminated, and then incubated covered in a fume hood for 
up to 8hours, checking periodically for the appearance of blue colonies. The p- 
galactosidase-producing colonies were identified by aligning the filter to the agar 
plate using the orienting marks. The corresponding positive colonies from the 
original plates were streaked onto fresh medium for further analysis.
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2.5.2.5 Yeast mating
Yeast mating is an alternative method to co-transformation for introducing two 
different plasmids into the same host cells and is convenient for confirming 
interactions. Yeast transformants in MATa (AH 109) and MATa (Y187) mating 
cassette types (Appendix 9) were grown on appropriate SD agar plates. One large 
fresh colony of each mating cassette was resuspended in 0.5ml YPDA in a 1.5ml 
eppendorf. Cell suspensions were incubated at 30°C overnight with shaking at 200 
rpm. 100ml aliquots of the mating culture were plated on SD-Leu/-Trp to select for 
diploids, confirming that mating had been successful and on SD-Leu/-Trp/-His/- 
Ade+12mM 3-AT to select for diploids in which a positive two-hybrid interaction 
was occurring. Plates were incubated at 30°C for 5-10 days or until colonies 
appeared and then tested for p-galactosidase activity (section 2.5.2.4.2).
2.5.2.5.1 Control mating experiments
As the interaction between murine p53 protein and SV40 large T-antigen is well 
characterised (Li, B et al, 1993), AH109[pGBKT7-53] and Y187[pGADT7-T] were 
used as positive controls for the system. The bait AH109[pGBKT7-USH1C] was 
mated with Y187[pACT2-CDH23], a known interactor, to act as a positive control 
for the bait protein. AH109[pGBKT7] was mated with Y187[pACT2] to ensure that 
there was no activation of the selectable markers through the vector(s) alone. 
AH 109[pGBKT7-USH 1C], AH109[pGBKT7-PDZ1], AH109[pGBKT7-PDZ2] and 
AH109[pGBKT7-PDZ3] were also mated with Y187[pACT2] for the same reason. 
[AH109]pGBKT7-Lam, which encodes a fusion of the DNA-BD with human laminin
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C and acts as a control for any fortuitous interactions between the bait and an 
unrelated prey protein (Bartel, P et al, 1993), was mated with Y187[pACT2] and 
also with Y187[pGADT7-T]. A prey protein that interacts with the bait and also with 
Laminin C is likely to be a false positive result. The mated yeast were plated onto 
nutritionally deficient media, any colonies that grew underwent a colony filter lift p- 
galactosidase assays (section 2.5.2.4.2) to confirm the phenotype.
2.5.3 Bovine retinal library screening by sequential transformation into A H 109 yeast
2.5.3.1 Amplification of the retinal cDNA library
The retinal cDNA library (Tai, A W et al, 1999), was amplified using 
electrocompetent E.coli. In this method, the uptake of DNA is facilitated by the 
application of a large electric field to the cells and is a modification of the method 
provided by the manufacturer (Invitrogen).
ElectroMAX DH10B cells (Invitrogen) were thawed on wet ice. 25pl of 
electrocompetent cells was added to ~40ng of bovine retinal library cDNA 
(~10ng/pl) in a pre-chilled eppendorf. Unused cells were quickly refrozen and 
stored at -80°C. The solution was carefully pipetted into a pre-chilled 0.1cm cuvette 
(Eppendorf), avoiding any bubbles and ensuring that the solution made-contact all 
the way across the bottom of the cuvette chamber. Samples were electroporated 
using the EC1 program (1.8kV for 5msec) of a Micropulser electroporator (Biorad) 
in 1mm cuvettes (Molecular Bioproducts). 1ml of SOC medium (Appendix 2) was 
added to the cells in the cuvette and the whole solution transferred to 3ml of 2xYT
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(Appendix 2) (double strength to be extra nutrient rich to increase DNA uptake and 
cell survival) in a 250ml sterile flask. The whole process was repeated again for a 
second aliquot of cells and once electroporated, was combined with the first cell 
aliquot in the 3ml of 2xYT broth. The cells were incubated at 37°C for 1 hour, with 
shaking at 225rpm. A serial dilution in LB-amp of the transformation mix was 
plated out on LB-amp plates at 1:10, 1:100 and 1:1000. Plates were incubated 
upside-down at 37°C overnight, to assess the transformation efficiency and library 
titre. The 1hour culture was then split over four 250ml LB-amp cultures in 1L flasks 
for excellent aeration and incubated at 37°C for overnight, with shaking at 225rpm. 
The plasmid cDNA was harvested using two maxiprep columns (Qiagen) (section
2.5.1.2.8.2) per 250ml culture and the resulting elution combined and aliquoted for 
storage at -20°C.
To check for representative amplification of different cDNAs within the library, 
individual colonies from the transformation efficiency plates underwent a 25pl 
standard PCR (section 2.5.1.2.6) as follows (95°C/15secs; 57°C/15secs; 
72°C/2.5mins for 35 cycles), using the pACT2FB & R vector primers (Appendix 
13). Two library aliquots also underwent restriction enzyme digestion (2pl library 
DNA; 5pl ddiH20; 1pl 10xNEB Buffer 2; 1pl EcoR1\ 1pl Xho1 were incubated at 
37°C for 2 hours and then the enzymes deactivated by incubation at 65°C for 
15mins) and were electrophoresed on 1% agarose gels (section 2.3.3.2.2.1), 
against uncut library DNA.
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2.5.3.2 Sequential co-transformation of baits and preys
The pGBKT7-USH1C(12) bait was streaked on SD-Trp agar and a 2-3mm colony 
<3 weeks old was used to produce a 1L YPDA mid-log phase culture (section
2.5.1.1.3). Cells were pelleted in 50ml aliquots by centrifugation (Legend RT, 
Sorval) at 1000xg for 5mins at room temperature. The pellets were resuspended 
in 500ml per transformant, of sterile 1x TE by vortexing, pooled and centrifuged as 
above. The pellet was resuspended in 8mls fresh sterile 1x TE/LiAc (Appendix 3). 
0.47mg of retina library cDNA was denatured alongside 20mg herring testes carrier 
DNA at 100°C for 20mins. 8ml of competent yeast cells was added to the 
denatured DNA mix and vortexed. 60ml of sterile PEG/LiAc solution was next 
added and vortexed to mix. Yeast cells were incubated at 30°C for 30min with 
200rpm shaking. Cell walls were permeabilised with 7ml of DMSO and gently 
inverted, followed by heat shocking at 42°C for 15mins, swirling occasionally to 
mix. Cells were chilled on ice for 1-2min and centrifuged for 5min at room 
temperature at 1,000xg. The supernatant was discarded and the cell pellet 
resuspended in 10ml of 1xTE.
To calculate cotransformation efficiency and library titre, serially diluted (1:20; 
1:100; 1:1000) transformed cells were plated on SD-Trp/-Leu agar and incubated 
at 30°C for 3-5 days.
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2.5.3.3 Library screening
Transformants can be selected for using high-, medium-, or low-stringency media. 
Less stringent screens increase the number of false positives, while more stringent 
screens may result in false negatives. Therefore the entire screening volume of 
transformed cells was plated out over ten 10cmx10cm SD-Trp/-Leu/-His/- 
Ade+12mM 3-AT agar plates and incubated at 30°C for 7-10 days. Prey were 
screened at high levels of stringency but a longer incubation time was used to try 
and catch low-affinity protein interactions.
Colony filter lift p-galactosidase assays (section 2.5.2.4.2) were carried out on all 
plates using 10cmx10cm filters which were unwieldy and left much of the colonies 
still on the plate. The results were poor, with most of the plate turning blue, giving 
a positive result after 7-8 hours of incubation with the substrate. The ten agar 
plates were re-incubated for a further two days to recover the colonies. The filter 
lift assay was repeated on the 10cmx10cm screening plates with replica plates 
produced simultaneously and incubated for three days at 30°C. Replica plating left 
most of the colony was on the replica plate and not on the filter so the p- 
galactosidase assay proved poor again. Therefore the large colonies from the 
replica plates and those that obviously activated Lac Z  on the filter lift assay and 
could be clearly identified were labelled and streaked out on smaller SI>Trp/-Leu/- 
His/-Ade+12mM 3-AT agar plates which were incubated at 30°C for 3-4 days for 
further analysis.
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2.5.3.4 Segregation of multiple library plasmids with a diploid and repeat analysis 
of activation of reporter genes
The initial library co-transformants may contain more than one AD/library plasmid, 
which can complicate the analysis of possible positive clones. Therefore positive 
interacting colonies were restreaked on SD -Leu/-Trp plates and incubated at 30°C  
for 4-6 days. This process was repeated once more to allow loss of some of the 
AD/library plasmids while maintaining selective pressure on both the DNA-BD and 
AD vectors. The full nutritional phenotype was then re-examined, with colonies 
streaked onto S D -L eu /-T rp /-H is / Ade + 12mM 3-AT plates and incubated at 30°C 
for 5-8 days. They were then re-examined for p-galactosidase activity (section
2.5.2.4.2), with the incubation period required to produce a positive result by the 
different bait-prey combinations, compared to the incubation time required by the 
positive control plasmid, pCL1. Colonies that turned blue within 2-4 hours are said 
to involve stronger protein-protein interactions than those that take 6-8 hours 
(Yeast Protocols, Clontech). Glycerol stocks of colonies passing nutritional and 
colourimetric selection procedures were produced (section 2.5.1.1.1).
2.5.4 Characterisation of candidate interactors
2.5.4.1 PCR amplification of library inserts
PCRs were set up (section 2.5.1.2.6), using the yeast colony directly as template 
and performed for 35 cycles (95°C/15secs; 56°C/15secs; 72°C/2mins) using 
primers to the MCS of the vector (pACT2FB and pACT2R; Appendix 13) in 96 well
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plates (ABgene). The initial enzyme activation step of 95°C/5mins for Bioline taq 
was lengthened to 15mins to permeabilise the yeast’s thick outer cell wall. Use of 
the yeast colonies themselves as templates proved successful for a number of 
interactors. The remaining interactors underwent PCR as above but were 
supplemented with 1M Betaine (final concentration) to increase yield by minimizing 
inhibitory secondary structure formation by the template which would prevent the 
primer from annealing. Where this alone failed, 3pl of yeast glycerol stock rather 
than the yeast streak was used as template. The total PCR volume was increased 
to 50pl whilst maintaining relative component concentrations, to minimize any 
inhibitory effect the glycerol may have on the reaction. 5pl of each product was 
electrophoresed on 1% agarose gels (section 2.3.3.2.2.1).
Those preys that would not PCR amplify directly from either the yeast glycerol 
stock or directly from a yeast colony itself, underwent plasmid extraction using 
phenol:chloroform or CHROMA SPIN 1000 columns (section 2.5.2.1). 1-3pl of 
extracted plasmid was then used as template in the above PCR.
2.5.4.2 Transformation of library inserts in DH5a and KC8 cells
In order to generate sufficient cDNA template for sequencing, yeast plasmid DNA 
for those preys not amplifying by PCR were transformed into E.coli. When 
transforming E. coli with plasmids isolated from yeast, it is best to use chemically 
competent E. coli cells that have a transformation efficiency of at least 107 cfu/mg 
(of pUC19 DNA). A large quantity of competent cells was produced (section
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2.5.1.2.5.3), from a stock of DH5a cells (Invitrogen; Appendix 8). Their 
competency was checked through transformation with the control plasmid pUC19 
(Appendix 10).
10pl of yeast plasmid was added to 100pl of chemically competent cells 
synthesized in section 2.5.1.2.5.3 or to 100pl KC8 cells (Appendix 8, Invitrogen), 
thawed on ice and then the cell suspensions were incubated on ice for 30min. 
Cells were heat shocked at 42°C for exactly 45secs and then returned to the ice for 
a further 2min, before 1ml of SOC (pre-warmed to 37°C) was added. Cells were 
allowed to recover at 37°C for 1 hour in a shaking incubator. Cell suspensions 
were then pelleted by centrifugation at 2500rpm for 5min. The supernatant was 
discarded and the pellet resuspended in the residual liquid. 50pl aliquots of cells 
were plated on pre-dried LB-amp plates (Appendix 2). Plates were incubated 
overnight at 37°C but no obvious growth was seen so incubation was increased to 
20 hours. Transformants were examined for the presence of the insert by PCR  
(sections 2.5.1.2.6 & 2.5.1.2.7). If positive for the presence of an insert, the colony 
was used to produce a 5ml overnight culture (sections 2.5.1.1.3) from which the 
plasmid DNA was isolated (section 2.5.1.2.8.1) for sequencing.
Transformation failure may be a result of a decreased amount of yeast plasmid 
DNA in the samples for transformation. Therefore plasmid extraction was repeated 
(section 2.5.2.1) but with growth of liquid colonies in 15ml falcons rather than 
eppendorfs and extra lyticase used during the cell lysis step. Transformation into 
bacteria was then repeated as above.
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2.5.4.3 DNA sequence analysis of library inserts
Amplified products were analysed on 1% agarose gels, and colonies displaying 
multiple bands had these isolated by gel extraction (Qiaquick gel extraction kit; 
section 2.5.1.2.2; Qiagen). Colonies with single bands were cleaned (section 
2.5.1.2.7). Sequencing was carried out (section 2.5.1.2.7) using ~80ng of template 
with the primer pACT2R. In an attempt to increase sequence data yield, the 
extension temperature on the sequencing thermocycler program was increased 
from 60°C to 64°C; Big Dye reaction mix was used at greater concentration with no 
dilution buffer; sequencing reactions were supplemented with Betaine at 1M final 
concentration and an alternative DYEnamic ET terminator sequencing kit was 
employed (section 2.5.1.2.7).
2.5.5 Confirmation and further characterization of positive interacting preys
2.5.5.1 Confirmation of prey-harmonin interaction by yeast mating
In order to confirm the protein-protein interactions in vivo, prey plasmids were 
isolated in AH 109 whilst the bait and control constructs were transformed into 
Y187, allowing for confirmation through yeast mating.
2.5.5.1.1 Segregation of veast plasmids
3ml of SD-Leu/+amp media (Appendix 2) was inoculated with one prey colony and 
incubated at 30°C for 1-2 days, shaking at 230-250rpm. 1:10 and 1:100 dilutions
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were plated on SD-Leu/+amp agar and incubated for a further 2-3 days at 30°C or 
until colonies appeared. Several colonies from the SD-Leu/+amp plates were 
transferred in a grid fashion to both SD-Leu (selecting for the prey plasmid thus 
colonies should grow again), and SD-Trp plates (selecting for the bait plasmid thus 
colonies should not grow). The isolated prey plasmids that only grew on SD-Leu 
could then be extracted in the normal way (section 2.5.2.1), and glycerol stocks 
made (section 2.5.1.1.1).
2.5.5.1.2 Transformation of bait and control plasmids into strain Y187 
Y187 yeast was transformed as described previously (section 2.5.1.2.9), with 
pGBKT7, pGBKT7-USH1C, pGBKT7-PDZ1, pGBKT7-PDZ2, pGBKT7-PDZ3 and 
pGBKT7-Lam.
2.5.5.1.3 Yeast mating
For each candidate prey plasmid to be tested, mating reactions were set up 
(section 2.5.2.5.1), between prey and each of the following: pGBKT7, pGBKT7- 
USH1C and pGBKT7-Lam.
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2.5.5.2 Further characterization of prey-harmonin interaction through yeast mating 
with the PDZ domain baits
For each remaining candidate prey plasmid to be tested, mating reactions were set 
up (section 2.5.2.5.1), between prey and each of the following: pGBKT7-PDZ1, 
pGBKT7-PDZ2 and pGBKT7-PDZ3.
2.5.5.3 Futher analysis of the candidate interactor -  Phosducin
2.5.5.3.1 Identification of the ORF of phosducin and confirmation of its interaction 
with harmonin by mating analysis
The complete DNA sequence of the prey inserts for interactors #1.3, 1.7 and 1.9 
were produced using the glycerol stock as template and the reaction mix 
supplemented with Betaine (section 2.5.4.1 & 2.5.4.3). Mating analysis was carried 
out (sections 2.5.5.1.3 & 2.5.5.2).
2.5.5.3.2 Analysis of Phosducin protein sequence
Phosducin sequences from different species listed by NCBI were aligned using 
CLUSTALW (Appendix 12) to search for regions of homology. This was*in order to 
determine whether the interaction seen here between a human harmonin protein 
and a bovine/mouse phosducin protein, could occur between both human proteins 
and that the interaction was not a species-dependent false positive.
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2.5.6 Methodology: Confirmation of an interaction between harmonin and 
phosducin by co-immunoprecipitation (CO-IP)
2.5.6.1 Synthesis of c-myc tagged harmonin and identification of phosducin in 
whole eye homogenate
2.5.6.1.1 Protein synthesis bv in vitro transcription and translation
pGBKT7-USH1C contained an in-frame 17  promoter sequence, so harmonin could 
be generated directly from the insert DNA sequence by in vitro transcription (IVT). 
Upon removal from storage at -70°C, the TNT® Quick Master Mix (Promega) was 
rapidly thawed by hand and placed on ice. All other components were thawed at 
room temperature and stored on ice. The reaction components were assembled in 
an RNase free 0.5ml eppendorf tube. 40pl TNT® T7 Quick Master Mix, 1pl 1mM 
methionine, 0.5pg DNA Template and Nuclease-Free water to a final volume of 
50pl was mixed gently by pipetting and briefly pulse centrifuged. The template 
should be free of ethanol, calcium, RNase and salt. The reaction was incubated at 
30°C for 90minutes and stored at -20°C.
MATCHMAKER control plasmids (Clontech) underwent IVT, replacing 2pl of 
nuclear-free water with Transcend™ Biotin-Lysyl-tRNA (Promega) to biotin-label 
the resulting protein and by-pass the need for the anti-HA antibody during Western 
blotting (section 2.4.4.3).
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The IVT USH1C protein used in section 4.3 was generated as above from a PDZ 
73 construct produced by Dr Blaydon of this lab, with the PDZ73 sequence 
positioned downstream of the Sp6 promoter sequence and using the Sp6 TNT® IVT 
Kit (Promega).
2.5.6.1.1.1 Introduction of the HA tag and the T7 promoter sequence to the MCC2 
positive control
The CO-IP positive control for harmonin interactions, MCC2, lacked both a T7 
promoter and an HA tag for detection. These were introduced in-frame upstream 
of the DNA sequence, in the primers HAT7MCC2F & MCC2R (Appendix 13). A 
standard 25pl PCR reaction was used (section 2.5.1.2.6), but Mg2+ ion 
concentrations were increased to 0.9pl/25pl reaction volume, since the primers 
used were very long and would decrease Mg2+ ions rapidly. 1pl pGEX-4T-1-MCC2  
#12 (Blaydon, D. 2004) was used as template. A ‘Touchdown’ thermocycler 
program (section 2.5.1.2.6) of 40 cycles with an extension time of 30secs was 
employed as the annealing temperature of the primers would vary as the reaction 
progressed. Initially only the 3’ region specific for MCC2 would anneal but as more 
tagged product was formed and used as template in later cycles, the whole of the 
long primer would anneal to the template, altering the annealing temperature.
The PCR product was purified from PCR reaction mix components (section
2.5.6.1.1.2) and then used to synthesise HA-tagged MCC2 by IVT (section 
2.5.6.1.1).
153
2.5.6.1.1.2 Purification of PCR products
This protocol is summarized from the manufacturer’s (Qiagen) protocol. 5 volumes 
of Buffer PB (Appendix 3) was added to 1 volume of the PCR sample, mixed and 
added to a QIAquick (Qiagen) spin column in a 2ml collection tube. Columns were 
centrifuged (Jencons PLC) at 13,000rpm/~17,000xg for 60sec at room 
temperature, to bind DNA to the column. The flow-through was discarded and the 
column washed with 0.75ml Buffer PE. The column was centrifuged as above, the 
flow through discarded and centrifuged again to remove any residual buffer. The 
DNA was eluted from the column into a clean 1.5ml eppendorf by incubating the 
column with 30-50pl ddih^O followed by centrifugation as above.
2.5.6.1.2 Simultaneous detection of phosducin and harmonin on Western blots 
The expression of native phosducin was examined in whole eye homogenate from 
SV129 adult mice (section 2.4.4.1.2). 1pl of eye homogenate was run on a 15% 
SDS-PAGE gel (section 2.4.4.2) alongside 1pl of IVT USH1C (section 2.5.6.1.1). 
Proteins were transferred to a nitrocellulose membrane for Western blotting 
(sections 2.4.4.3), using the following antibody combinations:
■ Antibody set A -  overnight incubation at 4°C with anti-c-Myc -AP (1:2000) 
and anti-phosducin (1:2000) (Sokolov, M et al, 2004), followed by anti-sheep 
IgG-AP (1:2000, Serotec) at room temperature for 1 hour.
■ Antibody set B -  overnight incubation at 4°C with anti-c-Myc -AP (1:2000) 
and anti-phosducin (1:2000), followed by anti-sheep IgG-AP (1:1000) at 
room temperature for 1 hour. The membrane was developed then re-probed
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to achieve a stronger harmonin band using monoclonal anti-harmonin 
(1:500) simultaneously incubated with the secondary antibody anti-mouse- 
AP (1:500) for 1 hr at room temperature.
■ Antibody set C -  overnight incubation at 4°C with anti-c-Myc -AP (1:2000) 
and anti-phosducin (1:2000), followed by anti-sheep IgG-AP (1:1000) at 
room temperature for 1 hour. The membrane was developed then re-probed 
to achieve a stronger harmonin band using the secondary antibody anti- 
mouse-AP (1:500) for 1 hr at room temperature.
• Antibody set D -  1 hour incubation at room temperature with anti-c-Myc -AP 
(1:1000) and anti-phosducin (1:2000), followed by anti-sheep IgG-AP 
(1:1000) at room temperature for 1 hour.
■ Antibody set E -  overnight incubation at 4°C with anti-phosducin (1:2000), 
followed by anti-sheep IgG-AP (1:1000) and anti-c-Myc -AP (1:500) at room 
temperature for 1 hour
2.5.6.2 CO-IP assay
2.5.6.2.1 Assay and bait control CO-IP reactions
5pl of IVT pGADT7-T and 5pl of IVT pGBKT7-53 (produced in section 2.5.6.1.1), 
were incubated with 30pl of 25mM Tris-buffered saline (TBS) pH7.2 in the 
stoppered columns for 4 hours at room temperature on a rotator (Stuart Scientific). 
The controls listed in Table 2.7 were set up and incubated in the same way.
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To each column, a further 30|jI TBS and 5pg anti-c-Myc antibody bound to agarose 
beads (Profound™ c-Myc Tag IP/CO-IP kit, Pierce) was added, all of which was 
then incubated on a rotator, overnight at 4°C. The column was then placed in a 
collecting tube, the cap loosened and the plug removed for a 10sec pulse spin at 
maximum centrifugation in a bench top centrifuge. The column was washed with 
0.5ml TBS-T (TBS pH 7.2 + 0.05% Tween 20); inverting each column 3 times to 
mix, then pulse spinning at maximum for 10seconds. The flow through was 
discarded and the column washed a further two times. The bound proteins were 
eluted by adding 20pl of 2x non-reducing sample buffer (made from 5x concentrate 
and provided with the kit), incubating both column and new collecting tube at 95- 
100°C for 5mins, and then pulse spun as above.
8pl of each eluate was loaded on a 15% SDS-PAGE gel and transferred to a 
nitrocellulose membrane for Western blotting (sections 2.4.4.2 & 2.4.4.3). Proteins 
were detected by incubating the membrane with Streptavidin-AP antibody at 
1:2500 for 1 hour at room temperature.
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Table 2.7 Pull down assay control reactions
Incubation mix Reason Expected
outcome
‘no DNA’ IVT reaction and 
TBS buffer
Tests for non-specific binding of 
proteins from the reticulosyte lysate
Blank
pGBKT7-53 protein 
(expressing c-myc tag) and 
TBS buffer
Checks the specificity of anti-c-myc 
antibodies for the c-myc tag (+ve 
control)
Single band 
of p53 protein
pGADT7-T protein 
(expressing HA tag) and 
TBS buffer
Checks the specificity of anti-c-myc 
antibodies for the c-myc tag (-ve 
control).
Blank
TBS buffer only Identifies any contaminants in the 
buffer that result in bands on the 
blot.
Blank
pGBKT7-53 protein and 
pGADT7-T protein
Checks that the system functions 
correctly (+ve control)
Two bands -  
p53 & T
The above incubations were repeated, substituting anti-c-myc beads for anti-HA 
beads to confirm the above points and that the proteins were not binding to the 
beads themselves.
pGBKT7-USH1C protein 
(expressing c-myc tag) and 
(expressing HA tag) 
pACT2-MCC2 protein
Checks that the system functions 
correctly with respect to the bait -  
harmonin is able to interact with a 
known interactor (+ve control)
Two bands -  
harmonin & 
MCC2
pACT2-MCC2 protein 
(expressing HA tag) and 
TBS buffer
Checks that the system functions 
correctly with respect to the bait -  
harmonin is able to interact with a 
known interactor (-ve control)
Blank
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2.5.6.2.2 PGBKT7-USH1C and phosducin
15pl IVT USH1C (section 2.5.6.1.1) was incubated with ~100[jg whole eye 
homogenate (section 2.4.4.1.2) and 20|jl 25mM TBS pH7.2 at 37°C overnight. This 
was then placed in an elution column (provided with Profound™ c-Myc Tag IP/CO- 
IP kit), with 30pl TBS and 5pg anti-c-Myc antibody bound to agarose beads 
(Profound™ c-Myc Tag IP/CO-IP kit, Pierce) and then incubated on a rotator 
(Stuart Scientific) at room temperature for 35mins. The column was then placed in 
a collecting tube, the cap loosened, the plug removed and pulse spun for 10 
seconds at maximum centrifugation in a bench top centrifuge. This initial flow 
through was kept on ice for immediate use or stored at -20°C for later analysis. The 
column was washed with 0.5ml TBS-T (TBS pH 7.2 + 0.05%  Tween 20); inverting 
each column 3 times to mix, then pulse spun at maximum for 10seconds. The flow 
through was discarded and the column washed a further two times as above. The 
bound proteins were eluted by adding 20pl of 2X non-reducing sample buffer 
(made from 5x concentrate and provided with the kit), incubating both column and 
new collecting tube at 95-100°C for 5mins, and then pulse spun as above. The 
eluate was kept on ice for immediate use or stored at -20°C for later analysis. A  
negative control was performed alongside, as above, substituting the IVT USH1C  
protein for buffer.
2pl p-mercaptoethanol was added to each eluate sample and the whole volume of 
eluate was loaded onto a 15% SDS-PAGE gel (Appendix 6 & 2.4.4.2) alongside 
aliquots of IVT USH1C alone and eye homogenate alone. A 10pl aliquot of initial 
flow through was denatured at 95°C for 3mins with 6xLlamelli loading buffer
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(Appendix 3) and loaded alongside the eluate. The separated proteins on the SDS- 
PAGE gel were transferred to nitrocellulose membrane for Western blotting and the 
membrane blocked. The membrane was immunoblotted with anti-Phosducin 
1:4000 and anti-sheep IgG-AP 1:1000 for 1hour at room temperature. The 
membrane was washed and then immunoblotted with monoclonal anti-harmonin 
1:500 and anti-mouse IgG-AP conjugated antibody 1:1000 for 1hour at room 
temperature (section 2.4.4.3).
2.5.7 Methodology: Validation of candidate interactor through protein localisation 
and gene expression analysis
2.5.7.1 Comparison of Phd and harmonin protein localisation in the normal adult 
retina
Fixed adult SV129 eyes were collected and sectioned (section 2.3.1.1). Sections 
were stained for the presence of Phosducin as described by Sokolov, M et al, 
2004. Controls substituted anti-Phosducin antibody for PBS. The primary antibody 
was detected using anti-sheep lgG-Cy3 (Jackson Laboratories) at 1:50 for 1 hour 
at room temperature. A nuclear counter stain was provided by 30 minutes 
incubation with Hoescht at 1:200 in PBS, at room temperature in the dark. Sections 
were washed and slides partly air dried before mounting with Citifluor (Citifluor Ltd) 
mounting media.
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Stained sections were stored at 4°C. Immunolabelled sections were analysed 
using a light microscope (Axioplan 2, Zeiss), and images captured using Openlab 
software (Improvision). Stained sections were compared to adult unfixed retinal 
sections labelled with anti-harmonin (2.3.1.3).
2.5.7.2  Comparison of Phd and harmonin protein localisation in the normal 
developing retina
Fixed postnatal CD1 eyes were collected and sectioned (section 2.3.1.1). Sections 
were stained for the presence of Phosducin (section 2.5.7.1) and compared to 
harmonin labelled (2.3.3.1) and semithin sections (2.3.3.1).
Immunolabelled sections were analysed using a laser scanning confocal 
microscope (SP2 Leica), with projection images gathered at 0.3pm throughout the 
whole section using Leica Confocal Software (version 2.5), before transfer to 
Adobe Photoshop.
2.5.7.3 Comparison of Pdc and Ushlc gene expression in the adult and 
developing ear
1pg of total RNA (0.1pg/pl) from an isolated adult murine cochlea and a P7 bulla, 
and 1pg of total murine adult eye RNA (~ 0.2pg/pl) (used in section 3.3.2), were 
used in a two step RT-PCR reaction (section 2.3.3.2.2). The success of cDNA
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production was examined using primers to the housekeeping gene Gapdh 
(Appendix 13) in a 25pl PCR amplification reaction (section 2.5.1.2.6) for 35 cycles 
(95°C/15s; 55°C/15s; 72°C/30s). The expression of Pdc in the ear used the same 
PCR reaction as the housekeeping gene and the following thermocycler program, 
(35 or 40 cycles at 95°C/15s; 55°C/15s; 72°C/30s), with maPhdF and maPhdR 
primers (Appendix 13). The adult eye cDNA was used as a positive control.
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3 RESULTS CHAPTER: Identification of the temporal and spatial 
expression of Ushic and harmonin within the normal murine 
eye.
In order to help understand its role in the pathology of Usher syndrome, the pattern 
of protein localisation and Ushic  gene expression was examined in the normal 
murine eye. Immunostaining analysis had already localised harmonin to the six 
sensory areas of the inner ear, restricted to the hair cells within these areas (Verpy, 
E et al, 2000). Due to the structural similarities between auditory hair cells and 
visual photoreceptor cells (sections 1.2.1.1 & 1.2.2.1), it is reasonable to 
hypothesise that harmonin could be localised within the retinal photoreceptors. 
This hypothesis is further supported by the demonstration of USH1C  expression in 
the outer neuroblastic layer of the retinal by Bitner-Glindzicz et al (2000), which is 
rich in newborn rod and cone photoreceptors.
Research Objectives:
■ To investigate the pattern of protein localisation of harmonin in the adult 
murine retina.
■ To investigate the hypothesis that the type 1 Usher proteins interact, by 
examining the protein localisation of harmonin in the absence of myosin 
VIIA and cadherin 23.
■ To explore possible functions of harmonin by determination of the age of 
onset of Ushic  gene expression.
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3.1 Identification of the pattern of protein iocaiisation of harmonin in 
the adult murine retina
3.1.1 Harmonin localisation in the adult murine retina
Adult murine retinal tissues were immunostained for the presence of harmonin 
(section 2.3.1.2.1). High levels of harmonin immunoreactivity were seen in the OS 
of the adult murine retina (Figure 3.1 B). This staining was not seen when PBS was 
substituted for the anti-harmonin antibody (Figure 3.1 A). Comparison of harmonin 
staining and phalloidin labelling (Figure 3.1 C.), clearly demonstrates the absence 
of harmonin in the RPE, and also demonstrates a gap in staining between the 
green harmonin (B) in the OS and the blue of the Hoechst in the ONL (A), edged 
with the red of the OLM (C), suggesting that harmonin is not localised to the IS in 
fixed adult retinal tissue sections.
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Figure 3.1 Localisation of harmonin in the adult murine retina
PHALLOJDINHARMONINCONTROL
(A) Replacement of the anti-harmonin antibody with PBS. A nuclear counter-stain is provided with 
Hoechst (blue). (B) Harmonin (green) is clearly localised as a discrete band within the OS of the 
photoreceptor. No harmonin immunostaining was detected in the inner retina or RPE (compare the 
lack of staining in B in the region of the RPE highlighted in C). Note the absence of harmonin 
immunoreactivity at the photoreceptor IS. (C) The RPE, OLM and parts of the OPL, were visualised 
using rhodamine conjugated phalloidin to label the F-actin found in these structures.
GCL, ganglion cell layer. IPL, inner plexiform layer. INL, inner nuclear layer. OPL, outer plexiform 
layer. ONL, outer nuclear layer. OLM, outer limiting membrane. IS, photoreceptor inner segments. 
OS, photoreceptor outer segments. RPE, retinal pigmented epithelium. Scale bars 50 >t/m.
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Retinal sections were double immunostained with antibodies to the OS-specific 
protein, rhodopsin, and to harmonin (section 2.3.1.2.2). The individual staining 
patterns of the two antibodies can be seen in Figure 3.2B. (rhodopsin) and C 
(harmonin). Where these images are overlaid (Figure 3.2D), a distinct yellow band 
in the OS can be seen, confirming the presence of harmonin in the photoreceptor 
OS. There is also a distinct lack of staining in the region between the OS and the 
outer nuclear layer, corresponding to the IS. Thus this experiment confirms the 
absence of harmonin in the photoreceptor IS in fixed retinal sections.
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Figure 3.2 Colocalisation of harmonin and rhodopsin in the photoreceptor outer segments
os
IS
ONL
OPL
INL
Retinal sections were stained for the presence of (B) rhodopsin (green), (C) harmonin (red) and 
counter stained with (A) Hoechst (blue). Punctate background staining from the secondary 
antibodies used is shown in C (white arrow). When the three images are overlaid in D, a yellow 
band is seen in the OS showing that the two proteins colocalise in this region and no staining is 
seen in the photoreceptor IS (white arrowhead), or any other region of the neural retina.
INL, inner nuclear layer. OPL, outer plexiform layer. ONL, outer nuclear layer. IS, photoreceptor 
inner segments. OS, photoreceptor outer segments. Scale bars 50 /ym.
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3.1.2 The effects of fixation upon harmonin, myosin VIIA and cadherin 23 
localisation
In fixed tissue, harmonin was confined to the photoreceptor OS. Reiners et al 
demonstrated further areas of harmonin immunoreactivity in the unfixed retina 
(Reiners, J et al, 2003). In order to confirm their findings, immunostaining on 
unfixed adult murine tissues was performed for harmonin, myosin VIIA and 
cadherin 23 (section 2.3.1.3).
In unfixed tissue, harmonin showed additional immunostaining, localising to the IS, 
OS and OPL (Figure 3.3C). In unfixed tissue, myosin VIIA is localised to the 
photoreceptor IS and OPL and to the RPE (Figure 3.3D); previously in fixed tissue, 
it was localised to the RPE and the photoreceptor connecting cilium only (Liu, X et 
al, 1997). Cadherin 23 was confined to the IS and OPL of the photoreceptor only 
(Figure 3.3E). No staining was seen in the photoreceptors in the negative controls 
for any of the primary antibodies (Figure 3.3A). In unfixed tissue, levels of 
immunostaining were generally higher throughout the retina, compared to fixed 
tissue (Figure 3.3C and B). These results support the findings of Reiners et al, 
showing all three USH1 proteins to colocalise in the photoreceptor IS and OPL 
(Figure 3.3C-E), and would suggest that paraformaldehyde fixation can mask the 
harmonin antigens and reduce the ability of the antibody to detect the protein.
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Figure 3.3 Immunolocalisation of USH1 proteins in unfixed and fixed murine retinas
UNFIXED FIXED UNFIXED UNFIXED UNFIXED
Control Harmonin Harmonin Myosin Vila Cadherin 23
OS
ONL
OPL
INL
I PL
GCL
(A) Example of a negative control section, substituting PBS for the primary antibody. Low level 
background is visible throughout the inner neural retina (INL, IPL & GCL). (B) Harmonin (green) is 
localised to the photoreceptor OS (white arrowhead) in fixed tissue. (C) Immunostaining on unfixed 
tissue (shown in green) for harmonin (D), myosin VIIA and (E) cadherin 23, shows all three to be 
present in photoreceptor IS and the OPL.
GCL, ganglion cell layer. IPL, inner plexiform layer. INL, inner nuclear layer. OPL, outer plexiform 
layer. ONL, outer nuclear layer. IS, photoreceptor IS. OS, photoreceptor OS. Scale bars 50/ym.
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3.2 Examination of harmonin localisation in fixed retinal tissue in the 
absence of myosin VIIA or cadherin 23
Myosin VIIA, cadherin 23 and harmonin are thought to form a macromolecular 
complex in the ear (section 1.3.4.1). Therefore harmonin localisation was 
examined in the retina of null mouse models for USH1B and USH1D, to determine 
whether it's spatial positioning was maintained in the absence of either protein 
(section 2.3.2).
Harmonin was localised in the photoreceptor OS in both the heterozygous 
littermate control and in the homozygous null Myo7a4626SB mutant retina (Figure 
3.4B&C), indicating that the loss of one or both myosin VIIA alleles has no effect on 
harmonin localisation in the OS. In the retina of the Cdh23v heterozygote and 
homozygote mice (Figure 3.4D&E), harmonin was also maintained in the 
photoreceptor OS, showing that cadherin 23 is not required for the localisation of 
harmonin to the photoreceptor OS either. Fixed tissue was used in this study as 
increased masking of harmonin by fixation had not been demonstrated at this time.
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Figure 3.4 Immunolocalisation of harmonin in normal and mutant murine retinas
Harmonin was visualised by FITC (green) with Hoechst nuclear staining (blue). (A) Negative control.
(B) In the heterozygote shaker-1 (Myo7a+/4626SB) (C) and the homozygote shaker-1
(Myo7a4626SB/4626SB), harmonin localised to the photoreceptor OS. In the heterozygote waltzer mouse 
(Cdh23+/V) (D), and the homozygote waltzer (Cdh23v/v) (E), harmonin localisation in the 
photoreceptor OS was also maintained.
GCL, ganglion cell layer. IPL, inner plexiform layer. INL, inner nuclear layer. OPL, outer plexiform 
layer. ONL, outer nuclear layer. OLM, outer limiting membrane. IS, photoreceptor inner segments. 
OS, photoreceptor outer segments. Scale bar 50/vm.
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3.3 Determination of the age of onset of Ushic gene expression
3.3.1 Harmonin localisation in the postnatal murine retina
In order to study the temporal expression of harmonin, the retinas from CD1 mouse 
pups were immunostained (section 2.3.3.1).
Development was examined from P2-P12, (covering the final stages of eye 
development, section 1.2.2.2). In Figure 3.5, at P2-P4, harmonin (green) is 
confined to the outermost layer of progenitor cells in the outer retina. These 
developmental stages are comparable to the 12 week stage in human foetal retina 
development, and these results are consistent with the findings from human 
expression studies, where harmonin was confined to the outer neuroblastic layer at 
12 weeks (Bitner-Glindzicz, M et al, 2000). At P8, harmonin staining is seen as a 
discreet layer above the ONL, in the location of the developing IS and OS. By P12, 
it is clear that in fixed tissue, harmonin is localised to the OS. No harmonin 
immunostaining was detected in the RPE or inner retina throughout development.
Unfixed tissue from developing eyes proved too unstable to examine, losing all 
discernable tissue architecture during the immunostaining procedure.
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Figure 3.5 Harmonin localisation in the developing (P2-P12) murine retina
Development of retinal photoreceptors from 
P2-P12 is shown using semithin sections 
(blue), simultaneous to analysis of the 
expression of harmonin by
immunofluorescence (green) in CD1 wildtype 
mouse retina.
At P2 and P4, harmonin is localised to the 
newborn photoreceptors (*) of the outer retina 
and later confined to the developing 
photoreceptor segments by P8. At P12, 
harmonin is clearly localised to the OS in fixed 
tissue. Replacement of the anti-harmonin 
antibody with PBS (bottom, P12 control panel) 
showed minimal non-specific background 
staining throughout the neural retina in fixed 
tissue. No harmonin immunostaining was 
detected in the RPE or inner retina at any 
developmental stage.
GCL, ganglion cell layer. IPL, inner plexiform 
layer. INL, inner nuclear layer. OPL, outer 
plexiform layer. ONL, outer nuclear layer. IS, 
photoreceptor inner segments. OS, 
photoreceptor outer segments. * Newborn 
photoreceptor layer. Scale bars 50/vm.
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3.3.2 Ush 1c expression in the prenatal murine retina
As harmonin was detected as early as P2, the age of onset of Ushlc  expression in 
embryonic murine eyes was then examined using semi-quantitative RT-PCR. 
Whole eye extracts from CD1 mouse embryos aged E12.5-E18.5 and adults were 
used (section 2.3.3.2).
Expression of Ushlc, Myo7a, Cdh23 and Pcdh15 was demonstrated from 
embryonic day E12.5 to E18.5 and into adulthood (Figure 3.6A). Semiquantitative 
PCR analysis of the expression of the USH1 genes, showed their expression levels 
to be fairly similar (Figure 3.6B). It is interesting to note, that there is not a 
significant alteration in transcript levels in adult life compared to embryonic life.
173
Figure 3.6 Usher type 1 gene expression during prenatal murine eye development
(A) Semi-quantitative RT-PCR analysis of USH1 gene expression during early murine eye development. The developmental stages examined are 
indicated above each lane. (100bp DNA size standard. A, Adult. C, Negative control.). (B) A comparison of the expression levels of the USH1 
genes by semi-quantitative PCR (Raw data can be found in Appendix 14). Error bars represent 2 standard deviations.
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3.4 Conclusions
■ In the developing murine eye, Ushlc  expression can be detected as early as 
E12.5.
• As the retina differentiates, harmonin is first localised to the new born 
photoreceptors and then to their developing segments.
■ In the adult it is clearly confined to the OS in fixed tissue.
■ Localisation in the OS is maintained in the absence of either myosin VIIA or 
cadherin 23.
■ Additional immunoreactivity is seen using unfixed tissue, with harmonin 
localised to the photoreceptor OS, IS and OPL. Myosin VIIA and cadherin 23 
were also localised to the photoreceptor IS and OPL in unfixed tissue.
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4 RESULTS CHAPTER: Generation of polyclonal antibodies to 
harmonin isoforms
Harmonin has multiple isoforms (section 1.3.3.2) which vary in protein 
localisation (Reiners, J et al, 2003) and binding partners (Boeda, B et al, 2002). 
Production of isoform specific antibodies will allow harmonin isoform-protein 
expression patterns to be investigated. Since the expression and localisation 
work has revolved around mice, it was decided to produce the antibodies 
against the murine harmonin isoforms. Antibodies were selected and raised by 
Sigma-Genosys (section 2.4.1), against peptide 1 (LTPRRSRKLKEVRLD -  
detecting all harmonin isoform classes) and peptide 2 (PADHLDGSTEEQRQQ -  
detecting isoform classes ‘a’ and ‘b’ only). Subsequent analysis is described in 
this chapter.
Research Objective:
■ To validate two new polyclonal antibodies to the different harmonin 
isoforms.
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Henceforth, the antibodies produced against peptide 1 are referred to as ‘anti- 
LTPR sera’ or ‘anti-LTPR IgGs’ if purified, whilst antibodies produced against 
peptide 2 are known as ‘anti-PADH sera’ or ‘anti-PADH IgGs’ if purified. The 
antibody produced by Dr Scanlan (Scanlan, M J et al, 1999) is known as the 
‘monoclonal anti-harmonin antibody’ and the antibody produced by Dr 
Kobayashi (Kobayashi, I et al, 1999) is known as the ‘polyclonal anti-harmonin 
antibody’. Analysis involving the native harmonin protein is listed by its tissue 
source, and IVT-produced harmonin protein is named IVT USH1C.
4.1 Analysis of the anthharmonin antibodies by ELISA
ELISA analysis (section 2.4.2) examined whether the host organism had raised 
IgGs against the antigenic peptides and is summarized in Table 4.1 and 4.2 for 
peptides 1 and 2 respectively. For both peptides there was an initial surge of 
antibody production between the preimmune and test bleed 1, due to the 
primary immune response on initial presentation of the antigen. This then fell 
slightly for test bleeds 2 and 3 as IgG levels plateaued and then declined. IgG 
levels rose again for the harvest bleed due to the secondary immune response 
to the antigen, reaching levels equal to or greater than those seen for test bleed 
1. Test bleed 3 for peptide 2, failed to produce a satisfactory result at the 
dilutions tested for unknown reasons but was successful for the harvest bleed.
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A comparison of the antigenicity of each peptide at different stages during the 
immunization protocol is seen in Figure 4.1. An initial surge in antibody 
production was seen for both peptides after the initial antigen inoculation, noted 
by a steep rise in IgGs levels between the preimmune bleed and test bleed 1. 
Levels dipped during test bleeds 2 and 3, but rose again after the fifth 
inoculation (as seen by the harvest bleed levels). IgG levels for peptide 2 did 
not recover as well as was seen for peptide 1. At all stages examined, peptide 2 
appeared to produce only 50% of the immune response seen from peptide 1. 
This maybe due to differences in the immune systems of the two host animals or 
the result of the different biochemistry of the two peptides. As a result, anti- 
LTPR serum raised against peptide 1 was chosen for further analysis.
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Table 4.1 Examination of the antigenicity of peptide 1 by ELISA.
A positive ELISA result is where the absorbance reading is 0.3 units greater than that of the value determined for the blank/negative control and is 
highlighted here in bold.
Pep1 Dilution
Blank 1:100 1:500 1:1000 1:5000 1:10000 1:50000 1:100000 1:500000
E
Pre-
immune 0.0639 0.0977 0.0662 0.0643 0.0658 0.0680
LOo Test 
bleed 1 0.0639 2.2781 1.4255 0.4810 0.2658
®
0o
Test 
bleed 2 0.0847 1.0223 0.3386 0.1693 0.1011 0.0790 0.0719cCD.Q
o
Test 
bleed 3 0.0847 0.2924 0.1819 0.1929 0.0862 0.0742
<
Harvest
bleed 0.0612 2.4447 1.6154 1.2945 0.4681 0.2867 0.1373 0.1098 0.1113
i
VO
Table 4.2 Examination of the antigenicity of peptide 2 by ELISA.
A positive ELISA result is where the absorbance reading is 0.3 units greater than that of the value determined for the blank/negative control and is 
highlighted here in bold.
Pep2 Dilution
Blank 1:100 1:500 1:1000 1:5000 1:10000 1:50000 1:100000 1:500000
Ab
so
rb
an
ce
 
@ 
40
5n
m
Pre-
immune 0.0646 0.0821 0.0695 0.0660 0.0711 0.0665
Test 
bleed 1 0.0639 0.8543 0.3236 0.1640 0.0813 0.0758
Test 
bleed 2 0.0696 0.3427 0.0923 0.0918 0.0649 0.0694 0.0647
Test 
bleed 3 0.0847 0.1230 0.0850 0.0671 0.0681 0.0662
Harvest
bleed 0.0675 1.9840 0.6655 0.4205 0.1798 0.1597 0.1089 0.0949 0.0856
i
Figure 4.1 Analysis of the immune response produced to the separate harmonin peptides
A comparison of the levels of IgGs raised against peptides 1 and 2, at the various stages of the immunisation procedure. Peptide 1 produced a 
greater immune response at all stages of the antibody production process.
Analysis of the immune response produced to the separate harmonin
peptides
O  t/3
■ Peptide 1
■  Peptide 2
Pre-immune Test bleed 1 Test bleed 2 Test bleed 3 Harvest bleed
oo
4.2 Analysis of the anti-harmonin antibodies by immunolabelling 
of murine retinas
Anti-LTPR and anti-PADH sera were used on fixed retinal sections from P10 
CD1 mice (section 2.4.3). Increased masking of harmonin by fixation had not 
been demonstrated at this time.
As previously seen in fixed tissue, the polyclonal anti-harmonin antibody 
localised harmonin to the developing OS of the photoreceptor (Figure 4.2B). 
Low level immunostaining was also seen in the OPL, a feature seen in some 
fixed sections but not consistently witnessed in all strains and developmental 
ages examined. When rabbit serum was substituted for the primary antibody 
(Figure 4.2A), background non-specific immunoreactivity was seen 
throughout the retina, including the OPL. Use of the anti-LTPR serum 
(Figure 4.2C) resulted in high levels of background staining throughout the 
retina, with a greater degree of immunostaining in the developing OS. 
Immunostaining with the anti-PADH serum (Figure 4.2D), gave a similar 
result to the negative control using rabbit serum (A), with high levels of 
background staining throughout the retina and the possibility of a limited 
degree of immunoreactivity in the developing OS.
With both of the new harmonin antibodies, the background staining levels 
were very high, similar to the rabbit serum negative control and both required 
further amplification for visualization, compared to the polyclonal anti- 
harmonin antibody. The high background levels may be the result of other 
IgGs present in the sera that were produced in response to the carrier
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proteins or other antigens the host was exposed to during the antibody 
synthesis protocol. This would suggest that although anti-LTPR serum 
produces better results that the anti-PADH serum, neither of the new anti- 
harmonin antibodies are suitable for immunostaining.
Figure 4.2 Comparative immunolocalisation of harmonin using the polyclonal anti- 
harmonin antibody, the anti-LTPR sera and the anti-PADH sera
Rabbit Serum Polyclonal________ LTPR__________CPAD
OS 
IS
ONL
OPL 
INL
IPL 
GCL
Fixed retinal sections from P10 CD1 mouse immunolabelled with polyclonal anti-harmonin 
antibody (B; positive control), anti-LTPR sera (C) and anti-PADH antibody sera (D).Rabbit 
serum was used as a negative control (A). Immunostaining for harmonin was visualised 
using FITC in the positive and negative controls. Further amplification was necessary for the 
anti-LTPR and anti-PADH sera. Single images were collected by confocal microscopy.
GCL, ganglion cell layer. IPL, inner plexiform layer. INL, inner nuclear layer. OPL, outer 
plexiform layer. ONL, outer nuclear layer. * developing photoreceptor inner and outer 
segments. Scale bar 50pm.
B D
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4.3 Analysis of the anti-harmonin antibodies by immunoblotting 
analysis
Anti-LTPR serum was used on a Western blot to visualize harmonin from 
various protein sources (sections 2.4.4.1 - 2.4.4.2 & 2.5.6.1.1). These 
tissues were first validated as sources of the harmonin protein by 
immunoblotting with either the monoclonal (Scanlan, M J et al, 1999) or 
polyclonal (Kobayashi, I et al, 1999) anti-harmonin antibodies (section
2.4.4.3).
IVT USH1C or harmonin can clearly be seen in their respective lanes (Figure
4.3) regardless of which antibody is used for detection. Three close bands 
are seen in lanes four and six containing the bound IVT protein. It is not 
known why three bands exist or why the IVT protein runs slightly smaller than 
the native protein (compare lanes 2 and 3). An alteration in glycosylation or 
phosphorylation of the protein in the IVT form has been suggested and 
investigated by Blaydon, D, 2004. Three bands can also be seen in the 
Caco2 cell line and two bands for whole eye homogenate samples, in lanes 
two and seven respectively.
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Figure 4.3 Validation of protein aliquots as sources of the harmonin protein
Monoclonal Polyclonal
Cell lines R28 & Caco2, whole eye homogenate and IVT USH1C were probed for the 
presence of harmonin using the anti-harmonin monoclonal and polyclonal antibodies. Lane 
1, protein standards. Lane 2, Caco2 cell lysate. Lane 3, R28 cell lysate. Lane 4, IVT 
USH1C. Lane 5, protein standards. Lane 6, IVT USH1C. Lane 7, whole eye homogenate. 
Lanes 1 to 4 were incubated with monoclonal anti-harmonin. Lanes 5 to 7 were incubated 
with polyclonal anti-harmonin.
The presence of the slightly smaller IVT USH1C protein in lanes four and six, is denoted by 
<. The native protein appears slightly larger than the 75 kDa protein standard mark and is 
denoted by « .  The polyclonal anti-harmonin antibody appears to produce higher 
background levels than the monoclonal (compare the extra non-specific bands in lanes four 
and six).
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The same experiment was repeated using the anti-LTPR serum on IVT 
USH1C protein and whole eye homogenate (section 2.4.4.4), but no clear 
bands around the 75kDa mark could be distinguished from the background 
(Figure 4.4, lanes 5 and 6). Harmonin was detected from both proteins 
sources in the positive control lanes (lanes 2 and 3).
Figure 4.4 Harmonin detection on western blots using anti-LTPR antibody sera
kDa
75
Pohclonal ajxti-hamiomn AntLLIPR  sera
IVT Eye
50
37
25
IVT Eye
-
T. m
? * T'V *
The presence of the slightly smaller IVT USH1C protein in lane two, is denoted by «  and 
the native protein in lane three is denoted by <.
Lanes 1, protein standards. Lane 2, IVT USH1C. Lane 3, whole eye homogenate. Lanes 4, 
protein standards. Lane 5, IVT USH1C. Lane 6, whole eye homogenate. Lanes 1-3 were 
probed with polyclonal anti-harmonin antibody, whilst lanes 4-6 were probes with anti-LTPR 
antibody sera.
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In order to try and improve immunoblotting results using anti-LTPR serum by 
reducing background/non-specific binding, affinity column purification of the 
IgGs from the sera was performed (section 2.4.4.5). Eight aliquots of ~500pl 
each were collected and absorbance taken at 280nm to monitor the elution of 
the IgGs from the beads (Table 4.3). Sample 2 was then used at 1:100 on 
western blots. Higher concentrations produced unusable background levels 
(data not shown).
Table 4.3 Elution readings from the purification of anti-LTPR IgGs from the 
antibody serum
An aliquot of anti-LTPR harvest bleed sera was purified on a Protein A column and eluted in 
500pl aliquots. The presence of IgGs in each aliquot was determined by the OD28o level. 
The highest level of anti-LTPR IgGs was in aliquot two.
Aliquot 1 2 3 4 5 6 7 8
O D 280 0.66 1.21 0.97 1.14 0.85 0.57 0.37 0.29
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The ability of purified anti-LTPR IgGs to detect harmonin from the IVT 
reaction, Caco2 cell lysate and R28 cell lysate, was compared to that of 
unpurified anti-LTPR serum and the monoclonal anti-harmonin antibody 
(section 2.4.4.6).
Figure 4.5 shows that harmonin can be detected using the monoclonal anti- 
harmonin antibody (lanes 2, 3 and 4) but no strong band can be seen at 
75kDa with the unpurified serum in either Caco2 or R28 cells (lanes 6 and 7). 
A band at exactly 75 kDa is seen in the Caco2 and R28 lanes (lanes 10 and 
11) using purified anti-LTPR IgGs, yet this not seen in the IVT USH1C protein 
lane (lane 9). This would suggest that the purified antibody could be cross­
reacting with a protein of similar size to harmonin.
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Figure 4.5 A comparison of the ability of purified anti-LTPR IgGs to recognise 
harmonin, compared to that of the unpurified anti-LTPR antibody sera
Mono clonal LTPR serum Purified LTP R IgGs
o  o
The monoclonal anti-harmonin antibody detects the harmonin protein from all three tissue 
sources in lanes 2-4. Unpurified anti-LTPR antibody sera does not detect a 75 kDa band in 
lane six and seven with the cell lines, although there is a distinct darker band for the R28 cell 
line in lane seven, greater than 75 kDa. Purified anti-LTPR IgGs show a strong band at 75 
kDa which is also seen in the Caco 2 cell line in lane 10. Purified anti-LTPR IgGs is unable to 
detect the IVT USH1C protein, lane nine.
Lanes 1,5&8, protein standards. Lane 2,6&10, Caco2 cell lysate. Lane 3,7&11, R28 cell 
lysate. Lane 4&9, IVT USH1C. The presence of the slightly smaller IVT USH1C protein is 
denoted by «  and the native protein by <.
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To confirm whether the dark band seen in lanes 10 and 11 of Figure 4.5 is 
actually harmonin, samples of purified and unpurified antibody were 
incubated with peptide 1 for one hour at room temperature, prior to 
incubation with the blot. The bands seen in the pre-absorbed anti-LTPR  
blots were compared with those of anti-LTPR treated as in previous 
experiments (section 2.4.4.7.).
Figure 4.6 shows that the 75kDa band seen with the cell line source using 
purified anti-LTPR IgGs (lane 11 & Figure 4.5, lane 10), disappears when the 
purified IgGs are pre-absorbed with the LTPR peptide (Figure 4.6, lane 14). 
This would indicate that this band does represent harmonin from the Caco2 
cell line. Yet the fact that harmonin could not be detected in the IVT USH1C  
lanes (Figure 4.6, lanes 2, 5, 9 and 12), or the whole eye homogenate lanes 
(lanes 3, 6, 10 and 13), whether using purified IgGs/unpurified serum/pre­
absorbed samples, supports the results of Figure 4.5, suggesting that the 
anti-LTPR antibody is picking up a non-specific band in the Caco2 cell line 
that is coincidentally the same size as harmonin.
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Figure 4.6 Examination of the specificity of the anti-LTPR antibody sera and purified 
anti-LTPR IgGs for harmonin
LTPR scrum Purified LTPR IgGs
+ LTPR ag r  ., ..^ ... ,1
IVT Eve Caco2
-LTPR ag 
  ..
IVT Eve Caeo2
- LTPR ag + LTPR ag— --------£---. y ... . ....
IVT Eve Cae«2 IVT Eve Caco2
Aliquots of the unpurified sera (lanes 5-7) and purified anti-LTPR IgGs (lanes 12-14) were 
preabsorbed with an excess of peptide 1.
There is very little difference in the banding pattern between the pre-absorbed and non pre­
absorbed unpurified anti-LTPR sera or purified anti-LTPR IgGs. At no point are any bands 
detected in the IVT USH1C or whole eye homogenate protein source.
Lanes 1&8, protein standards. Lanes 2,5,9&12, IVT USH1C. Lane 3,6,10&13 whole eye 
homogenate. Lane 4,7,11&14 Caco2 cell lysate.
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4.4 Analysis of antigenic peptide hydrophobicity
The biochemistry of the peptides was further examined in view of the poor 
immunostaining and immunoblotting analysis. On the Kyte-Doolittle and 
Hopp-Woods scales (section 2.4.5), both peptides were clearly hydrophilic, 
scoring below zero at all points (Figure 4.7). Examination of the complete 
harmonin protein using both hydrophilicity scales, showed that there were 
four clear regions of hydrophilicity, and that peptide 1 was located in the first 
region of hydrophilicity and peptide 2, in the third region (Figure 4.8). In 
theory, since peptide 2 was more hydrophilic than peptide 1, it would be 
expected to be more antigenic although in practice, this does not appear to 
be the case Neither of the peptides are rich in cysteines or threonines, 
meaning that they are unlikely to form disulphide bridges or other secondary 
structures. This data would suggest that both peptides have no biochemical 
properties that would prevent their success during antibody synthesis 
protocols.
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Figure 4.7 Kyte-Doolittle analysis of the hydrophobicity of the peptides
(A) The complete amino acid sequence of peptide 1 was plotted on a Kyte-Doolittle 
hydrophobicity plot, using a window size of 7 to promote clear detection of hydrophobic 
regions. Peptide 1 was seen to be hydrophilic throughout. (B) The complete amino acid 
sequence of peptide 2 was plotted on a Kyte-Doolittle hydrophobicity plot, also using a 
window size of 7 None of the amino acids of peptide 2 were hydrophobic in fact the C- 
terminal amino acids were particularly hydrophilic, suggesting that this peptide would be a 
good candidate for use in antibody synthesis.
A
Figure 4.8 A hydrophobicity plot of the complete murine harmonin isoform a 
amino acid sequence
Kyte-Doolittle and Hopp-Woods hydrophobicity plots were produced for the complete 
harmonin protein sequence. A window size of 20 was used to distinguish hydrophobic 
regions that would not be suitable as peptides to raise an antibody against. Amino acids 
scoring less than 0 on a Kyte-Doolittle plot are hydrophilic and those scoring more than 0 on 
a Hopp-Woods plot are also deemed hydrophilic.
There are four clear regions where the plots are polar, rich in hydrophilic amino acids. The 
most hydrophilic amino acids in these regions are listed in white on the plots, denoted the 
hydrophilic regions on the plot. The position of peptide 1 relative to these amino acids is 
denoted by the white circle of the plot, and peptide 2 buy the red circle. Both are within 
highly hydrophilic regions of the harmonin protein.
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4.5 Investigation into the presence of anti-harmonin IgGs in the 
anti-LTPR antibody sera
An initial control Ouchterlony plate was set up (section 2.4.6), to determine 
whether any anti-rabbit IgGs were present in the anti-LTPR serum. A distinct 
precipitate arc was formed between the anti-LTPR antibody sera and the 
undiluted anti-rabbit IgGs solution (Figure 4.9). The anti-rabbit IgG antibody 
(made in goat) and the anti-goat IgG antibody (made in donkey) are both 
conjugated to the FITC flurophore. The bright precipitate arc seen between 
the anti-rabbit IgG and anti-LTPR antibodies is not an artifact due to the 
presence of the flurophore, as no illumination is seen around the anti-goat 
IgG well.
In order to investigate whether the host animal inoculated with peptide 1 had 
produced IgGs against harmonin, another Ouchterlony plate was set up 
(Figure 4.10), using a variety of harmonin protein sources. Once again, only 
a precipitate formed between the anti-LTPR serum and the undiluted anti­
rabbit IgGs solution. This indicates that the anti-LTPR serum contains rabbit 
IgGs, but that these are not necessarily raised against peptide 1, and that 
they will not bind to the IVT USH1C or native harmonin protein.
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Figure 4.9 Ouchterlony analysis investigating the presence of anti-rabbit IgGs in the sera collected from the peptide 1 host.
A distinct precipitate arc was formed between the anti-LTPR antibody sera and the undiluted anti-rabbit IgGs solution.
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Figure 4.10 Ouchterlony analysis investigating the presence of anti-harmonin IgGs in the sera collected from the peptide 1 host.
A distinct protein precipitate could only be seen between the anti-LTPR serum and the undiluted anti-rabbit IgG antibody. The anti-LTPR serum did not 
recognise/precipitate with harmonin or with peptide 1 which it was raised against. Incubation for a further 24hrs did not lead to further precipitate formation.
Incubation time: 48hrs
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4.6 Conclusions
■ It is likely that the antibody synthesis protocol has resulted in the 
production of antibodies to peptides 1 & 2, as seen by the ELISA results 
(section 4.1), but these are not specific for harmonin.
■ The other IgGs in the sera could be due to the carrier protein or other 
antigens the host was exposed to during or before the anti-harmonin 
antibody synthesis period (section 1.5.1.2.1.2). It is likely that these are 
being detected in the Ouchterlony tests (section 4.10).
■ A low ratio of anti-harmonin lgGs:anti-rabbit IgGs in the sera would 
account for the poor immunostaining results, where background staining 
was high, similar to the rabbit serum control (Figure 4.2).
■ The inability of the antibody to detect harmonin from the IVT or eye 
homogenate samples by Western blot would suggest that the purified 
antibody cross-reacts with a protein of similar size to harmonin in the cell 
lysates (Figure 4.6).
* The anti-LTPR and anti-PADH sera/purified IgGs validated in this
chapter are therefore not suitable for use in immunostaining or 
immunoblotting research applications.
198
5 RESULTS CHAPTER: Identification of candidate
harmonin-interacting proteins in the eye.
Harmonin isoform ‘b’ has been shown to interact with myosin VIIA and 
cadherin 23 in the ear (Boeda, B et al, 2002). Since harmonin colocalised with 
myosin VIIA and cadherin 23 in the IS and OPL of the retinal photoreceptors, 
it is possible that similar interactions occur in the eye. Yet harmonin is also 
localised to the photoreceptor OS, where neither myosin V ila nor cadherin 23 
are localised, suggesting that harmonin may interact with other retinal 
proteins.
Aims:
■ To carry out a Yeast Two-hybrid screen of a bovine retinal library in order 
to identify candidate proteins that may interact with harmonin.
• To confirm any interactions discovered by alternative in vitro methods.
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5.1 A Yeast Two-hybrid screen of a bovine retinal library to find 
harmonin-interacting proteins
5.1.1 Confirmation of yeast strain phenotypes
The yeast strain phenotype was analysed (section 2.5.1.1), with Y187  
displaying the correct phenotype (Table 5.1; Y187 1-8), whilst the AH109 
strain grew on medium lacking histidine (AH109 A-H). Repeat streaking from 
the frozen stock on fresh plates resulted in the correct phenotype for all 1-8 
AH 109 colonies.
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Table 5.1 Analysis of the phenotype of the yeast host strains
The ability of the yeast strains to grow on minimal SD media lacking different amino acids is denoted alongside their predicted phenotype. 
+ = growth - = no growth
Strain Clone Identity SD/-Ade SD/-His SD/-Leu SD/-Trp SD/-Met SD/-Ura YPD YPDA
Y187 Expected phenotype - - - - - + - +
Tested phenotype 1,2,3,4,5,6,7,8 - - - - - + - +
AH 109 Expected phenotype - - - - + + - +
Tested phenotype A,B,C,D,E,F,G, H - + - - + + - +
Retested phenotype 1,2,3,4,5,6,7,8 - - - - + + +
5.1.2 Generation of bait and control fusion proteins
5.1.2.1 Production of bait and control fusion protein constructs
A ‘bait’ corresponding to the amino acid sequence of human USH1C isoform 
‘a’ (NCBI accession number NP_005700) fused to the GAL4-BD, was 
constructed in the pGBKT7 vector (Clontech; sequence under submission to 
NBCI; Appendix 15). Smaller baits corresponding to the individual PDZ 
domains were also constructed (section 2.5.1.2; Figure 5.1).
Figure 5.1 Schematic showing the structure of harmonin isoform ‘a’ and the 
peptides used to construct the bait fusion proteins.
The amino acids encompassing the region fused to the GAL4 domain and the individual 
structural domains have been labelled on pGBKT7-USH1C. The regions used to construct 
the PDZ domain baits are also labelled on the relevant schematic.
aa 87-196 aa 211-293 aa 310-377 aa 452-537
PDZ1 Coiled coil
pG BKT7-U SH1C
pGBKT7-PDZl
pGBKT7-PDZ2
aa 548 pGBKT7-PDZ3
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Constructs from this point on have been labelled as pGBKT7-USH1C which 
expresses the GAL4BD-harmonin fusion protein; pGBKT7-PDZ1 which 
expresses the GAL4BD-PDZ1 domain fusion protein; pGBKT7-PDZ2 which 
expresses the GAL4BD-PDZ2 and pGBKT7-PDZ3 which expresses the 
GAL4BD-PDZ3. Harmonin is known to interact with the C-terminus of 
cadherin 23 (Siemens, J et al, 2002), so this region was used as a positive 
control -  pACT2-cdh23 (Appendix 15; pACT2 NCBI accession number 
U29899).
5.1.2.2 Transformation of bait and control constructs into yeast
The individual vectors, bait constructs and control prey constructs were 
transformed into yeast (section 2.5.1.2.9). The transformation efficiencies 
(Table 5.2), were generally optimal, with only a slight decrease in efficiency 
for pGBKT7, pGBKT7-53 and pGBKT7-PDZ2, probably a reflection of a 
suboptimal plasmid preparation.
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Table 5.2 Calculation of the transformation efficiency of control and bait 
plasmids into the host yeast strains
Individual transformation efficiencies were calculated for the following, using Equation 5.1. 
Optimal transformation efficiency is £1x104 cfu/pg.
Strain[plasmid] Transformation efficiency 
(cfu/pg DNA)
AH109[pGBKT7] 9x1051
AH109[pGBKT7-USH1C (7)] 2x104
AH109[pGBKT7-USH 1C (12)] 7.4x104
AH 109[pGBKT7-PDZ1 ] 2.54x104
AH109[pGBKT7-PDZ2] 8.9x10“
AH 109[pGBKT7-PDZ3] 1.35x10“
AH 109[pGBKT7-53] 8.5x10“
AH 109[pGBKT7-Lam] 5x10“
Y187[pACT2] 1.9x10“
Y 187[pACT2-CDH23] 1.7x10“
Y 187[pGADT7-T] 2.5x10“
Equation 5.1 Transformation efficiency formula
cfu x total suspension volume (ul) = cfu/pg
DNA
Volume plated (pi) x dilution factor x amount of DNA used (pi)
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5.1.3 Validation of bait and control fusion proteins
5.1.3.1 Analysis of the DNA sequence of the baits
The complete DNA sequence for all of the bait constructs was analysed 
(section 2.5.2.1). No sequence variations were apparent, whilst the correct 
orientation and reading frame seen in the bacterial transformants was 
maintained in the yeast transformants (Figure 5.2).
Figure 5.2 The sequencing electropherogram of pGBKT7-USH1C(12)
The 3’ end of the c-Myc epitope tag can clearly be seen ( ->) leading into the initial part of 
the MCS of the vector. The sequence continues in frame into USH1C at 77nt on the 
electropherogram (block arrow) at the Sfi1 site.
c-Myc tag of pGBKT7 77nrt start of USH1C sequence
5.1.3.2 Confirmation that the bait fusion protein is harmonin
The protein content of both baits and controls was examined (section 2.5.2.2) 
by antibody staining of yeast protein extracts on Western blots.
In-frame stable expression of the correct fusion proteins was seen in Figure 
5.3. The expression of c-myc tagged ~23kDa GAL4-BD/pGBKT7 by AH 109 
is seen in lane 3. The bands of ~96kDa (lanes 9&10), ~36kDa (lane 4), 
~30kDa (lane 5) and ~32kDa (lane 6) represent the tagged fusion bait 
proteins, GAL4-BD/USH1C (~73kDa+GAL4-BD), GAL4-BD/PDZ1, GAL4- 
BD/PDZ2 and GAL4-BD/PDZ3 respectively. A comparison of pGBKT7- 
USH1C (12) (Figure 5.3, lanes 9&10) with pGBKT7-USH1C (7) (lanes 
11&12), showed that construct (#12) produced greater amounts of the BD- 
USH1C fusion protein than construct (#7), which only showed a faint band 
(Figure 5.3, lane 12). This suggests that construct (#12) would be a more 
suitable bait for the yeast two-hybrid screen.
The expression of a ~20kDa product in Figure 5.4; lanes 3&4, represents the 
expression of HA tagged GAL4-AD/pACT2 by Y187. The band of ~60kDa 
(lanes 5&6) represents GAL4-AD/CDH23. An appropriate sized 
immunoreactive band was absent from protein preparations isolated from 
untransformed AH 109 (Figure 5.3, lanes 2&8) and Y187, (Figure 5.4 J an e  2). 
The high level of background in all of the yeast protein extract lanes is due to 
the secondary antibodies used.
206
Figure 5.3 Expression of the GAL4BD-bait fusion proteins from the pGBKT7-bait
constructs by transformed AH109 yeast cells.
AH 109 pGBKT7 pGBKT7- pGBKT7- pGBKT7- 
PDZ1 PDZ2 PDZ3
<5
<3
pGBKT7- pGBKT7-
AH109
USH1C(12) USH1C{7)
7 8 9 10 11 12
Expression of the c-Myc tagged BD-fusion constructs by the yeast was detected using an 
anti-c-Myc antibody and is seen by the appropriately sized bands in lanes 3-6 or 9-12, 
denoted by < and lane number. None of these bands are seen in any other lane or in the 
untransformed yeast (lanes 2&8). The dark band seen in all protein extract lanes at 50kDa is 
an abundant background protein.
Lanes 1&7, Protein size standards. Lanes 2&8, untransformed AH109 cells. Lane 3, 
GAL4BD expressed by yeast transformed with pGBKT7. Lane 4, GAL4BD-PDZ1 expressed 
by yeast transformed with pGBKT7-PDZ1. Lane 5, GAL4BD-PDZ2 expressed-by yeast 
transformed with pGBKT7-PDZ2. Lane 6, GAL4BD-PDZ3 expressed by yeast transformed 
with pGBKT7-PDZ3. Lanes 9&10, GAL4BD-USH1C expressed by yeast transformed with 
pGBKT7-USH1C(12). Lanes 11&12, AL4BD-USH1C expressed by yeast transformed with 
pGBKT7-USH1 C(7).
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Figure 5.4 Expression of the GAL4AD-bait fusion proteins from the pACT2-positive
control constructs by transformed Y187 yeast cells.
pA C T 2-C dii23
5&6
m
a
Expression of the AD-fusion constructs by the yeast was detected using an anti-HA antibody 
and is seen in lanes 3-6, (denoted by < and lane number) but not seen in the untransformed 
yeast (lane 2). The dark band seen in all protein extract lanes at 50kDa is an abundant 
background protein
Lane 1, Protein size standards. Lane 2, untransformed Y187 cells. Lanes 3&4, HA tagged 
GAL4AD expressed by yeast transformed with pACT2. Lanes 5&6, HA tagged GAL4AD- 
CDH23 expressed by yeast transformed with pACT2-Cdh23.
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Confirmation that the fusion protein produced is actually harmonin (section 
2.5.2.2.1), not just a protein of a similar size, is shown by the presence of a 
~73kDa protein identified by all three antibodies (Figure 5.5 lanes 2, 5 & 8), 
and not seen in any control lanes (lanes 3, 6 & 9). Background bands 
around 50, 25kDa (lanes 5,6,8&9) and 100kDa (lanes 8&9) are a result of the 
secondary antibodies used to visualise the anti-harmonin antibodies.
Figure 5.5 Analysis of the pGBKT7-USH1C bait fusion protein with tag-specific and 
protein-specific antibodies
Monoclonal Monoclonal Polyclonal
anti c-Myc aoti-harmonin anti-harnionin
kBa 4- *• 4  *  4*
Expression of the USH1C bait protein produced by IVT from the pGBKT7-USH1C(12) is 
denoted by the presence of a band ~73kDa (labelled by <).
Lanes 1,4&7 Protein size standards. Lanes 2,5&8 IVT c-Myc/USH1C. Lanes 3,6&9 ‘No 
DNA’ lysate control with no protein bands. Lanes 1-3 were probed with the anti-c-Myc 
antibody. Lanes 4-6 were probed with the monoclonal anti-harmonin antibody. Lanes 7-9 
were probed with the polyclonal anti-harmonin antibody.
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5.1.3.3 Toxicity effects of the bait fusion protein on host yeast cells
All of the transformed yeast grew well (section 2.5.2.3), with both Clontech 
control fusion proteins (pGBKT7-53 and pGADT7-T) showing a very minimal 
drop in growth rate compared to the ‘empty’ vectors (Table 5.3). There was 
~10% drop in growth rate for the main bait construct (pGBKT7-USH1C), 
pACT2-CDH23 and pGBKT7-PDZ3 but in terms of ODeoo (<0.1 units), this is 
not significant. The growth rate appeared to increase for yeast transformed 
with pGBKT7-PDZ2 and pGBKT7- PDZ1.
Table 5.3 Comparison of the toxicity effects of the control and bait fusion 
jroteins to the empty vectors on yeast culture growth____________________
AH 109 Y187
Plasmid Av. ODeoo 
post 
incubation
%
change
Plasmid Av. ODeoo 
post 
incubation
%
change
pGBKT7 0.848 pACT2 0.694
pGBKT7- 
USH1C (7)
0.747 -12 pACT2-
CDH23
0.610 -12
pGBKT7-
USH1C
(12)
0.733 -13.5 pGADT7-T 0.680 -2
pGBKT7-
PDZ1
1.114 +31
pGBKT7-
PDZ2
0.862 +2
-
pGBKT7-
PDZ3
0.929 -10
pGBKT7-53 0.835 -1.5
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5.1.3.4 Verification that neither the bait fusion protein nor the DNA-BD alone 
is able to autonomously activate the reporter genes
All transformants bar pGBKT7-USH1C displayed the correct nutritional 
phenotype (section 2.5.2.4) and did not autoactivate either HIS3  or ADE2  
(Table 5.4). pGBKT7-USH1C (7) and (12) colonies able to grow in the 
absence of adenine were immediately eliminated from further use. Colonies 
#6 and #8 of pGBKT7-USH1C(12) that showed minimal growth in the 
absence of histidine, were grown on media supplemented with 3-AT (section 
1.5.2.1; Table 5.5). None of the remaining transformants were able to 
autoactivate the LacZ  reporter gene (section 2.5.2.4.2; Table 5.6).
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Table 5.4 Comparison of the ability of the bait and control proteins to autonomously activate transcription of nutritional 
reporter genes.
Multiple colonies from the stock plates were streaked onto the following SD media and incubated at 30°C for 10 days.
+ = growth - = no growth * = minimal growth/very small colonies
Strain Plasmid Selection
marker
SD/-Trp SD/-Trp/-Ade SD/-Trp/-His SD/-Leu SD/-Leu/-Ade SD/-Leu/-His
Y187 pCL1 LEU2 - - - + - -
pACT2 LEU2 - - - + - -
pACT2-CDH23 (9) LEU2 - - - + - -
pGBKT7 TRP1 + - - - - -
pGDAT7-T LEU2 - - - + - -
AH 109 pGBKT7-p53 TRP1 + - - - - -
pGBKT7-Lam TRP1 + - - - - -
pGBKT7 TRP1 + - - - - -
pGBKT7-USH1C (7) TRP1 +1-8 *6,7&8 +1-4.6&7
*5&8
pGBKT7-USH1C (12) TRP1 +1-8 *3&4 +1-5&7
*6&8
pGBKT7-PDZ1 TRP1 + - - - - -
pGBKT7-PDZ2
i
TRP1 + - - - - -
pGBKT7-PDZ3 TRP1 + - - - - -
Table 5.5 Determination of the concentration of 3-AT required to inhibit the ability of baits pGBKT7-USH1C (12-6&8) to 
autonomously activate transcription of the HIS3 and LacZ reporter genes
Any colonies that grew underwent a colony filter lift (3-galactosidase assay.
+ = growth - = no growth Blue = (3-galactosidase production White = no |3-galactosidase production
SD-Trp/-His supplemented with 3-AT
SD-Trp/-His 5mM 10mM 12mM 15mM 50mM 100mM 500mM
pGBKT7-USH1C (12-6) + + >5 colonies 
White/Blue
+ <5 colonies 
White/Blue
pGBKT7-USH1C (12-8) + + >5 colonies 
White
+ <3 colonies 
White
Table 5.6 Comparison of the ability of the bait and control proteins to autonomously activate transcription of the Lac Z reporter gene.
The ability of bait and control transformants to activate Lac Z was compared to pCL1 which endogenously expresses p-galactosidase. One of the pGBKT7- 
USH1C (7) bait colonies produced p-galactosidase, whilst the remaining seven stayed white.
+ = p-galactosidase production (cells turn blue) - = no p-galactosidase production (cells remain white)
pGBKT7 pGBKT7-USH1C
(12)
pGBKT7-
PDZ1
pGBKT7-
PDZ2
pGBKT7-
PDZ3
pGBKT7-
53
pGBKT7-
Lam
pACT2 pACT2-
CDH23
pGADT7-
T
pCL1
" “ - - - - - - - - +
5.1.3.5 Control yeast mating experiments
The compatibility of the yeast strains and vectors were checked through 
control mating (section 2.5.2.5.1). Growth on SD-Leu/-Trp/-His/-Ade media 
was only seen for matings between the system positive controls and the bait 
positive controls (Table 5.7). These matings also resulted in activation of the 
Lac Z  reporter gene.
Table 5.7 Results of Control Mating Analysis
+ = growth - = no growth
Mating reactions SD Minimal 
Medium
Growth P-gal
assay
Y187 [Plasmid] AH109 [Plasmid]
[pGADT7-T] [pGBKT7-53] -Leu/-Trp + Blue
-Leu/-T rp/-His/-Ade + Blue
[pGADT7-T] [pGBKT7-Lam] -Leu/-Trp + White
-Leu/-T rp/-His/-Ade -
[pACT2] [pGBKT7] -Leu/-Trp + White
-Leu/-T rp/-His/-Ade -
[pACT2] [pGBKT7-Lam] -Leu/-Trp + White
-Leu/-T rp/-His/-Ade -
[pACT2] [pGBKT7-USH1C] -Leu/-Trp + White
-Leu/-T rp/-His/-Ade -
[pACT2] [pGBKT7-PDZ1] -Leu/-Trp + White
-Leu/-T rp/-His/-Ade -
[pACT2] [pGBKT7-PDZ2] -Leu/-Trp + White
-Leu/-T rp/-His/-Ade -
[pACT2] [pGBKT7-PDZ3] -Leu/-Trp + White
-Leu/-T rp/-His/-Ade -
[pACT2-CDH23] [pGBKT7-USH1 C] -Leu/-Trp + Blue
-Leu/-T rp/-His/-Ade + Blue
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5.1.4 Bovine retinal library screening by sequential transformation into A H  109 
yeast
5.1.4.1 Prey library amplification
Amplification of the bovine retinal cDNA library aliquot, (Tai, A  W  et al, 1999), 
(section 2.5.3.1), resulted in an acceptable transformation efficiency of 
4.25x10® cfu/pg (Equation 5.2). The average concentration of amplified 
library aliquots was 0.6pg/pl, with a total amount of ~7.5mg of library DNA.
Equation 5.2 Calculation of the transformation efficiency during library amplification
CFU on control plate X 1x106 pa X volume of transformants X dilution factor 
pg plasmid DNA pg volume plated
3400 CFU X 1x106 do  X Imi X 103 = 4.25x108 cfu/fjg 
80000pg pg 0.1ml
The continued representation of the library contents post-amplification, was 
shown by the presence of a bright band on the gel around 8kb consisting of 
the vector backbone (Figure 5.6, lanes 3 and 4). This was followed by a 
spread of paler bands, ranging in size from 500bp-4kb in the same lanes, 
suggesting a representational amplification of the library and thus its 
suitability for the yeast two-hybrid screen.
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Figure 5.6 Examination of the bovine retinal library post-amplification amplification
Library inserts were digested from the vector backbone of amplified library aliquots. Lane 1, 
uncut amplified library - aliquot A. Lane 2, uncut amplified library - aliquot B. Lane 3, 
digested amplified library aliquot - A. Lane 4, digested amplified library aliquot - B. Lane 5, 
DNA size standards.
The library titre was calculated using Equation 5.3 and at 3.4x109 cfu/ml, 
further showed that the library was acceptable for screening.
Equation 5.3 Calculation of the bovine retinal library titre
licit Dusted 
« <  «
i l l !
1 2 3 4 5
Library titre (cfu/ml) # of colonies X dilution factor X 103
3400x 1000x 1000 -3 .4x109 cfu/ml
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5.1.4.2 Sequential co-transformation of bait and preys 
The transformation efficiency (Figure 5.7) of the sequential transformation of 
the bait and library of preys transformed into AH109 yeast (section 2.5.3.2 - 
2.5.3.3) was poor. The bait is not toxic to the yeast (section 5.1.3.3) which 
would suggest that some of the preys may be, or that aeration of the log 
phase culture was not optimal.
Figure 5.7 Calculation of the co-transformation efficiency and number of library 
clones screened
Cotransformation efficiency (cfu/fjg DNA)
cfu x total suspension volume (ul) 23 x (10ml x 103 ul/ml)
Volume plated (pi) x dilution factor x amount of DNA used 100 pi x 0.01 x 470 pg
(M9)
= 4.89x10?
Number of clones screened 
cfu/pg x pg of library plasmid used 4.89x102 x 470
= 2.3x10?
The recommended number of clones to screen is ~106 but this co­
transformation screened only 105 (Figure 5.7), probably due to the'reduced 
transformation efficiency. A repeat screen of 106 clones would require 2mg 
of library cDNA (Figure 5.8), which is fourfold greater than the upper limits for 
a library scale transformation (0.1-0.5mg) and therefore impossible. Based 
on the calculations in Figure 5.7 and Figure 5.8, it was decided to continue
218
the screen and examine the possible interactors within the 105 library inserts 
that were screened. Furthermore, interactions were examined between 
bovine and human proteins, which may also reduce the number of possible 
interacting proteins picked up by the screen.
Figure 5.8 The amount of library cDNA required to screen 106 independent clones.
mg DNA needed = 106 clones
(# of clones screened/ pg DNA used)
= JMDf = 2.05mg
(2.3x105)/470
5.1.4.3 Library screening
The number of large colonies per screening plate was counted after seven 
days incubation (Table 5.8). The plates were incubated for a further four 
days to try and catch slow growing colonies which would represent weak 
interactors. Unfortunately during this period, colony numbers multiplied 
massively making it difficult to identify the colonies in Table 5.8 and the 
colony filter lift assay was poor. Therefore to ensure that no possible 
interactors were missed, all large colonies and those that could easily be 
identified as positives (blue) on the (3-galactosidase assay filters were 
collected for further analysis (section 2.5.3.3; Appendix 16).
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Table 5.8 Initial colony numbers resulting from the Yeast Two-hybrid screen 
after seven days incubation at 30°C.
The number of large (2-4mm in diameter) colonies of the correct colour resulting from the 
screen were identified per plate.
Plate ID Number of colonies 
that grew after seven 
days at 30°C
1 12
2 5
3 12
4 8
5 3
6 11
7 8
8 12
9 5
10 8
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5.1.4.4 Segregation of multiple library plasmids with a diploid and repeat 
analysis of activation of reporter genes
The behaviour of each of the 337 colonies selected (Appendix 16), was 
further examined by: growth on SD-Trp/-Leu to eliminate diploids; growth on 
SD-Trp/-Leu/-His/-Ade+ 12mM 3-AT to reconfirm the interaction by nutritional 
selection; and examination of their ability to activate LacZ  (section 2.5.3.4). 
Results for each colony can be found in Appendix 16 and are summarised in 
Table 5.9.
128 of these colonies failed to grow past the initial streak site and were 
eliminated from further investigation. Of those colonies that did grow on SD- 
Trp/-Leu/-His/-Ade+ 12mM 3-AT, a further 63 were eliminated as they failed 
to activate Lac Z, leaving 145 colonies for further investigation.
Of those colonies producing (3 galactosidase, 10 did so at a comparable rate 
to the positive control which turned blue within 2 hours of introduction of the 
substrate (Table 5.10). A further 47 turned blue within four hours of 
introduction of the substrate, suggesting that these were physically strong 
interactions and unlikely to be false positives.
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Table 5.9 Summary of Appendix 16, showing the elimination of diploid and 
false positive colonies from further analysis.
No. of colonies originally isolated from the yeast two-hybrid 
screen
337
No. of interacting colonies failing to grow on SD-Trp/-Leu 1/337
No. of interacting colonies failing to grow on 
SD-Trp/-Leu/-His/-Ade+ 12mM 3-AT
128/336
No. of interacting colonies failing the (3 galactosidase assay 63/208
No. of interacting colonies for further investigation 145
Table 5.10 Examination of the strength of bait-prey interactions as a measure 
of the speed of their activation of LacZ in comparison to pCL1
No. of hours of incubation 
for a positive result 
(colonies turned blue)
2 3.5 4 4.5 5 5.5 6.5 7 7.5 8
No. of interacting colonies 10 46 1 33 3 33 2 10 6 1
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5.1.5 Characterisation of candidate interactors
145 colonies underwent further analysis by sequencing and/or yeast mating.
5.1.5.1 DNA sequence analysis of library inserts
A full detailed list of the sequence identity (section 2.5.4) of each interactor 
can be found in Appendix 19, but has been summarized in Table 5.11. 115 
interactors have been sequenced to date, whilst the remaining interactors 
failed to either PCR amplify or sequence.
Of the 115 sequenced interactors, 6 were sections of UTR (untranslated 
regions), 45 were known false positives (including ribosomal & mitochondrial 
proteins), whilst 29 were out of frame transcripts. 9 of the interactors were in­
frame, making them high priority for further investigation.
Table 5.11 A summary of the sequence data produced from the sequenced 
preys listed in Appendix 19.
Insert type # of colonies
Ribosomal proteins 19
Mitochondrial proteins 25
Sequence known but failed mating controls 9
5’ or 3’UTR 6
Clones 11
Out of frame transcripts 29
Vector only 5
Known false positives 2
In-frame transcripts 9
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5.1.6 Confirmation and further characterization of positive interacting preys
5.1.6.1 Confirmation of prey-harmonin interaction by yeast mating
Table 5.12 shows the results of yeast mating experiments (section 2.5.5.1.3) 
between segregated prey plasmids (section 2.5.5.1.1) and Y187[pGBKT7- 
USH1C] or controls (section 2.5.5.1.2; transformation efficiencies are listed in 
Appendix 17).
A number of interactors were excluded from further analysis because they 
activated the reporter genes when mated with controls. Positive results 
confirmed the initial screening result, showing that the preys interacted with 
harmonin (Table 5.12, highlighted in yellow). 32 of these interactors were 
subsequently excluded from further investigation through sequence analysis, 
with most of these interactors being ribosomal proteins (Appendix 18 and 
Appendix 19)
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Table 5.12 Confirmation of interactions between prey proteins and harmonin 
in vivo by yeast mating analysis
v^=Growth of yeast colonies on selective media *=Failure to grow on selective media
=Prey proteins that did not interact with control prey(s) += Positive ^-galactosidase assay
Colony ID # pGBKT7 all USH1C Lam
Growth 
on SD- 
2DO
Growth 
on SD- 
4DO
LacZ
activity
Growth 
on SD- 
2DO
Growth 
on SD- 
4DO
LacZ
activity
Growth 
on SD- 
2DO
Growth 
on SD- 
4DO
LacZ
activity
pACT2-cdh23 y X y y + y X
1.3 V X y y + y X
1.4 y X y y + y X
1.7 y X y y + y X
1.9 y X y y + y X
1.11 ✓ X y y + y X
1.13 V X y y + y X
1.22 V X y y + y X
1.35 y X y y + y X
1.41 y X y y + y X
2.1 y X y y + y y +
2.3 y X y y + y y +
2.15 y X y y + y X
2.18 y X y y + y X
2.32 y X y y + y y +
3.5 y X y y + y X
3.7 V X y y + y X
3.10 y X y y + y X
3.33 ✓ X y y + y X
4.1 y X y y + y X
4.14 y X y y + y y +
4.23 y X y y + y y +
5.4 y X y y + y y +
5.6 y X y y + y y +
5.17 y X y y + y X
5.18 y X y y + y y +
6.3 y X y y + y X
6.5 y X y y + y X
6.9 y y + y y + y y +
6.11 y y + y y + y y +
6.12 y X y y + y X
6.29 y X y y + y y +
7.1 y X y y + y X
7.12 y X y y + y X
7.14 y X y y + y ✓ - +
7.20 y X y y + y X
7.23 y X y y + y X
8.3 y X y y + y X
8.4 y X y y + y X
8.6 y y y y + y X
8.15 y y + y y + y y +
8.21 y X y y + y X
8.28 y X y y + y X
10.25 y / + y y + y X
10.41 y X y y + y y +
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Of the interactors eliminated from further study by sequence or mating 
analysis (Appendix 18 summarized in Table 5.13), 12 encoded clones with 
no known open reading frame (ORF) and were therefore low priority for 
further investigation. The same 9 interactors from Table 5.11 were confirmed 
here as high priority candidates for further investigation (#1.3, #1.7, #1.9, 
#1.22’ #2.15, #6.12, #7.1, #7.23 & #8.3).
Table 5.13 A summary of the reasons for excluding individual interactors from 
further analysis.
Interacting colonies were excluded from further investigation for the following reasons on the 
basis of sequence and mating analysis.
No. of colonies
No sequence data available 30
Failed mating controls 15
Excluded on basis of sequence analysis (known 
false interactors, out of frame, UTR etc)
80
Low priority sequenced interactors 11
High priority sequenced interactors 9
Total =145
Table 5.14 briefly decribes the 6 different proteins encoded by the 9 high 
priority sequenced interactors from Table 5.13.
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Table 5.14 A brief description of the six high priority sequenced interacting 
proteins
Colony
ID #
Protein (NCBI accession 
number)
Published data
1.3;
1.7;
1.9
Phosducin (M33529) ■ Small cytosolic protein that 
undergoes site-specific 
phosphorylation.
■ Known to interact with G protein 
subunits and 14-3-3 proteins.
1.22 NICE 3 (NM_138740) ■ Member of the Epidermal 
Differentiation Complex family of 
proteins.
■ Expressed in a variety of tissues, 
including the ear and eye.
2.15 Retbindin 
(NM_001024961)
■ Highly retina-preferred protein.
■ Significantly similar to riboflavin 
binding proteins.
6.12 TUBB (Beta tubulin) 
(NM_001003900)
■ Component of the microtubule 
cytoskeleton.
7.1 IK cytokine 
(NM_006083)
■ Small secretory molecule 
involved in the immune system.
7.23;
8.3
Hypothetical Protein
LOC83640
(NM_031452)
■ No published data at present.
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5.1.6.2 Further characterization of prey-harmonin interaction through yeast 
mating with the PDZ domain baits
No preys were found to interact with PDZ3 or with PDZ2 (Table 5.15) through 
yeast mating analysis (section 2.5.5.2), whilst 4 preys interacted with PDZ1. 
Prey #7.23 and gave a single colony that was positive for Lac Z expression 
when mated with pGBKT7-PDZ1. This is most likely to be a spontaneous 
mutation rather than a true interaction since #7.23 and #8.3 are the same 
cDNA clone, and #8.3 did not interact with any of the PDZ domains. The 
remaining 8 preys that passed the mating controls and interacted with 
pGBKT7-USH1C did not interact with any of the individual PDZ domains 
(Table 5.15).
Table 5.15 Characterisation of the interactions between pGBKT7-USH1C and 
the prey proteins through yeast mating with PDZ domain bait constructs.
^G rowth of yeast colonies on selective media *=Failure to grow on selective media 
+=Yeast turned blue, positive LacZ assay ★= 1 LacZ positive colony only 
(Preys for which sequence data is unavailable/BLAST searches failed
Colony
ID# PDZ1 PDZ2 PDZ3
Mated
Grew
on
SD-
4DO
LacZ
activity Mated
Grew
on
SD-
4DO
LacZ
activity Mated
Grew
on
SD-
4DO
LacZ
activity
1.3 X y X V X
■ -/ V + z X s X
1.7 s X V X s X
1.9 s X s X V X
1.22 V s + s X y X
2.15 V X V X s X
3.33 ■/ X s X s X
6.3 z X V X s X
6.12 V X s X v X
7.1 V + V X z X
7.23 s •/ ★ + s X s X
8.3 s X X y X
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5.1.6.3 Analysis of possible PBI sequences within prey protein sequences
Analysis of the protein sequence of the 6 candidate interacting proteins, 
showed the presence of class 1 C terminal PBIs in Retbindin (#2.15) and 
NICE-3 (#1.22) and a class 3 terminal PBI in TUBB (#6.12) (Figure 5.9) when 
compared to the C terminal region of cadherin 23. Both Retbindin and NICE- 
3 also contained multiple internal class 1 PBIs as defined by Siemens, J et al, 
2002 and Adato, A et al, 2005b (Figure 5.9 in yellow).
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Figure 5.9 CLUSTALW alignments of possible harmonin interacting proteins against 
the PBI region of cadherin 23
Protein sequence (human) comparison (Appendix 12) between Cadherin 23 (NM_022124) 
and (A) Nice 3, (B) IK cytokine, (C) Phosducin, (D) LOC83640, (E) Retbindin and (F) TUBB.
means that the residues in that column are identical in all aligned sequences; means 
that conserved substitutions have been observed for amino acids of similar character [Small
(smali+ hydrophobic (incl.aromatic -Y)); Acidic; Basic; (Hydroxyl + Amine + Basic -  Q)]; H." 
means that semi-conserved substitutions are observed. Q  Boxed regions are C terminal 
class 1 PBIs whilst internal class 1 PBIs are shaded yellow.
(A) Cadherin 23 and Nice 3 (NM_138740)
CDH23 --------------------------------------------------------------- RYLRAAIQEYDNIAKLGQIIREGPIKGSLLKV 32
N IC E -3  MASGSNWLSGVNWLVMAYGSLVFVLLFIFVKRQIMRFAMKSRRGPHVPVGHNAPKDLKE 60
• • •  *  •
CDH23 VLEDYLR-------------------------------- LKKLFAQRMVQKASSCHSSIS--ELIQTELDEEPGDHSP 7 6
N IC E -3  EIDIRLSRVQDIKYEPQLLADDDARLLQLETQGNQSCYNYLYRMKALDAIRTSEIPFHSE 120
• • • • •  'ie ie *
CDH23 GQG— SLRFRHKPPVELKGPDGIHWHGSTGTLLATDLNSLPEE-----------------DQKGLGRSL 127
N IC E -3  GRHPRSLMGKNFRSYLLDLRNTSTPFKGVRKALIDTLLDGYETARYGTGVFGQNEYLRYQ 180
•Ar •  ★
CDH23 ETLTAAEATAFERNARTESAKSTPLHKLR--DVIMETPLE|ITEL|---------------------------------------- 169
N IC E -3  EALSELATAVKARIGSSQRHHQSAAKDLTQSPEVSPTTIQVTYLPSSQKSKRAKHFLELK 240
★ • *  • • •  ★ • •  •  ^ J  ^ *  *
CDH23 ----------------------------
N IC E -3  SFKDNYNTL|ESTL| 253
(B) Cadherin 23 and IK cytokine (NM_006083)
CDH23
I K
--------------------------------------------------- RYLRAAIQEYDNIAKLGQI IR E G P IK G -------------------------27
MPERDSEPFSNPLAPDGHDVDDPHSFHQSKLTNEDFRKLLMTPRAAPTSAPPSKSRHHEM 60
. . .  . . .  * ★ + +
CDH23
I K
CDH23
IK
---------------------------------------- SLLKWLEDYLRLKKLFAQRMVQKASSCHSSIS--------------E L I 63
PREYNEDEDPAARRRKKKSYYAKLRQQEIERERELAEKYRDRAKERRDGVNKDYEETELI 120
QTELDE-------------EPGDHSPGQGSLRFRHKPPVELKGPDGIHWHGSTGTLLAT------ DLNS 114
STTANYRAVGPTAEADKSAAEKRRQLIQESKFLGGDMEHTHLVKGLDFALLQKVRLEIAS 180
CDH23
I K
LPEEDQKGLGRSLETLTAAEAT-------------------------------------------------AFERNARTESAKSTPL 152
KDKEEEELMEKPQKETKKDEDPENKIEFKTRLGRNVYRMLFKSKAYERNELFLPGRMAYV 240
• • •
CDH23
169
I K
HKLRDVIMETPLE|ITEL|- -
VDLDDEYADTDIPTTLIRSKADCPTMEAQTTLTTNDIVISKLTQILSYLRQGTRNKKLKK 300  
★ ★  • ★  • ★  •
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CDH23 -----------------------------------------------------------
IK KDKGKLEEKKPPEADMNIFEDIGDYVPSTTKTPRDKERERYRERERDRERDRDRDRERER 360
CDH23 -----------------------------------------------------------
IK ERDRERERERDREREEEKKRHSYFEKPKVDDEPMDVDKGPGSTKELIKSINEKFAGSAGW 420
CDH23 -----------------------------------------------------------
IK EGTESLKKPEDKKQLGDFFGMSNSYAECYPATMDDMAVDSDEEVDYSKMDQGNKKGPLGR 4 80
CDH23 -----------------------------------------------------------
IK WDFDTQEEYSEYMNNKEALPKAAFQYGIKMSEGRKTRRFKETNDKAELDRQWKKISAIIE 540
CDH23 ----------------
IK KRKKMEADGVEVKRPKY 557
(C) Cadherin 23 and Phosducin (M33478)
phosducin MEEAKSQSLEEDFEGQATHTGPKGVINDWRKFKLESQDSDSIPPSKKEILRQMSSPQSRN 60 
CDH23  RYLRAAIQEYDNIAK-LGQIIREGPIK 26
* • • k . k  k ★ .
phosducin GKDSKERVSRKMSIQEYELIHKEKEDENCLRKYRRQCMQDMHQKLSFGPRYGFVYELETG 120 
CDH23 GSLLKWLEDYLRLKKLFAQRMVQKASSCHSSISELIQTELDE---------------EPG 72
I I I I • ; I . . ^ I I I  k k
phosducin KQFLETIEKELKITTIWHIYEDGIKGCDALNSSLTCLAAEYPIVKFCKIKASNTGAGDR 180 
CDH23 DHSPGQGSLRFRHKPPVELKGPDGIH------------------------VVHGSTGTLLA 109
• k k  k • • k  k  •
phosducin FSLDVLPTLLIYKGGELISNFISVAEQFAEEFFAGDVESFLNEYGLLPEREVHVLEHTKI 24 0 
CDH23 TDLNSLPEEDQKGLGRSLETLTAAEATAFERNARTESAKSTPLHKLR DVIMETPL 164
★ k k • k .
phosducin EEEDVE 24 6 
CDH23 E|ITEL|- 169
(D) Cadherin 23 and LOC83640 (NM_031452)
CDH23 REPAAVKPDDDRYLRAAIQEYDNIAKLGQIIREGPIKGSLLKWLEDYLR 50
LOC83640 ----------------------------------------MTDTAEAVPK 10
: . . * :
CDH23 LKKLFAQRMVQKASSCHSSISELIQTELDEEPGDHSPGQGSLRFRHKPPV 100
LOC83640 FEEMFASRFTENDKEYQEYLKRPPESPPIVEEWNSRAG-GNQRNRGNRLQ 59
I ! ! ! * * . * ! . ! !  • I ; •• k • k k  k  k •
CDH23 ELKGPDGIHVVHGSTGTLLATDLNSLPEEDQKGLGRSLETLTAAEATAFE 150
LOC83640 DNRQFRGRDNRWGWPSDNRSNQWHGRSWGNNYPQHR-QEPYYPQQYGHYG 108 ~
1 1  *  I . I 1 . I * k  k
CDH23 RNARTESAKSTPLHKLRDVIMETPLE|ITEL| 180
LOC83640 YNQRPPYGYY-------------------- 118
k
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(E) Cadherin 23 and Retbindin (NM_031429)
CDH23
Retbindin
-REPAAVKPDDDRYLRAAIQEYDNIAKLGQIIREG PIKGSLLKW 4 4
MDEALETQLKTSRGRFSATESLPTLELLSQVDMDCRVHMRPIGLTWVLQL 50
k • k • k • • k  k  • • k k  • • •
CDH23
Retbindin
LEDYLRLKKLFAQRMVQKASSCHS--------------- SISELIQTEL 78
TLAWILLEACGGSRPLQARSQQHHGLAADLGKGKLHLAGPCCPSEMDTTE 100
m • -k m k • k k -k • • k
CDH23
Retbindin
DEEPGDH SPGQGSLRFRHKPPVELKGPDGIHVVHGSTGTLLATDL 123
TSGPGNHPERCGVPSPECESFLEHLQRALRSRFRLRLLGVRQAQPLCEEL 150
★ . *
CDH23
Retbindin
NS--------------- LPEEDQKG----------------------LG 135
CQAWFANCEDDITCGPTWLPLSEKRGCEPSCLTYGQTFADGTDLCRSALG 200
CDH23
Retbindin
RSLETLTAAEATAFER--------- NARTESAKSTPLHKLRDVIMETPL 175
HALPVAAPGARHCFNISISAVPRPRPGRRGREAPSRRSRSPRTSILDAAG 250
• • k  • k  k  k  • k k • • •
CDH23
Retbindin
E|lTEL|-------180
sgsgsgs|gsgp| 2 61
(F) Cadherin 23 and TUBB (NM_001003900)
CDH23
TUBB
---------------------------- RE PAAVKP DDDRYLRAAIQEY 21
MREIVHIQAGQCGNQIGAKFWEVISDEHGIDPTGSYHGDSDLQLERINVY 50
• * .  *  * .  *
CDH23
TUBB
DNIAK------------------------ LGQIIRE--------------33
YNEAAGNKYVPRAILVDLEPGTMDSVRSGPFGQIFRPDNFVFGQSGAGNN 100
CDH23
TUBB
-------- GPIKGSLLKWLEDYLRLKKLFAQRMVQKASS-CHSSISEL 73
WAKGHYTEGAELVDSVLDWRKESESCDCLQGFQLTHSLGGGTGSGMGTL 150 
* . * * * . .  *  . . .  * .  *
CDH23
TUBB
IQTELDEEPGDHSPGQGSLRFRHKPPVELKGPD GIHWHGSTGTLL 119
LISKIREEYPDRIMNTFSVMPSPKVSDTWEPYNATLSVHQLVENTDETY 200 
. . . * * * .  * .  *  . *  . * .  *
CDH23
TUBB
ATDLNSLPEEDQKGLGRS----- LETLTAAEATAFERNARTESAKSTPL 163
SHDNEALYDICFRTLKLTTPTYGDLNHLVSATMSGVTTCLRFPGQLNADL 250
• k  • • k  • . k  . k • k • k k • k
CDH23
TUBB
HKLRDVIMETP--------------------- LE|lTEL|------------180
RKLAVNMVPFPRVHFFMPGFAPLTSRGSQQYRALTVPELTQQMFDSKNMM 300
CDH23
TUBB AACDPRHGRYLTVAAIFRGRMSMKEVDEQMLNVQNKNSSYFVEWIPNNVK 350
CDH23
TUBB TAVCDIPPRGLKMSATFIGNSTAIQELFKRISEQFTAMFRRKAFLHWYTG 400
CDH23
TUBB EGMDEMEFTEAESNMNDLVSEYQQYQDATADEQGEFEEEEGjEDEAj 44 5
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5.1.6.4 Further analysis of the candidate interactor -  phosducin
5.1.6.4.1 Identification of the ORF of phosducin and confirmation of its 
interaction with harmonin by mating analysis.
Figure 5.10 shows that phosducin interacts with the whole harmonin bait but 
not with any of the individual PDZ domains (sections 2.5.5.2 & 2.5.5.3), 
suggesting that phosducin interacts with a region of harmonin other than the 
classical PDZ binding motifs i.e. the coiled coil region.
Figure 5.10 Results of the direct mating analysis between phosducin and bait/control 
constructs.
Successful interaction with only the whole USH1C protein activated the nutritional selection 
reporter genes and allowed growth on SD-Trp/-Leu/-His/-Ade+12mM 3-AT (4DO) drop out 
media.
pGBKT7- pGBKT7- pGBKT?- pG B K T ?- pGBKT7 pGBKT7-
USH1C FDZ1 PDZ2 PD23 Lam
4 DOnd 
£
(Ni 
1
2DO
233
Phosducin was identified as a possible interactor with harmonin on three 
separate occasions during the library screen (Appendix 19 - #1.3, #1.7 and 
#1.9), and each colony was found to contain the same cDNA clone (Figure 
5.11). The insert sequence starts with 15 amino acids in frame with the 
GAL4BD of the pACT2 vector, which have shown no homology to other 
sequences in NCBI databases but may be part of the 5’UTR of phosducin 
which has not yet been published. There then followed the whole of the 
coding region (245 amino acids) and a large region of the 3’UTR, with no 
further ORFs apparent. Four amino acids upstream of phosducin’s start 
codon is a stop codon but as stated in section 5.1.5.1, yeast can read 
through the stop codon and produce the prey fusion protein.
Figure 5.11 Schematic of the library cDNA clone extracted from yeast colonies 
#1.3/1.7/1.9, containing the open reading frame of phosducin
3aa of published 
bovine 
5’UTR
TAA stop codon
phosducin
15aa -junk sequence/possibly unpublished bovine 
5’UTR
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5.1.6.4.2 Analysis of phosducin protein sequence
Figure 5.12 shows the complete protein sequence of phosducin is highly 
conserved between species. The human sequence shares 89% amino acid 
homology with the bovine sequence, 87% with the murine sequence, 77% 
with the avian sequence and 17% with the invertebrate c.elegans sequence. 
The C terminal 150-200 amino acids in particular are highly conserved 
between all species. This supports the hypothesis of an interaction between 
phosducin and harmonin in bovine, murine and human tissues and that it was 
not a false positive due to species compatibility problems.
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Figure 5.12 An alignment of the protein sequence of phosducin from various species to examine protein homology and areas of 
conservation.
ClustalW protein sequence alignment (Appendix 12) of phosducin amino acid sequence from multiple species, denoting the degree of conservation 
of each amino acid. means that the residues in that column are identical in all aligned sequences; means that conserved substitutions have 
been observed for amino acids of similar character [Small (small+ hydrophobic (incl.aromatic -Y)); Acidic; Basic; (Hydroxyl + Amine + Basic -  Q)]; 
means that semi-conserved substitutions are observed.
Human
Chimp
Dog
Cat
Cow
Horse
Rat
Mouse
Red Fowl
C.elegans
(A35422) 
(XP_524 997) 
(NP_00100307 6) 
(S52096) 
(A38379) 
(AAD26865) 
(NP_037004) 
(NP_077778) 
(XP_42 6634)
(NP 502574)
SIQEYELIHKEKEDENCLRKYRRQCMQDMHQKLSFGPRYGFVYELETGKQFLETIEKELKITTIWHLYEDGIKGCDALNSSLTCLAAE 89 
SIQEYELIHKEKEDENCLRKYRRQCMQDMHQKLSFGPRYGFVYELETGEQFLETIEKELKITTIWHIYEDGIKGCDALNSSLTCLAAE 89 
SIQEYELIHRDKEDENCLRKYRRQCMQDMHQKLSFGPRYGFVYELETGEQFLETIEKEQKITTIWHIYEDGVKGCDALNSSFTCLAAE 89 
SIQEYELIHRDKEDENCLRKYRRQCMQDMHQKLSFGPRYGFVYELETGEQFLETIEKEQKITTIWHIYEDGIKGCDALNSSFTCLAVE 89 
SVQEYELIHKDKEDENCLRKYRRQCMQDMHQKLSFGPRYGFVYELESGEQFLETIEKEQKITTIWHIYEDGIKGCDALNSSLICLAAE 89 
SIQEYELIHQDKEDENCLRKYRRQCMQDMHQKLSFGPRYGFVYELETGEQFLETIEKEQKITTIWHIYEDGIKGCDALNSSLACLAAE 89 
SIQEYELIHQDKEDEGCLRKYRRQCMQDMHQKLSFGPRYGFVYELETGEQFLETIEKEQKVTTIWNIYEDGVRGCDALNSSliECLAAE 89 
SIQEYELIHQDKEDESCLRKYRRQCMQDMHQKLSFGPRYGFVYELETGEQFLETIEKEQKVTTIWNIYEDGVRGCDALNSSLACLAVE 89 
SMQEYELINDEKEDESCLQKYRKRCMQDMHQRLSFGPKYGYLCELQNGEQFLEAIEKERKTTTVIVHIYEDGIKGCNALNSSLTCLAAE 89 
KEEREKAQREDDEDEDFEMTLEGLKAKRLREMRKIAANR— VIEMTDKKQYSDAVDGS-SSYLLCVLIYEPESDECEYLTRIVKILAAD 86
Human
Chimp
Dog
Cat
Cow
Horse
Rat
Mouse
Red Fowl
C.elegans
(A35422) 
(XP_524 997) 
(NP_00100307 6) 
(S52096) 
(A38379) 
(AAD26865) 
(NP_037004) 
(NP_077778) 
(XP_426634)
(NP 502574)
YPIVKFCKIKASNTGAGDRFSLDVLPTLLIYKGGELISNFISVAEQFAEEFFAGDVESFLNEYGLLPEREVHVLEHTKIEEEDVE 174 
YPIVKFCKIKASNTGAGDRFSLDVLPTLLIYKGGELISNFISVAEQFAEEFFAGDVESFLNEYGLLPEREVHALEHTKIEEEDVE 174 
YPMVKFCKIKASNTGAGDRFSSDVLPTLLIYKGGELLSNFISGTEQFAEEFFAGDVESFLNEYGLLPEREIHALDQTNME-EDTE 173 
YPMVKFCKIKASNTGARDRFSSDVLPTLLVYKGGELISNFISVSEQFAEEFFAGDVESFLNEYGLLPERETHALDQTNME-EDIE 173 
YPMVKFCKIKASNTGAGDRFSSDVLPTLLVYKGGELLSNFISVTEQLAEEFFTGDVESFLNEYGLLPEKEMHVLEQSNME-EDME 173 
YPMVKFCKIKASNTGAGDRFSSDVLPTLLVYKGGELISNFLSVAEQFAEEFFAGDVESFLNEYGLLPEREIHALEQTSME-EDVE 173 
YPMVKFCKIRASNTGAGDRFSSDVLPTLLIYKGGELISNFISVAEQFAEDFFAADVESFLNEYGLLPEREIHDLGQTNTEDEDIE 174 
YPMVKFCKIKASNTGAGDRFSTDVLPTLLVYKGGELISNFISVAEQFAEEFFAVDVESFLNEYGLLPEREIHDLEQTNMEDEDIE 174 
YTTVKFCKIKASNTGAGDRFSDEVLPTLLVYKGGELLSNFISVSEQFNEEFFAVDVESFLNEYGLLPERELPALGNVNTDEQDVE 174 
CPKTKFVRATSTLLEMSRAFRTNGVPCLQFYSNGNLIGNFVKISAILGQDYDCKKLTKFLRGQHIDLMAGGYASDSDNESEDDD- 170
5.2 Confirmation of an interaction between harmonin and 
phosducin by co-immunoprecipitation (CO-IP)
5.2.1 Synthesis of c-myc tagged harmonin and identification of phosducin in 
whole eye homogenate
To confirm the interaction between harmonin and phosducin, proteins had to 
be sythesised (section 2.5.6.1.1) or a suitable tissue source found (section 
2.4.4.1.2). Figure 5.13 clearly shows Phosducin in the murine eye 
homogenate as a dark band on the western blot under ail immunoblotting 
conditions. Previous western blots conducted during this research have also 
detected harmonin in whole eye homogenate (data not shown), but these 
used much higher concentrations of eye homogenate than used here to 
detect phosducin.
In vitro translated c-Myc tagged harmonin can be detected in the IVT USH1C 
lanes and is not affected by the antibodies used to visualize Phosducin 
(Figure 5.13). The harmonin band appears darker when using the 
monoclonal anti-harmonin antibody (lane 4) than the anti-c-Myc antibody 
(lane 2). Use of the anti-harmonin antibody and its AP conjugated secondary 
antibody resulted in additional pale bands at ~25 and 50kDa in the eye 
homogenate lanes (lane 5&8). These are not the correct size to_be 
alternative harmonin protein isoforms from the eye homogenate and are most 
likely to be background from the use of mouse eye tissue with an anti-mouse 
IgG secondary antibody. Multiple faint bands can also be seen in the IVT 
USH1C (lanes 4, 7 and 14) and also in the ‘no DNA’ lysate control lane (lane
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9). Neither harmonin nor phosducin can be detected in the control lane, 
suggesting that these background bands are a byproduct of the antibodies 
used.
Figure 5.13 Western blots showing the presence of phosducin in murine retinal 
homogenate
A B C D E
< Hanncuiin
1 2  3 4 5 6 7 8 9 10 11 12 13 14 15
Western blots of the native phosducin protein from mouse whole eye homogenate (P) 
alongside IVT c-Myc tagged harmonin (1C) were probed simultaneously with an antibody to 
phosducin and either an antibody to the c-Myc tag (A, C-E) or to harmonin (B), to determine 
the optimal detection method of both proteins. Immunoblotting conditions for A-E are 
described in section 2.5.6.1.2.
Harmonin and phosducin (Phd) proteins are denoted by < at ~72kDa and ~33kDa 
respectively. Protein size standards are shown in lanes 1, 6, 10 & 13. Neither protein is seen 
in the control ‘No DNA lysate’ lane (L).
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5.2.2 CO-IP assay
The reliability of the CO-IP/ pull down assay was first confirmed using known 
interactors (Appendix 20) and then repeated with harmonin and phosducin 
(section 2.5.6.2.2). Phosducin was pulled out in the presence of harmonin 
(Figure 5.14, lane 4) but not in controls with the coated beads alone (lane 6), 
confirming the interaction of harmonin and phosducin. The presence of 
phosducin in the negative control flow-through (lane 7) proves that phosducin 
was present in the control (lane 6) but was only seen in the eluates when 
incubated with the beads and harmonin (lane 4). A fainter phosducin band is 
detected in the initial flow-through from incubations with the c-Myc beads, 
harmonin and the eye homogenate (lane 5). This is due to saturation of the 
harmonin protein with phosducin, with the excess unbound phosducin 
showing up in this flow-through lane. A further band is seen in lanes 4&5 at 
~50kDa. This band is sometimes present in the negative control lane, due to 
a protein from the eye homogenate binding to the beads that is detected by 
the secondary antibodies used (see section 5.2.1 and Figure 5.13).
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Figure 5.14 Interaction of harmonin and phosducin confirmed in vitro through 
pull down analysis.
Eye c-Myc bcads+lVT c-Myc beads + eye
IV T  US H1C hmragerute USHIC+ eye hamogcmlc homogenate
kDa
75
50
37 mb
25
FT E FT
<Phd
Phosducin was isolated from whole murine eye homogenate through CO-IP with c-Myc 
tagged harmonin using immobilized antibodies to the c-Myc. Western blots of pulled-down 
proteins were probed simultaneously with antibodies to harmonin and phosducin.
Lane 1, Protein size standards. Lane 2, c-myc tagged harmonin detected by anti-harmonin 
antibody. Lane 3, phosducin protein detected by anti-phosducin antibody. Lane 4, phosducin 
and harmonin detected from c-Myc pull down of eye homogenate and c-Myc tagged 
harmonin. Lane 5, phosducin detected in the initial flow through solution of proteins 
unbound to the c-Myc beads in lane 4. Lane 6, neither phosducin nor harmonin was 
detected from c-Myc pull down in the absence of harmonin. Lane 7, an intense band of 
phosducin protein detected in the initial flow through solution of proteins unbound to the c- 
Myc beads in the absence of harmonin from lane 6.
E: Eluate FT: Column flow through H: Harmonin
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5.3 Validation of candidate interactor through protein
localisation and gene expression analysis
5.3.1 Comparison of phosducin and harmonin protein localisation in the 
normal adult retina
Figure 5.15 shows that harmonin is localised to the photoreceptor OS, IS and 
OPL in adult retina (section 2.3.1.3), whilst phosducin is localised to the IS 
and ONL of the adult retina, with the highest immunoreactivity in the OPL 
(section 2.5.7.1). Both harmonin and phosducin localise to the IS and OPL, 
which is consistent with a physical interaction.
Figure 5.15 Immunolocalisation of phosducin and harmonin in the adult 
murine retina
Harmonin is labeled in green and phosducin in red. Replacement of the anti- 
phosducin antibody with PBS showed no non-specific background staining in the 
neural retina in fixed tissue (Hoescht control lane).
Iloescht Phosducin H arm onin
os 
IS
O M .
CKTL 
EVL
GCL, ganglion cell layer. I PL, inner plexiform layer. INL, inner nuclear layer. OPL, 
outer plexiform layer. ONL, outer nuclear layer. IS, photoreceptor inner segments. 
OS, photoreceptor outer segments. Scale bars 10 pm.
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5.3.2 Comparison of phosducin and harmonin protein localisation in the 
normal developing retina
Figure 5.16 shows that Pdc (encoding Phosducin) expression is initiated 
between P2 and P4, with phosducin localised to the perinuclear region within 
the developing photoreceptor (section 2.5.1.2). Ushlc expression starts 
earlier than Pdc, with harmonin detectable at P2. During the very early 
developmental stages (P2-P4), Ushlc looks to be expressed by far fewer 
cells than Pdc, with harmonin specifically localised to cells of the outermost 
edge of the developing photoreceptor layer. By P8, immunolabelling of 
harmonin is restricted to the developing segments, whilst phosducin is seen 
throughout the newly formed ONL. At P12, the strongest harmonin 
immunoreactivity was seen in the photoreceptor OS layer of fixed tissue. In 
contrast, phosducin immunoreactivity was highest in the IS but also seen 
strongly throughout the ONL. As the retina develops, the levels of phosducin 
at the developing OPL increases but immunoreactivity at these stages 
examined is much less than that seen in the OPL of the adult retina (Figure 
5.15).
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Figure 5.16 Localisation of
phosducin and harmonin in
the developing retina.
Semithin sections (stained with 
methyl blue) are shown for 
comparison to demonstrate 
development of retinal layers from IPL
P2-P12 (section 1.2.1.2).
GCL
Harmonin (green) is present in the 
newborn photoreceptors prior to 
phosducin (red). As development 
proceeds, phosducin is clearly 
labelled in the ONL and IS (P8 and 
P12).
INL
GCL, ganglion cell layer. IPL, inner
plexiform layer. INL, inner nuclear ,PL
layer. OPL, outer plexiform layer.
ONL, outer nuclear layer. IS, 
photoreceptor inner segments. OS, 0NL
photoreceptor outer segments.
OPLScale bars 10 pm.
INL
IPL
GCL
RPE
OS
IS
ONL
OPL
INL
IPL
Harmonin Phosducin
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5.3.3 Comparison of Pdc and Ushlc gene expression in the adult and 
developing ear by RT-PCR
RT-PCR showing Pdc expression was noted in the adult murine eye (section
2.5.7.3 & Figure 3.6), but was not seen in the adult or developing ear (Figure 
5.17, 35 cycles). Production of cDNA was successful as positive results were 
obtained for the housekeeping gene, Gapdh. Increasing the cycle number to 
40 produced a band in the P7 ear sample but still nothing in the adult ear. 
Although the data is qualitative, it would suggest that phosducin expression 
in the ear is far less than in the eye, and that the gene is not expressed in the 
adult ear.
Figure 5.17 Investigation of Pdc expression in developing and adult murine ear
Pdc expression was examined in a P7 developing inner ear (P7), an isolated adult cochlea 
(A), and in CD1(CD) & SV129 (SV) adult eyes
10Obp: DNA size standards -ve: control reaction substituting ddiH20  for DNA as 
template.
5.4 Conclusions
■ Six candidate harmonin-interacting proteins were isolated: all were seen 
to interact with full length harmonin, whilst two also interacted with PDZ1 
and the remaining four with a region other than the three PDZ domains.
■ Phosducin was demonstrated by yeast mating and a pull down assay to 
interact with full length harmonin but not through direct binding with any of 
the three PDZ domains. It’s interaction with harmonin was confirmed by 
CO-IP analysis.
* Phosducin’s pattern of localisation in the adult and developing retina was
similar to that of harmonin, with both proteins localised to the 
photoreceptor IS and OPL.
■ Pdc expression was also seen in the developing ear (in the bulla that 
contained cochlear and vestibular tissue), but not in the adult cochlea.
245
6 DISCUSSION
This study examined the localisation of the Ushlc protein, harmonin, both in 
normal murine eyes and in models of Usher syndrome types 1B and 1D. 
Harmonin was localised to the photoreceptor OS of fixed retinal tissue, with 
further protein expression seen in the IS and OPL of unfixed retina. 
Maintenance of harmonin localisation in the OS of fixed tissue from both 
murine models resulted in a Yeast Two-Hybrid assay to investigate 
alternative harmonin-interacting proteins. Six candidate proteins were 
identified. Interaction of one of these proteins, Phosducin, was confirmed by 
a pull-down assay and shown by immunofluoresence staining to colocalise 
with harmonin in the photoreceptor IS and OPL. These findings and the 
further insights they have provided into the possible pathogenic mechanisms 
of Usher syndrome, are discussed in the following chapter.
6.1 Determination of the temporal and spatial expression of 
Ushlc and harmonin within the normal murine eye
■ In the developing murine eye, Ushlc expression can be detected as early 
as E 12.5 by RT-PCR.
The fact that all the USH1 genes examined here are expressed 
simultaneously in the retina from E12.5, would support the hypothesis that in
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the retina, all the USH1 proteins are involved in the same functional pathway 
or directly interact to form a macromolecular complex. Expression of Ushlc 
at such an early stage of development would suggest that it was essential for 
correct eye development, as seen in the ear, where it plays a role in 
organising the developing stereocilia bundle on the auditory hair cells. Yet 
although Usher patients have profound congenital deafness, they have 
normal vision at birth; therefore harmonin is unlikely to play a role in correctly 
organizing the developing photoreceptor.
■ As the retina differentiates, harmonin is first localised to the new born 
photoreceptors and then to their developing segments. In the adult it is 
clearly confined to the OS in fixed tissue.
The localisation of harmonin to the photoreceptor OS could implicate it in 
phototransduction. Harmonin may be embedded in the OS disks where it 
may anchor the photopigments ready for phototransduction. Colocalisation of 
harmonin and rhodopsin, and the fact that rhodopsin has a C terminal PBI, 
supports this hypothesis. Other PDZ-domain-containing proteins involved in 
phototransduction include I NAD, which acts not only as a ‘transducisome’ but 
has been postulated to have a direct role in termination of the photoresponse 
whilst also contributing to the rapidity of the activation response (Sheng,~M. 
Annu Rev Neurosci, 2001). However, comparative mRNA expression studies 
have shown that visual transduction protein expression in vertebrates, is 
initiated alongside outer segment disk emergence (or slightly prior to disk
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emergence, in cones) (Timmers et al 1993; Johnson, P T et al, 2001). In 
humans this is around 5V* months gestation but in the mouse this occurs as 
late as P6. The fact that Ushlc is expressed prior to this reduces the 
likelihood of a role for harmonin in phototransduction.
■ Additional immunoreactivity is seen using unfixed tissue, with harmonin 
localised to the photoreceptor OS, IS and OPL.
A comparison of harmonin localisation in fixed and unfixed tissue saw the 
protein confined to the OS in fixed tissue but further immunoreactivity noted 
in the IS and the OPL. It has been hypothesized that the discrepancy 
between immunostaining results in different fixation states may be due to 
antigen masking by fixation of the retinal tissue (Reiners, J et al, 2003), 
resulting in lower levels of staining generally. The work here supports this 
hypothesis since consistently higher levels of harmonin staining were seen in 
all parts of the photoreceptor using unfixed tissue. Furthermore, myosin VIIA 
could only be detected in the RPE and connecting cilium in fixed tissue (Liu, 
X et al, 1997), but could also be seen in the OPL and IS of unfixed tissue. 
The additional myosin VIIA staining in the OPL published by Reiners et al, 
was claimed by others to be an artifact of the antibody used (Williams, D S et 
al, 2004). Yet the work carried out here with an alternative commercially 
available antibody to myosin VIIA disputes this statement, also finding 
myosin VIIA in the IS and OPL.
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The colocalisation of harmonin, myosin VIIA and cadherin 23 to the IS and 
OPL in unfixed tissue (Figure 3.3 and Wolfrum, U et al, 2004), would suggest 
that the USH1 proteins could form a complex in the eye, similar to that seen 
in the ear. In the OPL, the ribbon synapses are formed between the 
photoreceptors and the second order neurons. PDZ proteins are known to be 
important in structurally organizing the synaptic apparatus at the pre and post 
synaptic densities (Garner, C C et al, 2000) and so this could be a potential 
function for harmonin. Alternatively, the co-localisation of the three proteins to 
the IS would suggest that the Usher proteins could have a function relating to 
disk formation/organization. In both the OPL and IS, the function of harmonin 
and the other Usher proteins must not be essential for developing normal 
vision as patients can see at birth.
■ Localisation in the OS is maintained in the absence of either myosin VIIA 
or cadherin 23.
The localisation of harmonin to the photoreceptor OS using fixed tissue was 
maintained in the retinas of shaker-1 and waltzer mice that are null mutants 
for myosin VIIA and cadherin 23 respectively (Figure 3.5). In the ear, myosin 
VIIA is thought to be essential for the correct localisation of harmonin isoform 
‘b’, which in turn is postulated to link cadherin 23 in the hair cell stereocilia, to 
the actin cytoskeleton during development (Boeda, B et al, 2002). It is 
interesting to note that Reiners et al (2003) saw differences in harmonin 
isoform localisation in the retina, with isoform ‘b’ restricted to the OS whilst
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isoforms ‘a’ and ‘c’ were found in the OS, IS and OPL. Whilst here 
immunostaining data on the mutant mice does show that at least one 
harmonin isoform does not require myosin VIIA or cadherin 23 for localisation 
to the OS, the possibility that one or more isoforms of harmonin are 
mislocalised cannot be excluded without the use of isoform-specific 
antibodies. Furthermore, the possibility that one or more isoforms are 
mislocalised in the OPL or IS cannot be excluded since visualisation of 
harmonin labelling in these regions was not possible with fixed tissues.
Since harmonin has been postulated to interact with cadherin 23 in the ear 
(Boeda, B et al, 2002; section 1.3.4.1), it would have been interesting to 
investigate the localisation of cadherin 23 in the absence of harmonin, using 
the mutant mouse for Ushlc, deaf circler (Johnson, K R et al, 2003), to see if 
its expression is maintained in the IS and OPL. Furthermore it would be 
interesting to compare cadherin 23 staining in the deaf circler mouse (which 
is null for all forms of harmonin), to cadherin 23 staining in the deaf circler 2 
Jackson mouse. Although this mouse also has mutations in Ushlc, these 
effect the alternatively spliced exons of isoform ‘b’ but allow correct 
expression of harmonin isoforms ‘a’ and ‘c \ resulting in nonsyndromic 
deafness (Johnson, K R et al, 2003). Furthermore, cadherin 23 isoforms 
have different expression patterns in the ear and eye (Siemens, J et al,
2002), thus different cadherin 23-harmonin complexes may form in both the 
two tissues. This would be a further interesting aspect to investigate, both in 
wild type and in the Usher mutant mice waltzer and deaf circler.
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6.2 Investigation into candidate harmonin-interacting proteins 
within the normal eye
■ Six candidate harmonin-interacting proteins were isolated: all were seen 
to interact with full length harmonin, whilst two also interacted with PDZ1 
and the remaining four with a region other than the three PDZ domains.
Of the six candidate harmonin-interacting proteins identified in the yeast two- 
hybrid screen, NICE-3 was isolated from two different clones, one encoding 
the N-terminal half (#6.29) and the other, the C-Terminal half (#1.22). NICE- 
3 is one of the five family members of the NICE proteins that are part of the 
epidermal differentiation complex, localised to chromosome 1. NICE-3 is 
alternatively spliced, with one of its three transcripts corresponding to the 
predicted human protein HSPC012 (Zhang, Q H et al, 2000), expressed in 
CD34+ hematopoietic stem/progenitor cells. NICE-3 is widely expressed at 
low levels in many tissues, including the blood, brain, prostate, lungs, ovary 
and the ear and eye. The protein is predicted to contain an N-4 cytosine- 
specific DNA methylase signature, although the functional significance of this 
is unknown (Marenholz, I et al, 2001). The mating analysis, following the 
initial yeast two-hybrid screen, showed the N-terminal clone to be a false 
positive, interacting with the pGBKT7-Lam control protein. The C-terminal 
region, which contains a class 1 PBI at the carboxyl end of the protein, 
interacted with the whole pGBKT7-USH1C fusion protein and with the PDZ1 
construct. The mating with the PDZ1 construct produced multiple blue 
colonies but could not be repeated on further mating experiments: the reason
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for this is unknown but may be due to spontaneous mutations within the 
fusion protein during storage. Although a large proportion of clone #1.22 was 
successfully sequenced, a portion of the 3’ insert sequence most likely 
containing the 3’UTR of NICE-3, remains unanalyzed despite the use of a 
variety of sequencing reaction conditions and supplements. NICE-3 also 
proved difficult to synthesise by IVT and since no known antibody to the 
protein is available, confirmation of its interaction with harmonin has not been 
possible.
Another possible candidate protein with a C-terminal class 1 PBI was 
Retbindin (#2.15). The Retbindin gene is located at 19p13 and predicted to 
have multiple promoters producing a highly retina-preferred protein. 
Retbindin has a weak but significant similarity to riboflavin binding proteins, 
with distant similarity to mammalian folate receptors. It is rich in cysteines 
and conserved glycosylation sites, suggesting that this protein is secreted 
and post translationally modified. Its predicted ligands include carotenoids, 
suggesting it may play a role in sequestering flavinoids and protecting the 
retina from free radical damage (Wistow, G et al, 2002). Although Retbindin 
possesses a class 1 PBI, it only interacted with the pGBKT7-USH1C 
construct and its predicted role does not fit into that postulated for harmonin 
in the retina. Furthermore, the identified sequence was canine which could 
lead to false positives (section 1.5.2.1). There was also a stop codon in the 
insert sequence upstream from the coding region of Retbindin, such that 
harmonin may have been acting with a fusion protein produced from the 
upstream insert sequence and not interacting directly with Retbindin. These
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factors when combined reduce the likelihood of Retbindin being a candidate 
for a harmonin-interacting protein.
An IK cytokine (#7.1) was also identified from the initial screen and was 
shown to interact with both pGBKT7-USH1C and pGBKT7-PDZ1, yet it did 
not have a PBI. The fact that this is a small secretory molecule involved in 
the immune system reduces the likelihood of this being a binding partner 
central to harmonin’s function. The hypothetical protein LOC83640 was 
identified twice (#7.23 and #8.3) from the same cDNA clone and was shown 
to interact with the full length harmonin protein only.
Beta tubulin, a component of the microtubule cytoskeleton with a class 3 PBI, 
interacts with pGBKT7-USH1C but none of the PDZ domains directly. In the 
developing retina, beta tubulin is localised to virtually all cell types but is 
especially strong in the OPL and IPL. In the adult retina, staining was seen 
in the OPL and IPL but was also present in the photoreceptor OS (Sharma, R 
K et al, 2003). It is interesting to uncover another component of the 
cytoskeleton as a potential interactor of harmonin, since harmonin is already 
known to interact with the actin cytoskeleton in the developing stereocilia. 
The connecting cilium of the photoreceptor is rich in microtubules: although 
harmonin has been seen in the photoreceptor IS and OS (Figure 3.6), 
definitive proof of its presence in the connecting cilium has not yet been 
determined by high resolution analysis. However the identification of a 
protein highly expressed in the connecting cilium as a potential interactor of
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harmonin would support the argument of harmonin localisation in the 
connecting cilium.
■ Phosducin was demonstrated by yeast mating and a pull down assay to 
interact with full length harmonin but not through direct binding of any of 
the three PDZ domains. It’s interaction with harmonin was confirmed by 
CO-IP analysis.
Phosducin is a small acidic cytosolic protein, which undergoes site specific 
phosphorylation at many of its serine residues. The protein’s phosphorylation 
state is altered by cAMP and Ca2+ levels which are controlled in a light- 
dependent manner and ultimately affect phosducin’s ability to bind to certain 
binding partners (Lee, B Y et al, 2004). Structurally similar proteins, thought 
to be family members, are the phosducin-like proteins (PhdLPs) and 
phosducin-like orphan proteins (PhdLOP). PhdLPs are localised throughout 
the inner retinal layers and can bind j3y subunits of G proteins (Schulz, R, 
2001 and references therein). A novel germ line specific PhLP has been 
found in mice and exerts a function in germ cell maturation (Lopez, P et al,
2003). PhdLOPs are localised to the cell nucleus (phosducin and PhdLPS 
are cytosolic) and are missing the amino terminus seen in phosducin and 
PhdLPs. They are thought to play a role in transcriptional activation, 
interacting with SUG1 (Zhu, X et al, 1998) and the retinal and pineal gland- 
specific transcription factor, CRX (Zhu, X et al, 2000).
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Phosducin does not interact with harmonin via any of the PDZ domains but 
instead may bind to the very end of the C terminus, the coiled coil domain or 
the linker regions between the structural domains. The use of alternative 
binding sites on PDZ proteins has been seen in the case of INAD, the 
Drosophila 5-PDZ-domain-containing protein. INAD uses its linking region 
between PDZ1 and PDZ2 to bind calmodulin, bringing it into close proximity 
with other participants of the phototransduction cascade (Huber, A, 2001).
■ Phosducin’s pattern of localisation in the adult and developing retina was 
similar to that of harmonin, with both proteins localised to the 
photoreceptor IS and OPL.
Although phosducin protein synthesis is initiated after harmonin, the 
localization of the proteins during development in the newborn 
photoreceptors is similar. In addition, their appearance in the developing 
photoreceptor projections occurs simultaneously (as these structures 
develop), further supporting the theory of a functional interaction between 
these proteins. Phosducin was shown to be localised to the IS, ONL and 
OPL, with phosducin staining in the OPL reaching its peak, at a time when 
the ribbon synapses have fully developed (P12-P15) (Grun, G, 1982), 
supporting the hypothesis that phosducin and harmonin are localised to 
these particular structures within the OPL (Reiners, J et al, 2003;Chen, J et 
al, 2005).
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Phosducin has also been shown to be expressed in the OS of the 
photoreceptors by serial tangential sectioning (Sokolov, M et al, 2004). Here 
it was hypothesized to have a role in phototransduction through its interaction 
with the (3y subunits of Transducin, a photoreceptor specific heterotrimeric G- 
protein, acting as an antagonist to the a subunit and facilitating light driven 
Transducin translocation. Yet phosducin protein levels are relatively low in 
the OS compared to what would be expected for a protein with this proposed 
function (Sokolov, M et al, 2004) and is in fact expressed at seven-fold higher 
levels in the OPL than in the OS (Chen, J et al, 2005). Thus phosducin has 
been suggested to have alternative/multiple roles including: acting as a 
phosphorylation-dependent switch in signalling cascades involved in light 
adaptation; involvement in transcriptional activation (Schulz, R, 2001); and in 
shielding G-proteins from proteosome degradation (Sokolov, M et al, 2004; 
Chen, J et al, 2005).
■ Pdc expression was also seen in the developing ear (in the bulla that 
contained cochlear and vestibular tissue), but not in the adult cochlea.
Pdc (the gene encoding phosducin), expression was detected in the 
developing murine ear but absent from the adult cochlea. This may mean 
that phosducin plays a role during ear development but does not have a 
function in ear maintenance/homeostasis and thus is not required in the adult 
ear. Alternatively Pdc may in fact be expressed in the vestibular system 
rather than in the cochlea, since the tissue from the developing mouse ear 
consisted of developing cochlear and vestibular tissue, whilst in the adult, an
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isolated cochlea was used. Immunostaining for phosducin on ear tissue 
sections would clarify this point. Phosducin has also been observed in other 
tissues that have been seen to show pathology in some cases of Usher 
syndrome, including the olfactory system (Danner et al 1996) where it is 
found at comparable levels to that in the brain (levels in the brain are higher 
than in most tissues but significantly lower that that found in the retina 
(Schulz, R, 2001)).
It is interesting to note that in auditory transduction unlike in 
phototransduction (section 1.2.1.2 & 1.2.2.3), a second messenger cascade 
system (including G proteins) is not used to amplify and transmit the signal but 
instead employs direct gating of the transducer channel (Alessandro Martini, 
1996). Therefore G-proteins and their binding partners (including phosducin 
which is able to interact with a whole range of G-proteins (Bauer, P H et al, 
1998)) are not necessary in the cochlea ribbon synapses.
6.3 Possible pathogenic mechanisms in Usher syndrome.
Harmonin and phosducin
Phosducin is known to bind to the photoreceptor inner segment and synaptic 
protein 14-3-3 in its phosphorylated form (Nakano, K et al, 2001). Decreases 
in intracellular Ca2+ levels blocked this interaction by inhibiting 
phosphorylation at two specific serines (54 and 73). This led to the 
supposition that phosducin may be involved in Ca2+ dependent light
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adaptation (Thulin, C D et al, 2001). In the fly photoreceptor cell, calcium 
homeostasis is maintained through light-induced Ca2+ ion influx through 
designated Ca2+ ion channels (of the TRP family which is correctly localised 
through interactions with the PDZ containing INAD protein (Huber, A, 2001), 
with extrusion by Na+/Ca2+ exchange. The influx results in two separate Ca2+ 
signals: the global rise that mediates light adaptation; and the rapid transient 
amplitude that shapes quantum bumps into all or nothing signals 
(Oberwinkler, J, 2002). Free 14-3-3 has been postulated to potentiate the 
release of glutamate at retina synapses and be involved in light adaptation 
(Nakano, K et al, 2001).
Furthermore, since phosducin can interact with alternative G-proteins to 
Transducin, it has been suggested that it could interact with the G protein 
associated with the group III metabotropic glutamate receptor, since both are 
localised to the rod IS, (Nakano, K et al, 2001). This particular glutamate 
receptor acts as an autoreceptor, down regulating intracellular Ca2+ to control 
light-regulated release of glutamate from the photoreceptor synapses. This 
provides a negative feedback system that is thought to aid in fine adjustment 
of the light-regulated release of glutamate from the synapses and to act as a 
safety device against excitotoxic glutamate levels that would damage the 
photoreceptor (Koulen, P et al, 1999). Harmonin may compete with 14-3-3 or 
the G protein subunits for the same binding site within phosducin, or it may 
alternatively bind to the C terminus. It is also unclear whether harmonin has 
a preference for binding to the phosphorylated or dephosphorylated form of 
phosducin.
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Pdc has been investigated as a candidate gene for Usher syndrome and 
other retinal disease (Nishiguchi, K M et al, 2004; Ara-lwata, F et ai, 1996). In 
dogs, a sequence variant close to the region of the protein that directly 
interacts with the G-protein subunits, was associated with photoreceptor 
dysplasia but did not account entirely for the genetics of inherited retinal 
degeneration in the breed (Zhang, Q et al, 1998). Human patients with 
retinitis pigmentosa, dominant RP, recessive RP, Leber Congenital 
Amaurosis, or cone-rod degeneration, were screened for mutations in Pdc. 
Single cases of a polymorphism in the 5' untranslated region or a rare single­
base sequence variant (only three variants ever noted), were seen in 
separate heterozygous patients but none were interpreted as pathogenic 
(Nishiguchi, K M et al, 2004b; Nishiguchi, K M et al, 2004a). Two different 
heterozygous mutations in highly conserved amino acids were individually 
seen in an USH2 and an Acute Zonal Occult Outer Retinopathy (AZOOR) 
patient. Yet a lack of further patients with mutations in Pdc, did not support a 
relationship between Pdc with either of these ocular disorders (Ara-lwata, F 
et al, 1996). It has been suggested that the addition of a heterozygous 
mutation in particular cases of AZOOR could be the reason for the increase 
in severity of the phenotype seen in these patients (Ara-lwata, F et al, 1996): 
it would therefore not be unreasonable to suggest that Pdc could be a 
modifier gene in both AZOOR and Usher syndrome.
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Harmonin and the USH1 proteins
Harmonin, cadherin 23 and myosin VIIA have been shown to interact and 
now a direct binding link has been established between the SAM domain of 
sans with both PDZ1 and PDZ3 of harmonin (Figure 6.1), thereby recruiting 
Sans to the actin filaments. It is localised to the cuticular plate where it 
contributes to hair bundle cohesion via an activity exerted from underneath 
the hair cell bundle (Adato, A et al, 2005b). Interactions have also been 
established between sans and myosin VIIA via the central region of sans and 
the tail of myosin VIIA. Sans also uses this region for homodimerisation and 
is unable to bind to harmonin or myosin VIIA as a single protein. At the apical 
region of the hair cells it is expected to form homodimers allowing it to 
interact with either harmonin or myosin VIIA but never both simultaneously or 
in situations where harmonin and myosin VIIA have already formed a 
complex (Adato, A et al, 2005b). This would indicate a very specific role for 
both Sans-based protein complexes and for the separate harmonin-myosin 
VIIA complex in the hair cell. Whether similar interactions are seen in the 
retina has yet to be established.
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Figure 6.1 Interaction of the USH1 and USH2 proteins via harmonin
Frotocadherin 15 ^
-««(«««#—  J
A c tiii
cytoskeleton
Cadherin 23
Harmonin ‘b
Myosin VIIA
NBC3
Usherin
Vlgrlb
A schematic summarizing the protein interaction data discussed above and in section 1.3.4 
(references are included therein).
The proteins are collated into labelled boxed groups according to the region of harmonin with 
which they interact. Proven interactions are denoted with a double headed arrow. The ability 
of certain proteins to dimerise is denoted with a curved arrow.
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Harmonin was also shown to interact with the C terminal PBI of 
protocadherin 15 via its PDZ2 domain (Figure 6.1). Although protocadherin 
15 is also present in the growing hair bundle it shows a different expression 
pattern to cadherin 23 in the cochlea so the two are unlikely to compete for 
PDZ2 of harmonin. Cadherin 23 is thought to be the tip link (Siemens, J et 
al, 2004), whilst protocadherin 15 is thought to form more lateral links 
between the stereocilia and is also localised to the cuticular plate region 
(Adato, A et al, 2005b). The subcellular distribution of protocadherin 15 
within the unfixed murine retina has also recently been verified by electron 
microscopy. The protein was localised to the OPL, IS (where it was 
concentrated to the OLM) and throughout the OS. In the OS, 
immunoreactivity was greater distal to the connecting cilium although the 
connecting cilium itself remained unstained and protein levels were more 
abundant in cone photoreceptor OS than in rod OS. It has therefore been 
hypothesised that since only protocadherin 15 and harmonin have been 
localised to the photoreceptor OS, that harmonin isoform ‘b’ links 
protocadherin 15 at the OS disk membranes to the actin cytoskeleton 
(Boeda, B et al, 2002), thereby rigidly organizes the newly synthesized disks 
starting at the connecting cilium with respect to the actin cytoskeleton 
(Reiners, J et al, 2005a). Figure 6.2 summarises the recent developments in 
the understanding of Usher protein localisation in the retina.
Since harmonin is a multidomain protein and likely to be able to bind to 
multiple proteins simultaneously, it is possible that harmonin may interact 
with protocadherin 15 and phosducin at the IS/OS, thus fulfilling the role
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postulated by Reiners et al (2005) in organising the newly synthesized OS 
disks. Yet, as discussed previously, it is unlikely that the USH1 proteins are 
involved in correct sensory cell development in the retina, in contrast to their 
role in the ear (section 1.3.4.1), since patients have normal vision at birth. 
Therefore although harmonin/protocadherin 15 and harmonin/phosducin may 
indeed interact within the IS or OS, it is unlikely to be the site of pathology for 
Usher syndrome type 1.
263
Figure 6.2 A summary of the localisation of phosducin and the Usher proteins
in the murine retina
Myosin Harmonin Cadherin Protocadherin Sans Usherin Nbc3 Vlgrlb Clarin 1 Phosducin
VHA 23 15
The majority of the Usher proteins and phosducin colocalise to the OPL. Clarin-1 is also 
postulated to colocalise to the OPL but may function on the post synaptic membrane of the 
ribbon synapses of OPL, since it is expressed by the horizontal and Muller cells and not the 
photoreceptors. The patterns of protein expression of the Usher proteins support the 
argument that the OPL and more likely the ribbon synapses is the site of Usher pathology 
within the retina.
1= Usherin is localised to the Bruch’s membrane above the RPE rather than the RPE itself.
?- Due to the presence of the protein in both the OS and IS, it is possible that it also localises 
to the CC but this has not yet been proved/disproved.
2ryN, second order retinal neurons. OPL, outer plexiform layer. ONL, outer nuclear layer. IS, 
photoreceptor inner segments. CC, connecting cilium. OS, photoreceptor outer segments. 
RPE, retinal pigmented epithelium.
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The homogeneous nature of the clinical phenotype of Usher type 1, and the 
overlapping expression patterns of the USH1 genes and proteins: both 
temporally (Figure 3.6) and spatially (Figure 3.3), point to the USH1 proteins 
being involved in a single pathway or macromolecular complex. Their 
colocalisation in the photoreceptor OPL has led to the hypothesis that the 
ribbon synapses within the OPL are the site of retinal pathology in Usher type 
1 patients (Reiners, J et al, 2003).
It has been argued that the defective ERG responses of the retinas of 
shaker-1 mice (Libby, R T et al, 2001), where there is a reduction in b-wave 
amplitude, is indicative of a synaptic dysfunction (Wolfrum, U et al, 2004), 
supporting the hypothesis of Reiners et al. However, others argue that the 
shaker-1 ERGs did not show the same abnormalities of b:a wave ratio 
observed in mice with proven synaptic defects (Williams, D S et al, 2004). 
Examples of such mice include the Bsn, nrc and Lamb2 mice, all of whom 
have floating ribbons at the presynaptic membrane of the photoreceptor 
synapse (Libby, R T et al, 2004 and references therein). But as stated earlier, 
the murine models for Usher syndrome type 1 do not have a clinically 
significant degree of retinal dystrophy, and therefore findings in these mice 
must be viewed with that in mind.
However, some ‘proven’ synaptic defects display a more subtle decrease in 
b-wave and a-wave amplitude on an ERG (Libby, R T et al, 2004), more in 
keeping with the ERG data for certain waltzer alleles (Libby, R T et al, 2003). 
For example, myosin Va has been shown to be unnecessary for anchoring
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the ribbon but may be important in recycling or replenishing the synaptic 
vesicles (Libby, R T et al, 2004). In the myosin Va mutant, this decrease may 
be as a consequence of feedback from post synaptic activity upon the 
photoreceptor or alternatively may be due to defects in the IS where myosin 
Va is also expressed (a similar pattern of expression seen for four of the 
USH1 proteins to date). This leaves the question as to whether any of the 
USH1 proteins play a similar role to myosin Va in the photoreceptor ribbon 
synapses, in replenishing the synaptic vesicles, or whether they play a more 
structural/organisational role in keeping with their function in the ear.
In addition, many members of the cadherin/protocadherin superfamily are 
expressed in the CNS synapses, where they are involved in segregation of 
neuronal precursor populations, in axonal outgrowth and in synapse 
formation. Many cadherins are localised to the synaptic junctions where they 
modulate synaptic structure and transmission properties e.g. N-cadherin or 
protocadherin 7 (Frank, M et al, 2002).
Furthermore, it is relevant to note that the Shank protein, a proline-rich 
multidomain protein consisting of SH3, PDZ and SAM domains, binds the 
metabotropic glutamate receptor interacting protein, Homer 1a, at synapses 
to help link it to the cytoskeleton (Garner, C C et al, 2000). Sans also 
contains a SAM domain and so could potentially be involved in a structural 
complex involving harmonin, phosducin and glutamate receptors at retinal 
synapses, although its individual expression pattern within the retina has not 
yet been determined. All this would support the hypothesis of a role for the
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USH1 proteins in the modulation of retinal ribbon synapse structure and 
transmission, further supported by the new found interaction of an USH1 
protein with phosducin.
Harmonin. phosducin and the USH2 & USH3 proteins 
The interaction of harmonin and phosducin would argue a role for harmonin 
and maybe other Usher proteins in synaptic transmission/control of vesicle 
release. This is also supported by the proposed roles of the USH2 proteins, 
which have also been shown to interact with harmonin via PDZ1 (Figure 6.1) 
and be expressed in the photoreceptor OPL (Figure 6.2) (Reiners, J et al, 
2005b). NBC3 has been postulated to interact with PMCA Ca2+-ATPase 
plasma membrane channels, which are also suggested to complex with PSD- 
95 (a PDZ domain containing protein), in the photoreceptor synaptic 
terminals. NBC3 could therefore interact with harmonin indirectly through the 
PCMA ion channels or directly, using its C terminal PBI. Studies have shown 
that the function of L-type voltage gated Ca2+ channels in the photoreceptor 
synaptic terminal is very sensitive to changes in pH thus NBC3 could play a 
role in buffering H+ loads for these channels (Bok, D et al, 2003 and 
references therein).
As discussed in section 1.3.3.8, Vlgrlb may act as an extracellular Ca2+sink, 
as a Ca2+ dependent cell adhesion molecule or to monitor intra- and 
extracellular Ca2+ trafficking. Disruption of Ca2+ metabolism is known to 
affect both hearing and vision as has been shown with the deaf waddler
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mouse, which has mutations in PMCA2 (note the postulated interaction 
between PMCA channels and NBC3 discussed above) (Weston, M D et al,
2004). It would be interesting to determine whether the USH2B and USH2C 
proteins are involved in Ca2+ and H+ ion level regulation for correct 
photoreceptor synaptic function, and whether their behaviour is influenced by 
an interaction with harmonin.
The long isoform of usherin has now been localised to the OPL and 
connecting cilium of the photoreceptors, in addition to the Bruch’s membrane 
where the small isoform is also expressed. It is interesting to note that as well 
as complexing with harmonin, usherin can form dimmers with Vlgrlb. The 
interaction of these two very large proteins is thought to help stabalise Usher 
protein complexes formed in the ear and may do so in the retina also. No 
interactions have been noted between the USH2 proteins and any of the 
other USH1 proteins aside from harmonin (Reiners, J et al, 2005b).
Clarin-1 shows protein sequence homology to Stargazin: which has been 
shown to play a key role in the shaping and maintenance of cerebellar 
synapses. It is also involved in control of expression and mobilisation of 
particular glutamate receptors in the post-synaptic cleft in cerebellar granular 
cells, as well as possibly playing a role in forming protein-protein contacts 
across the synaptic cleft (Chen, L et al, 2000; Ottersen, O P et al, 1998). 
Although Clarin-1 has been found near both pre- and post- synaptic 
membranes, it is not clear whether it has a PBI (Adato, A et al, 2002) and the 
ability to complex with harmonin directly. Instead it may also be involved in
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controlling synaptic transmission via the glutamate receptors and Ca2+ as has 
been postulated above for harmonin, phosducin and the USH2 proteins.
In conclusion, the subcellular localisation of the USH1 proteins and putative 
localisation data on the USH2 proteins reveals co-localisation of ail these 
Usher proteins within the OPL of the retinal photoreceptors (Figure 6.2). It 
has been postulated that the site of retinal pathology in Usher type 1 patients 
is in the photoreceptor ribbon synapses, with harmonin acting as a scaffold to 
organise the proteins at the synapse membranes (Reiners, J et al, 2003). 
This may also be the site of pathology in Usher types 2 and 3, due to the 
overlapping protein localisation patterns of all the Usher proteins. In this case 
the defect may be in control mechanisms of vesicle release rather than 
structural/organisational (Reiners, J et al, 2005a) as postulated for type 1. 
However, it is not known whether the USH1, 2 & 3 proteins complex 
altogether or whether separate USH1 and USH2 complexes are formed, with 
harmonin being the link within and maybe between these complexes. Yet 
dysfunction of any of the USH complex proteins would result in synaptic 
dysfunction causing the retinal phenotype of Usher syndrome. This 
argument is further supported by the finding of an interaction between 
harmonin and phosducin, suggesting that the OPL and more specifically the 
ribbon synapses are the site of Usher pathology within the retina.
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Appendix 1 Suppliers
Chemicals were obtained from the following suppliers. Those not listed here 
but discussed in this work were of reagent grade from Sigma.
Name of company Reagent
AB gene Plate sealers
96-well PCR plates
Agar Scientific LR gold
Amersham Pharmacia Biotech Hybond ECL nitrocellulose membrane
ET terminator sequencing kit
Amresco 5xTBE
Athene 200nm nickel mesh grids
BBInternational Biomount
BDH Formaldehyde
Sucrose
Tris
HCI
Glycerol
|3-mercaptoethanol
Na2H P 04
KCI
M gS04
Acetone
Superfrost uncoated glass slides
Methanol
MOPS
MES
KOH
RbCI2
CaCI2
MnCI2
NaCI
Bioline dNTPs
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Taq polymerase, 10x buffer 
& 50 mM MgCh
Bio-Rad 10x TGS buffer
Gel Doc™ 2000 imaging system
Precision plus protein™ standards
Protein assay dye
SDS PAGE gel preparation apparatus 
and electrophoresis system (Mini- 
PROTEAN II cell)
Bright B1009DR solid knife
Citifluor Ltd Glycerol/PBS mounting solution
Clontech YPD
SD drop out medium supplements
SD minimal base media
CLP 50ml Falcon tubes
Corning Incorporated 72cm2 cell culture flask/vented cap
Diatome 2.7mm Diamond Knife
Eppendorf AG PCR film
Spectrophotometer cuvette
Fermentas PageRulerIM Prestained Protein 
Ladder
FLUKA PMSF
GIBCO MEM vitamins
MEM non-essential amino acids
Hayman Absolute Ethanol
International Biotechnologies Bromophenol Blue
Invitrogen™ 100bp ladder
Agarose
Dnase I
DMEM with L-Glutamate
Hind III DNA fragments
LB broth
1kb DNA ladder
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One Shot® TOP10 competent cells
S.O.C. medium
Superscript™ II Reverse 
transcriptase
5x First Strand Buffer
T4 DNA Ligase
Trizol™
KPL Protein A kit
Kontes Pellet Pestle® Motor Homogeniser
Marvel 5% non-fat powdered milk
MWG Oligonucleotides
National Diagnostics 37:5:1 Acrylamide/Bis-acrylamide 
(Protogel)
Histoclear
New England Biolabs (NEB) Restriction endonuclease enzymes
NUNC 96-well flat bottom ELISA plates
Inoculating Loops
PAA Fetal Calf Serum
Perkin Elmer (PE) Applied 
Biosystems
BigDye™ cycle-sequencing kit
Pierce ProFound™ c-MycTag IP/CO-IP kit 
and amplification set
Promega TNT® Quick Coupled 
T ranscription/T ranslation 
system
Transcend™ Biotin-Lysyl-tRNA
ProtoBlot® Western Blue® Stabilized 
Substrate
Qiagen HotStarTaq™ DNA polymerase
QIAprep spin miniprep kit
QIAprep spin maxiprep kit
QIAquick PCR purification kit
QIAquick gel extraction kit
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Raymond A. Lamb Optimal Cutting Temperature 
compound (OCT)
Heamatoxylin staining solution
Eosin staining solution
Sigma All other chemicals
The Binding Site PAP-PEN
USB Shrimp Alkaline Phosphatase
Whatman Filter paper (various sizes)
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Appendix 2 Media
Media were produced as follows, autoclaved at 121°C for 20 minutes and 
stored at 4°C.
10X Drop-out (DO) Solution
DO solutions are a mixture of specific amino acids and nucleosides used to 
supplement SD base to make SD medium, normally missing one or more of 
the nutrients required by untransformed yeast to grow on SD medium.
L-Adenine hemisulfate salt 200 mg/L
L-Arginine HCI 200 mg/L
L-Histidine HCI monohydrate 200 mg/L
L-lsoleucine 300 mg/L
L-Leucine 1000 mg/L
L-Lysine HCI 300 mg/L
L-Methionine 200 mg/L
L-Phenylalanine 500 mg/L
L-Threonine 2000 mg/L
L-Tryptophan 200 mg/L
L-Tyrosine 300 mg/L
L-Uracil 200 mg/L
L-Valine 1500 mg/L
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LB broth and agar (Luria’s Broth)
10g/L Tryptone
5g/L Yeast extract
10g/L NaCI
Double distilled H20  
15g/L BactoAgar (plates only)
SD medium (Synthetic Drop-out Medium)
26.7g/L SD Minimal Base
20g/L Agar (plates only)
10Oml/L Appropriate 10x drop-out solution
12 mM 3-AT (3-amino-1,2,4-triazole) (for pGBKT7-USH1C only)
Adjust the pH to 5.8 if necessary
soc
950ml Double distilled H20
20g/L Tryptone
5g/L Yeast extract
0.5g/L NaCI
10ml/L 250mM KCI
Adjust to pH 7 with NaOH. Make up to 1L with double distilled H20  and 
autoclave.
Just prior to use, add 5ml sterile 2M MgCI2and 20ml sterile 1M glucose.
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YPDA (Adenine-supplemented Yeast Peptone Difco)
50 g/L Yeast Peptone Difco
15 ml/L 0.2% adenine hemisulfate (final concentration is 0.003%)
20g/L Agar (plates only)
Adjust the pH to 6.5 if necessary
YT broth
950ml Double distilled H2O
16g/L Tryptone
10g/L Yeast extract
5g/L NaCI
Adjust to pH 7 with NaOH. Make up to 1L with double distilled H20  and 
autoclave.
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Appendix 3 Buffers and solutions
Buffers were made up as follows. Solutions were stored at 4°C unless 
otherwise stated. Solutions were autoclaved 121°C for 20 minutes if stated.
DNA loading buffer
50% Glycerol
0.05% Orange G
DEPC water
0.1% DEPC incubated at 37 degrees for 12 hours then autoclaved.
6x Llamelli loading buffer
0.35M Tris-HCI pH 6.8
10.28% SDS
36% Glycerol
5% (3-mercaptoethanol
0.012% Bromophenol blue
10X Li Ac
1 M lithium acetate Autoclave 
Adjust to pH 7.5 with dilute acetic acid
1M MES (Morpholino ethane sulfonic acid)
19.5g/100ml MES
Adjust pH to 6.2 using KOH, filter-sterilize and store at 4°C
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1M MOPS (3-(N-morpholino) propane sulfonic acid)
1 1 .5 1g/50ml MOPS
Filter (0.22pm) and store at 4°C
50% PEG 3350 (Polyethylene glycol) warm solution to 50°C to help the PEG 
go into solution.
PBS (Phosphate buffered saline)
137mM NaCI
2.7mM KCI
10mM Na2H P 04
1.8mM KH2P 0 4
Adjust to pH7.4 using HCI
PBS-T
PBS+0.1% TWEEN 20
PEG/LiAc solution (polyethylene glycol/lithium acetate) (Prepare fresh just 
prior to use)
To prepare 10 ml of solution 
8 ml/10ml 50% PEG
1 ml/10ml 10XTE
1 ml/10ml 10X LiAc
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Protease inhibitor cocktail for protein extraction from tissue/cells
2mM AEBSF 
1mM EDTA 
130|jM Bestatin 
14pM E-64 
1|jM Leupeptin 
0.3pM Aprotinin
Protease Inhibitor Solution for protein extraction from yeast
(concentrated) (Prepare solution fresh just prior to use on ice)
0.1 mg/ml Pepstatin A (in DMSO)
0.03 mM Leupeptin
145 mM Benzamidine
0.37 mg/ml Aprotinin
Qiagen DNA preparation buffers
Resuspension Buffer P1 50mMTris-HCI
10mM EDTA
100 pg/ml RnaseA (store at 4°C)
Lysis Buffer P2 0.2 M NaOH
1%SDS
Neutralization Buffer P3 3.0M Potassium acetate pH5.5
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Equilibration Buffer QBT 750mM NaCI
50mM MOPS, pH7.0 
15% isopropanol (v/v) 
0.15% Triton X-100 (v/v)
Wash Buffer QC 1.0M NaCI
50mM MOPS, pH7.0 
15% isopropanol (v/v)
Elution Buffer QF 1.25M NaCI 
50mM TrisCI, pH8.5 
15% isopropanol (v/v)
The compositions of the remaining buffers used in these kits are not freely 
available.
buffer
5ml/100ml 3M NaCI
1 ml/100ml NP-40
0.5g/100ml sodium deoxycholate
1 ml/100ml 10% SDS
2ml/100ml 2.5M Tris pH8
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SDS/glycerol stock solution
7.3% w/v SDS 
29.1% v/v Glycerol 
83.3 mM Tris-base (not pH-adjusted) 
Spatula tip-full Bromophenol blue 
Deionized H2O
TBE (Tris-borate buffer) (5x stock)
54g/L Trisbase
27.5g/L Boric acid
20ml/L 0.5M EDTA (pH5)
25mM TBS (Tris buffered saline)
3g/L Tris base
8g/L NaCI
0.2g/L KCl
Adjust to pH7.4 using HCI and autoclave.
TCA Buffer (Prepare solution fresh just prior to use on
20 mM Tris-HCI (pH 8)
50 mM Ammonium acetate
2 mM EDTA
50 pl/ml Protease inhibitor solution
100 pi PMSF (100X stock)
Deionized H2O
TCA-Laemmli loading buffer (Prepare fresh just prior to use)
480 pl/ml SDS/glycerol stock solution
400 pl/ml Tris/EDTA solution
50 pl/ml p-mercaptoethanol
20 pl/ml PMSF (stock solution 100X)
20 pl/ml Protease inhibitor solution
Deionized H20
10X TE buffer pH 7.5 Autoclave 
0.1 M Tris-HCI 
10 mM EDTA
TFB1
5ml/500ml MES 1M (pH 6.2)
6.045g/500ml RbCI2
0.735g/500ml CaCI2.2 H 20
4.94g/500ml MnCI2.4 H 20
All salts are added as solids. Adjust pH to 5.8 with acetic acid and then filter 
the solution through a pre-rinsed 0.22pm filter. Store at 4°C.
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TFB2
1.102g/100ml CaCI2. 2H20
0.120g/100ml RbCI2
15ml/100ml glycerol
1 ml/100ml 1MMOPS
Bring the pH to 6.5, filter-sterilize and store at 4°C.
TGS (Running buffer)
25 mM Tris
192 mM Glycine 
0.1%(w/v) SDS pH8.3
Transfer buffer
48m M Tris
39mM Glycine
20% (v/v) Methanol
pH 9.2
Store at 4°C.
Tris/EDTA solution
200 mM Tris-base (not pH-adjusted)
20 mM EDTA
Deionized H20
X-gal stock solution
Dissolve 5-bromo-4-chloro-3-indolyl-|3-D-galactopyranoside in N,N- 
dimethylformamide (DMF) at a concentration of 20 mg/ml. Store in the dark 
a t-2 0°C .
Z buffer
16.1 g/L Na2HP0 4 .7 H20
5.50 g/L NaH2P 0 4.H20
0.75 g/L KCI
0.246 g/L M gS04.7H20
Double distilled H20  
Adjust to pH 7.0 and autoclave. Store at room temperature for up to 1 year.
Z buffer/X-gal solution
100 ml/100ml Z buffer
0.27 ml/100ml p-mercaptoethanol
1.67 ml/100ml X-gal stock solution
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Appendix 4 Antibiotics
Ampicillin
Kanamvcin
50mg/ml stock stored at -20°C.
To prepare, filter solution through a 0.2pm syringe filter 
Add 1 pi stock per 1 ml of agar/broth
10mg/ml stock stored at -20°C.
Add 2.5pl stock per 1ml of agar/broth
298
Appendix 5 Fixatives and cryopreservation buffers
Dissected tissues and cells were preserved through the use of fixatives. 
Fixatives function by cross-linking the amino groups of proteins and nucleic 
acids to each other, thereby rendering degradative enzymes inoperative.
4% Paraformaldehyde (PFA)
The powder is toxic so the solution is made in a fume hood. Make up to 4% 
using DEPC treated PBS, dissolving on a heated stirring plate at 60°C. 
Remove any residual cloudiness if necessary, using a drop of dilute NaCI, 
then aliquot into 10ml portions and freeze at -20°C.
Sucrose/PBS cryopreservation buffer
Make up a 20% sucrose solution in PBS.
Filter-sterilize and store at room temperature.
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Appendix 6 Agarose and SDS-PAGE gel recipes
1% DNA agarose gel
1 g Agarose/100ml TBE 
0.5|jl/ml Ethidium bromide
5% SDS-PAGE stacking gel
330|jl/2ml 30% acrylamide mix
250|jl/2ml 1.5M Tris (pH 6.8)
20|jl/2ml 10% SDS
20pl/2ml 10% ammonium persulfate
2pl/2ml TEMED
1.4ml/2ml ddiH20
10% SDS-PAGE resolving gel
3.3ml/10ml 30% acrylamide mix
2.5ml/10ml 1.5M Tris (pH 8.8)
100pl/10ml 10% SDS
100pl/10ml 10% ammonium persulfate
4pl/10ml TEMED
4.0ml/10ml ddiH20
12% SDS-PAGE resolving gel
4.0ml/10ml 30% acrylamide mix
2.5ml/10ml 1.5M Tris (pH 8.8)
100|jl/10ml 10% SDS
100|jl/10ml 10% ammonium persulfate
4pl/10ml TEMED
3.3ml/10ml ddiH20
15% SDS-PAGE resolving gel
5.0ml/10ml 30% acrylamide mix
2.5ml/10ml 1.5M Tris (pH 8.8)
100pl/10ml 10% SDS
100pl/10ml 10% ammonium persulfate
4pl/10ml TEMED
2.3ml/10ml ddiH20
Appendix 7 Antibodies and cell labelling solutions
A list of the antibodies, the host they were raised in and their label ie FITC (and suppliers) 
used in this research.
Company Antibody/Label
Affinity BioReagents Polyclonal rabbit anti-myosin VIIA
Amersham Pharmacia Goat anti-rabbit IgG-Horse radish 
peroxidase (HRP) conjugated
Invitrogen Monoclonal mouse anti-c-Myc alkaline 
phosphatase (AP) conjugated
Jackson Laboratories Donkey anti-sheep IgG -  Cy3 conjugated
Donkey anti-goat IgG-FITC conjugated
Kirkegaard and Perry 
Laboratories (KPL)
Biotinylated goat anti-mouse IgG
Biotinylated goat anti-rabbit IgG
Molecular Probes Rhodamine conjugated Phalloidin
Promega Streptavidin-AP conjugate
Rockland Donkey anti-goat lgG-Cy5 conjugated
Goat anti-FITC
Santa Cruz 
Biotechnology Inc.
Goat anti-mouse IgG -  AP conjugated
Rabbit serum
Goat serum
Monoclonal mouse anti-HA
Goat polyclonal anti-rhodopsin
Serotec Donkey anti-sheep IgG AP conjugated
Vector Laboratories Horse serum
Goat anti-rabbit IgG-FITC conjugated
Avidin-D conjugated to Rhodamine
Gift from Dr Scanlan, 
(Ludwig Institute for Cancer 
Research, NY USA)
Monoclonal mouse anti-harmonin
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Gift from Dr Kobayashi, 
(Hokkaido University 
Graduate School of 
Medicine and University 
Hospital, Japan)
Polyclonal rabbit anti-harmonin
Gift from Dr Arshavsky, 
(Harvard Medical School 
and the Massachusetts Eye 
and Ear Infirmary, MA USA)
Polyclonal sheep anti-phosducin
Gift from Dr Mueller, 
(Scripps Research Institute, 
CA USA)
Polyclonal rabbit anti-cadherin 23
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Appendix 8 Genotype and phenotype details of E.coli strains
A variety of E.coli strains were used throughout this work. They are documented below alongside their genotype and use in this work.
Strain Genotype Company Function
Max Efficiency 
DH5a
F- <fr80dlacZAM15 A(lacZYA-argF) U169 recA1 endA1 
hsdR17(rk-, mk+) phoA supE44 k- thi-1 gyrA96 relA1
Invitrogen Y 2 H -  
Isolation of 
preys
ElectroMAXIM
DH10B™
F- mcrA .(mrr-hsdRMS-mcrBC) <p80lacZ.M15 ,lacX74 
recA1 endA1 araD139.(ara, leu)7697 galU galKe- rpsL 
nupG
Invitrogen Y2H-library
amplification
One Shot® TOP10 
Chemically 
Competent E. coli 
Cells
F- mcrA A(mrr-hsdRMS-mcrBC) $80lacZAM15 AlacX74 
recA1 araAl39 A(ara-leu)7697 galU galK rpsL (StrR) 
endA1 nupG
Invitrogen Y 2H -
Propagation 
of baits 
TA cloning
KC8 hsdR, leuB600, trpC9830, pyrF::Tn5, hisB463, lacDX74, 
strA, galU.K
Clontech Y 2 H -  
Isolation of 
preys
Appendix 9 Genotypes of yeast strains used in the Yeast Two-hybrid 
screen
All yeast strains were a kind gift from Dr J. Achermann and Dr L. Lin (Institute of Child Health 
and Great Ormond Street Hospital for Sick Children, London UK) and further information can 
be obtained from the Yeast Strain Handbook, Clontech. AH 109 was used for bait protein 
expression and sequential co-transformation library screening. Consequently, isolated prey 
proteins were then expressed in AH 109, therefore Y187 was used for bait and control protein 
expression in yeast mating experiments.
Yeast
strain
Genotype Reporters
AH 109 MATa, trp1-901, leu2-3, 112, ura3-52, his3- 
200, gal4A, gal80A, LYS2 :: GAL1UAS- 
GAL1TATA-HIS3, MEL1 GAL2 UAS- 
GAL2TATA-ADE2, URA3::MEL1UAS- 
MEL1TATA-lacZ
HIS3, ADE2, 
lacZ, trp1, 
Ieu2, MEL1
Y187 MATa, ura3- 52, his3- 200, ade 2-101, trp 1- 
901, leu 2- 3,112, gal4A, met-, gal80A, 
URA3 : : GAL1UAs -GAL1TATA-lacZ, MEL1
lacZ, MEL1
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Appendix 10 Plasmids used in the Yeast Two-hybrid screen and 
associated experiments
Prominent features and details of suppliers are shown below.
Name Function Features Suppliers
pGBKT7 Y 2 H -
construction of 
bait fusion 
protein
• Expressed in yeast only
• Tryptophan and kanamycin 
selective
• c-myc tagged
• T7 promoter for in vitro 
translation
(Clontech) 
Donated by 
Dr J.
Achermann 
And Dr L.Lin
pACT2 Y2H -  in which 
prey library of 
fusion proteins 
was produced
• Expressed in yeast and bacteria
• Leucine and ampicillin selective
• HA tagged
(Clontech) 
Donated by 
Dr C. Sung 
(Tai, A W et 
al, 1999)
pGADT7 Y2H -  in which 
control fusion 
proteins were 
produced
• Expressed in yeast only
• Leucine and ampicillin selective
• HA tagged
• T7 promoter for in vitro 
translation
(Clontech) 
Donated by 
Dr J.
Achermann 
And Dr L.Lin
pCL1 Y2H -  positive 
control for p- 
galactosidase 
assay
• Expressed in yeast
• Endogenous over expression of 
P-galactosidase assay
(Clontech) 
Donated by 
Dr J.
Achermann 
and Dr L.Lin
pUC19 Positive control 
vector for 
bacterial 
transformation 
efficiency
• Expressed in bacteria
• Ampicillin selective
• Expresses p-galactosidase 
allowing blue/white selection
Invitrogen
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Appendix 11 Equipment
A list of the equipment (and suppliers) used in this research is shown below.
Supplier Equipment
Bio-Rad Mini Trans-Blot® Electrophoretic Transfer 
Cell
Mini-PROTEAN II cell
Power Pac 200
Bio-Rad Transgenomic™ Chemidoc, agarose gel transilluminator
Bright Cryostat (OFT model with 5040 microtome)
Eppendorf BioPhotomter, Spectrophotometer
Heraeus Stationary plate incubator
Hera Cell culture incubator
Hybaid Agarose gel tanks
Jencons PLC Biofuge PICO, bench top centrifuge
Jenoptik Jenoptik ProgRes C14 Imaging Microscope 
Camera
Leica, Milton Keynes, UK Confocal Microscope (SP2)
Orion Orion 410A pH meter
Patternson Scientific EB A12 bench top centrifuge
Philip Harris Laboratory Centrifuge 6K15, Sigma
Reichert Ultracut E microtome
RMC UV 6500 Freeze Substitution Polymerization 
Apparatus
Sorval Legend RT, Centrifuge
Stuart Scientific 360° Rotator
Shaking Incubator
TECAN Genios Multifunction Microplate Reader
Zeiss Axioplan 2 Imaging Microscope
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Appendix 12 Software
A list of the software (and suppliers) and its use in this research is shown below.
Application Product Supplier
Capture of confocal 
microscopy images
Leica confocal 
software
Leica microsystems
Capture of 
fluorescent 
microscopy images
Openlab Improvision
DNA sequence 
analysis
Chromas Technelysium Pty Ltd
ELISA plate reader XFIuor4 TECAN
Hydrophobicity plots Kyte-Doolittle and 
Hopp-Woods
Colombia State University 
http://arbl.cvmbs.colostate. 
ed u/mol kit/hyd ropathy/
Gel image capture Quantity One 4.4.0. Bio-Rad Transgenomic™
Primer design Primer 3 http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi
Protein sequence 
alignments
CLUSTALW European Bioinformatics 
Institute
http://www.ebi.ac.uk/ClustalWw/
Storage and 
presentation of 
images
Photoshop 6.0 Adobe
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Appendix 13 List of primers used I Sequence of oligonucleotide primers
All oligonucleotide primers were synthesized by MWG. Primers used in the construction of 
the bait and control fusion proteins introduced restriction digest sites (Sfi7 |  and Xma1[J) to 
the insert sequences (section 2.5.1.2.1).
Name O ligonucleotide  Sequence (5’ -> 3’) Chapter
Semi-quantitative RT-PCR primers
USH1BF GTTCTCCGTGTTGGTCCTGT 2.3.3.2
USH1BR GAAGCCTGACTCCTCACCAG
USH1CF AAGGAACGGGTCGTGCAACG
USH1CR TGGGAGATGAAGAGCCCACAGC
USH1DF ACGAGAGTGTACCCGACCAC
USH1DR ATGAGACCCGTGTCCTTGTC
USH1FF AACCCGCGT CAAT CTTAAT G
USH1FR T AATGGCAGCAGCAGAAATG
GapdhF CCCTT CATT G ACCT CAACT A
GapdhR TTCTCCATGGTGGTGAAGAC
Yeast two-hybrid bait and control fusion protein construction and analysis primers
pGBKT7-
USH1CF
GGOGATQQAQOOCJGAATTCCGGCATAAGG’ G 2.5.1.2.1
pGBKT7-
USH1CR
t c c c c c c g g Gc a g c a a tta g a g c a g a g g
pGBKT7-PDZ1 F ®$fGATG0A8<SQ$CTG AAG CACC AG GTG G AAT
pGBKT7-PDZ1 R TCCCCCCCGGGlGCCCAGATTCCGACACAAACT
pGBKT7-PDZ2 ■■(^TMWittGKlAAGGTCTTCATCAGCCTGGTA
pGBKT7-PDZ2R TCCCCCCCGGGGCAGCTACAATGGAGATGGTC
pGBKT7-PDZ3 ■ ■ ^ M M a a g g a tg tc c g g c tc c ta c
pGBKT7-PDZ3R TCCCCCCCGGGGCTCATCGTCATACTCCTTTGG
309
CDH23Y2HF ttrt^H H H IlA T C T A C A T C C T G A G G G A C G A
CDH23Y2HR T CCCCCCCGGGAAT CCT CCAGGACCACCTT C
PGBKT7R GT C ACTTT AAAATTT GT AT ACACTT
T7 GTAATACGACTCACTATAGGG
Y2HCDH23INTE
RN
TCGATGAGAACAAGGAGCAG
Yeast two-hybrid control fusion protein and prey idenity analysis primers
pACT2FB GAGATGGTGCACGATGCACAGTT G 5.1.5.1
pACT2R CT ATT CGATGATGAAGATACCCCAC
phosducin sequencing primers
cowPHD250 TTCGTAAATACCGCAGACAGTG 2.5.5.3.1
cowPHD459 GCCGAATACCCTATGGTCAA
cowPHD689 GCAGAGCAAAATGGAAGAGG
cowPHD932 GC AAT AT GTT AGTAG ACAAAG AG
CowPhosducin
sequencingR
TAGGACATGCATCTCCTTTTCAGG
Primers for production of tagged control proteins for control CO-IP experiments
T7+HA+mcc2F AAAATTGTAATACGACTCACTATAGGGCGAGCCGCC 
ACCATGTACCCATACGATGTTCCAGATTACGCTAGC 
AGCGGGGACGAGGAAGAGTGG
2.5.6.1.1 
.1
MCC2R AGGGGCCTACAGAAAGGTGTCCCCAAG
Primers for the examination of Pdc expression in the murine ear
maPhdF (exon3) C AAG AAGG AAATCCT CAG ACAAA 2.5.7.3
maPhdR (exon4) TGTTT CCAGCT CAT ACACAAACC
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Appendix 14 Semi-quantitative PCR raw data examining the expression of the USH1 genes during embryonic eye 
developmental stages and in the adult eye.
The intensity reading for each gene at each developmental stage was normalized to the Gapdh intensity of the same stage in that experiment. 
The average normalized intensity for each developmental stage was calculated from the results of the three experiments.
For example: Exp1: E12.5 Myo7a Intensity = 813.5448 Normalised intensity = 813.5448/3062.082 = 0.265684.
Exp1: E12.5 Myo7a Average = (0.265684+0.305298+0.48794)/3 = 0.352974 
This data is represented graphically in Figure 3.6.
Myo7a Ushlc Cdh23 Pcdh15 Gapdh
Developmental
stage
Intensity
/mm2
Normalised 
Intensity to 
Gapdh
Intensity
/mm2
Normalised 
Intensity to 
Gapdh
Intensity
/mm2
Normalised 
Intensity to 
Gapdh
Intensity
/mm2
Normalised 
Intensity to 
Gapdh
Intensity
/mm2
Normalised 
Intensity to 
Gapdh
Exp 1: E12.5 813.5448 0.265684 1401.374 0.457654 1563.509 0.510603 3395.895 1.109015 3062.082 1
E14.5 966.7901 0.315062 1479.759 0.482231 1430.273 0.466105 3444.254 1.122431 3068.567 1
E16.5 1010.201 0.338105 1522.434 0.509545 1734.73 0.580599 3404.465 1.139445 2987.827 1
E18.5 791.0506 0.260524 1480.054 0.487439 1939.937 0.638897 3410.211 1.123115 3036.386 1
Adult 799.0613 0.329689 1634.033 0.674194 980.8554 0.404696 3243.234 1.338142 2423.685 1
Exp 2: E12.5 961.7554 0.305298 1517.722 0.481782 1499.709 0.476065 2622.272 0.832409 3150.223 1
E14.5 1005.13 0.308016 1382.107 0.423538 1495.236 0.458206 3543.41 1.085856 3263.24 1
E16.5 1161.5 0.334172 1504.873 0.432964 1829.98 0.526499 3290.468 0.946693 3475.748 1
E18.5 805.2657 0.260915 1577.881 0.511251 1741.095 0.564134 3166.597 1.026012 3086.314 1
Adult 728.1427 0.273257 1654.948 0.621067 945.5206 0.354834 3069.72 1.152001 2664.685 1
Exp 3: E12.5 1472.48 0.48794 1784.697 0.5914 1655.096 0.548454 945.4473 0.313295 3017.751 1
E14.5 2260.174 0.688197 1610.138 0.490269 1666.708 0.507494 1240.291 0.377655 3284.194 1
E16.5 1895.066 0.638008 1669.831 0.562179 1411.744 0.475289 1087.795 0.366226 2970.284 1
E18.5 2047.972 0.676915 2065.437 0.682688 1421.546 0.469863 1155.793 0.382023 3025.45 1
Adult 1843.661 0.732329 1894.645 0.752581 1019.904 0.405121 1564.548 0.621461 2517.531 1
Average: E12.5 0.352974 0.510279 0.511707 0.751573
E14.5 0.437092 0.465346 0.477268 0.861981
E16.5 0.436762 0.501563 0.527463 0.817455
E18.5 0.399451 0.560459 0.557631 0.843717
Adult 0.445091 0.682614 0.388217 1.037201
Appendix 15 Yeast Two-hybrid Vector Information
Schematics of the ‘bait’ (pGBKT7) and ‘prey’ (pACT2) vectors used in the Yeast Two-hybrid screen, showing the relative positions of the 
GAL4BD/GAL4AD, the nutritional selection markers, the antibiotic selection markers, details of the ORF, details of the MCS and the position of the 
T7 promoter (if present). Data is available at http://www.clontech.com/clontech/
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Appendix 16 Yeast 2 Hybrid Harmonin screening results
The initial colonies resulting from the sequential co-transformation of pGBKT7-USH1C(12-8) 
and pACT2-bovine retinal library plasmids, were each examined for their continued ability to 
activate the nutritional and colourmetric selection markers.
P = partial growth of streak/ small individual colonies 
F = full growth of streak/ large colonies 
X = no growth/minimal growth only at the initial site of streak 
- = negative (3 galactosidase assay (colonies remain white)
Colony
ID# Growth on SD-Trp/-Leu
Growth on SD- 
Trp/-Leu/-His/- 
Ade + 12mM 3- 
AT
No. of hours required for a 
positive (3 galactosidase 
assay result
1.1 y y P 7
1.2 y y P -
1.3 V y P 3.5
1.4 V y F 3.5
1.5 y y P 3.5
1.6 y y P 7.5
1.7 y y P 4.5
1.8 y y P 4.5
1.9 y y P 4.5
1.10 y y P 4.5
1.11 y y P 4.5
1.12 y y P 7
1.13 y y P 3.5
1.14 y y P 7
1.15 y y P 7
1.16 y y X
1.17 y y F 7
1.18 y y F -
1.19 y y X
1.20 y y X
1.21 y y P 3.5
1.22 y y F 3.5
1.23 y y F 7
1.24 y y P 3.5
1.25 y y F 7
1.26 y y F -
1.27 y y X
1.28 y y X
1.29 y y F 3.5
1.30 y y F 4.5
1.31 X
1.32 y y P 3.5
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1.33 V y P 5.5
1.34 V y F 3.5
1.35 y y F 7
1.36 V y P -
1.37 y y P 3.5
1.38 y y X
1.39 y y P 3.5
1.40 y y X
1.41 y y F 3.5
1.42 y y P -
2.1 y y F 4.5
2.2 y y P 5.5
2.3 y y F 5.5
2.5 y y P -
2.6 y y P -
2.7 y y P -
2.8 y y P 8
2.9 y y P -
2.10 y y X
2.11 y y P 4.5
2.12 y y P 5.5
2.13 y y X
2.14 y y X
2.15 y y p 7.5
2.16 y y p -
2.17 y y p -
2.18 y y p 5.5
2.19 y y p 3.5
2.21 y y p 3.5
2.22 y y p -
2.23 y y p 4.5
2.24 y y X
2.25 y y X
2.26 y y X
2.27 y y p 4.5
2.28 y y p 7.5
2.29 y y X
2.30 y y X
2.31 y y X
2.32 y y F 3.5
2.33 y y X
2.34 y y X
2.35 y y p 7.5
2.36 y y p 7.5
2.37 y y X
2.38 y y X
2.39 y y p 4.5
2.41 y y X
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2.42 y y P -
2.43 y y X
2.44 y y P 4.5
3.1 y y P 5.5
3.2 y y P -
3.3 y y X
3.4 y y X
3.5 y y p 4.5
3.6 y y F 4.5
3.7 y y F 3.5
3.8 y y X
3.9 y y P 3.5
3.10 y y F 3.5
3.11 y y X
3.12 y y P 5.5
3.13 y y P -
3.14 y y P 4.5
3.15 y y X
3.16 y y p 5.5
3.17 y y p 7.5
3.18 y y X
3.19 y y p
3.20 y y X
3.21 y y p 3.5
3.22 y y X
3.23 y y X
3.24 y y X
3.25 y y X
3.26 y y p 4.5
3.27 y y X
3.28 y y X
3.29 y y p 4.5
3.30 y y X
3.31 y y X
3.32 y y p 5.5
3.33 y y p 2
3.34 y y X
3.35 y y p 4.5
3.36 y y p 3.5
3.37 y y p 5.5
3.38 y y p 3.5
3.39 y y X
3.40 y y X
3.41 y y F -
3.42 y y p 5.5
3.43 y y X
3.44 y y p 3.5
3.45 y y p 5.5
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3.46 V y X
3.47 V y P 4.5
3.48 y y P 4.5
4.1 y y F 6.5
4.2 y y P 5.5
4.3 y y P 3.5
4.4 y y P 5.5
4.5 y y P 3.5
4.6 y y F -
4.7 V y P 3.5
4.8 V y F 7
4.9 V y X
4.10 y y P 3.5
4.11 y y P -
4.12 y y X
4.13 V y p -
4.14 V y F 3.5
4.15 y y P -
4.16 V y P -
4.17 y y P -
4.18 V y P 4.5
4.19 V y X
4.20 y y P 5.5
4.21 y y X
4.22 y y X
4.23 y y F 3.5
5.1 V y X
5.2 V y p 4.5
5.3 s y F -
5.4 V y P 3.5
5.5 y y X
5.6 V y F 3.5
5.7 y y P -
5.8 V y X
5.9 s y X
5.10 V y F 3.5
5.11 V y P 6.5
5.12 y y X
5.13 V y P -
5.14 V y P 6.5
5.15 y y P -
5.16 y y X
5.17 y y p 2
5.18 y y F 2
6.1 y y P 5.5
6.2 y y X
6.3 y y F 3.5
6.4 y y P -
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6.5 V y F 3.5
6.6 V y P 5.5
6.7 y y X
6.8 y y X
6.9 y y P 3.5
6.10 y y X
6.11 y y p 3.5
6.12 V y p 5.5
6.13 y y p -
6.14 V y p -
6.15 V y p 3.5
6.16 y y X
6.17 y y X 5.5
6.18 V y p 3.5
6.19 y y p 5.5
6.21 V y p 5.5
6.22 y y p 3.5
6.23 y y X
6.24 V y X
6.25 y y X
6.26 y y p -
6.27 y y X
6.28 y y p -
6.29 V y F 2
6.30 V y P -
6.31 y y X
6.32 V y F -
6.33 V y X
6.34 s y F 5.5
7.1 V y F 4.5
7.2 V y F 4
7.3 V y X
7.4 s y P 7.5
7.5 V y P 7.5
7.6 y y F 5.5
7.7 y y P -
7.8 y y X
7.9 y y F 4.5
7.10 y y P -
7.11 y y P -
7.12 y y F 3.5
7.13 y y X
7.14 y y F 2
7.15 y y X
7.16 y y X
7.17 y y P -
7.18 y y X
7.19 y y X
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7.20 V y F 2
7.21 y y X
7.22 y y X
7.23 V y P 5.5
7.24 y y F 4.5
8.1 y y P 4.5
8.2 y y X
8.3 y y P 5.5
8.4 V y F 3.5
8.5 y y X
8.6 y y F 2
8.7 y y F -
8.8 y y X
8.9 V y X
8.10 y y X 5
8.11 V y X
8.12 y y p 5
8.13 y y p 5
8.14 y y X
8.15 y y F 2
8.16 y y P -
8.17 V y P 5.5
8.18 y y P -
8.19 y y P -
8.20 V y P -
8.21 y y F 2
8.22 V y X
8.23 y y P -
8.24 y y X
8.25 V y p -
8.26 y y p 4.5
8.27 y y X
8.28 V y F 2
8.29 V y X
8.30 y y X
8.31 y y X
8.32 V y X 3.5
8.33 y y p 5.5
8.34 y y X 5.5
8.35 V y p 3.5
8.36 y y X
9.2 y y F -
9.3 y y F -
9.4 y y X
9.5 y y F 4.5
9.6 y y X
9.7 y y X
9.8 y y X
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9.9 y Y P 5.5
9.10 y Y P -
9.11 y Y X
9.12 y Y X
9.13 y Y p 4.5
9.14 Y Y F 4.5
9.15 y Y X
9.16 Y Y P 5.5
9.17 Y Y X
9.18 Y Y F 5.5
9.19 y Y X
9.20 y Y X
9.21 Y Y X
9.23 y Y P -
9.24 y Y X
10.1 y Y p -
10.2 Y Y X
10.3 y Y p
10.4 Y Y X
10.5 Y Y p -
10.6 y Y p -
10.7 Y Y p -
10.8 y Y p -
10.9 Y Y X
10.10 Y Y X
10.11 y Y X
10.12 y Y F -
10.13 Y Y X
10.14 y Y p 4.5
10.15 y Y p 5.5
10.16 Y Y X
10.17 y Y X
10.18 Y Y X
10.20 Y Y X
10.21 Y Y X
10.22 y Y p -
10.23 y Y F 5.5
10.24 y Y X
10.25 Y Y F 4.5
10.26 Y Y F -
10.27 Y Y X
10.28 Y Y F 4.5
10.29 Y Y X
10.30 Y Y X
10.31 Y Y X
10.32 Y Y X
10.33 Y Y X
10.34 Y Y X
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10.35 V X
10.36 V X
10.37 V P 3.5
10.38 V V X
10.40 s V X
10.41 s V p 3.5
10.42 s s X
10.43 s X
10.44 s V X
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Appendix 17 Calculation of the transformation efficiency of control and 
bait plasmids into Y187 yeast
Individual transformation efficiencies were calculated for the following, using Equation 5.1. 
Optimal transformation efficiency is £1x104 cfu/pg.
Strain [plasmid] Transformation efficiency (cfu/pg DNA)
Y 187[pGBKT7-USH 1C] 1.5x104
Y 187[pGBKT7-PDZ1 ] 3.4x103
Y 187[pGBKT7-PDZ2] 1.8x103
Y 187[pGBKT7-PDZ3] 2.8x103
Y187[pGBKT7-Lam] 1.5x104
Y187[pGBKT7] 2x104
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Appendix 18 Colony Exclusion Data
Interacting colonies were excluded from further investigation for the following reasons on the
basis of sequence and mating analysis.
Failed
mating
controls
Excluded on 
basis of 
sequence 
analysis
Clones/ Low 
priority 
sequenced 
interactors
No
sequence
data
available
No seq 
but 
passed 
mating
High priority 
sequenced 
interactors
2.1 1.1 4.1 1.32 1.5 1.4 1.3 phosducin
2.3 1.6 4.2 1.37 1.14 3.33 1.7 phosducin
2.32 1.8 4.4 2.11 1.21 6.3 1.9 phosducin
4.14 1.10 4.7 2.12 1.24 1.22 NICE 3
4.23 1.11 4.10 3.45 1.29 2.15 Retbindin
5.4 1.12 4.18 4.5 1.30 6.12 TUBB
5.18 1.13 4.20 6.1 1.33 7 .11K cytokine
6.9 1.15 5.2 6.17 1.39
7.23
hypothetical
protein
6.11 1.17 5.6 7.2 2.19
8.3
hypothetical
protein
6.29 1.23 5.10 7.4 2.23
7.14 1.25 5.14 8.32 2.36
8.6 1.34 5.17 3.6
8.15 1.35 6.5 3.12
10.25 1.41 6.6 3.14
10.41 2.2 6.15 3.16
2.8 6.18 3.21
2.18 6.19 4.3
2.21 6.21
2.27 6.22 8.1
2.28 6.34 8.10
2.35 7.5 8.13
2.39 7.6 8.34
2.44 7.9 8.35
3.1 7.12 9.9
3.5 7.20 9.14
3.7 7.24 9.18
3.9 8.4 10.14
3.10 8.12
3.17 8.17
3.26 8.21
3.29 8.26
3.32 8.28
3.35 8.33
3.36 9.5
3.37 9.13
3.38 9.16
3.42 10.15
3.44 10.23
3.47 10.28
3.48 10.37
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Appendix 19 Colony identity
The 145 colonies remaining for further analysis from the initial 377 (section 5.1.4.4) are listed below according to their colony ID 
number. Where possible, each colony was assessed as being a true interactor of harmonin through sequence and mating analysis, 
the results of which are also listed below.
^Activated both nutritional and colourmetric reporter genes during yeast mating analysis 
*=Failure to activated reporter genes mating during yeast mating analysis 
- = Not tested
Colony
ID#
Mated Encoded protein (NCBI accession 
number)
In frame?
All
USH1C
PDZ1 PDZ2 PDZ3 PGBKT7 Lam
1.1 T complex (BT006969) NO
1.3 X X X X X Phosducin (M33529) YES
1.4 ^1
colony
X X X X
1.5
1.6 Pyruvate kinase (BC023328) Mitocondrial
1.7 v ' X X X X X Phosducin (M33529) YES
1.8 MOB1 (NM_024761)/clones 3’UTR
1.9 X X X X X Phosducin (M33529) YES
1.10 S36 (NM_033281) Ribosomal
1.11 X X X X X Spectrin (U83867) NO
1.12 Deltex 3 (NM-178502) NO
1.13 X X X X X TAFA 3 (AY325116) NO
1.14
1.15 NADH dehydrogenase (AF493542) Mitochondrial
1.17 NRL (XM_547742) -
1.21
1.22 / /  X X X X X NICE 3 (NM_138740) YES
1.23 FTH1 (NM_174062) NO
1.24
1.25 Hypothetical proteins (NM_138820) NO
1.29
1.30
1.32 Chr16 clones (AC135782)
1.33
1.34 Sec 61 beta (NM_006808) NO
1.35 / X X X X X MAP2K1 (NM_002755) -
1.37 Chr 1 clones (AL611962)
1.39
1.41 X X X X FLJ45246 zinc finger protein 
(ZNF621)(NM .198484)
Poor blast 
match
2.1 s - - - X Pellino 3 alpha (BC025723) NO
2.2 NADH dehydrogenase (AF493542) Mitochondrial
2.3 s - - - X / NADH dehydrogenase (AF493542) Mitochondrial
2.8 Solute carrier (NM_006358) Mitochondrial
2.11 Clones (AC0107065); MHC class2 
(NG 004658)
Mitochondrial
2.12 Clones (AC092496); solute carrier 
(AY078403)
2.15 s X X X X X Retbindin (NM_03429) YES
2.18 X X X X X S antigen (NM 18100); arrestin 
(BTU08346)
NO
2.19 70kDa heat shock protein 
(NM 174345)
2.21 Vector (U29899)
2.23
2.27 Vector (U29899)
2.28 UNQ431 (AY358431) NO
2.32 - - - X / Zinc finger protein (XM_372751) YES
2.35 Clones (BC029876); ribosomal 
protein (U13369)
Ribosomal
2.36
2.39 ROM1 (NM_174147) NO
2.44 L9 (AY017376) Ribosomal
3.1 ATP synthase (NM_174717) Mitochondrial
3.5 / X X X X FLJ45246 zinc finger protein 
(ZNF621)(NM_ 198484)
Poor blast 
result
3.6
3.7 X X X X X RBM4 (BC032735); Lark (U89505) NO
3.9 S antigen (BTANTSRI); arrestin 
(BTU08346)
NO
3.10 / X X X X UNQ431 (AY358431); C type Lectin 
(XM542117)
x stop and no 
ATG
3.12
3.14
3.16
3.17 GLUT3 (SHPGLUT3A)
3.21
3.26 NADH dehydrogenase (AF493542) Mitochondrial
3.29 NADH dehydrogenase (AF493542) Mitochondrial
3.32 Vecto (U29899)r NO
3.33 X X X X X Clone (AL713994)
3.35 CDC10 (NM 001001168) ?
3.36 Opsin (BVOPSA) NO
3.37 Transducin (NM_181022) NO
3.38 NADH dehydrogenase (AF493542) Mitochondrial
3.42 NADH dehydrogenase (AF493542) Mitochondrial
3.44 Cofilin 1 (NM_005507) NO
3.45 Mouse chr 2 clones (AL844903)
3.47 Cytochrome C oxidase (BC0000187) Mitochondrial
3.48 Cofilin 1 (NM_005507) NO
4.1 X X X X X 14-3-3 epsilon (AF043735) NO
4.2 P0 (AB098998) Ribosomal
4.3
4.4 P0 (AB098998) Ribosomal
4.5 Clones (AC114484)
4.7 Peripherin (NM_001003289) 3’UTR
4.8
4.10 Peripherin (NM_001003289) 3’UTR
4.14 - - - X OS9 (HSU41653) -
4.18 ATP synthase (NM_175796) Mitochondrial
4.20 BSMAP (AF186264) NO
4.23 - - - X Clones (AC026701)
5.2 Hes 4 (NM_021170) NO
5.4 - - - X Cdc42 (AF502289); TRIP10 
(NM 004240)
NO
5.6 Cytokine (BC051295); LDH-A 
(BOVPLDH9)
Mitochondrial
5.10 Ribosomal protein (D50107) Ribosomal
5.11
5.14 Vector (U29899)
5.17 X X X X X S16 (NM_001020) Ribosomal
5.18 / - - X / S16 (NM_001020) Ribosomal
6.1 Clones (BC069216)
6.3 X X X X X Very CG rich-BLAST failed
6.5 / / X X X X L11 (NM_000975) Ribosomal
6.6 NADH dehydrogenase (NM_175783) Mitochondrial
6.9 / - - - / / EBNA1 (BC009175) -
6.11 / - - - / P0 (AB098998) Ribosomal
6.12 X X X X X Beta tubulin (TUBB) (N MO01003900)) YES
6.15 Beta tubulin (chicken GGCB7TUB!) ?
6.17 Clones (AC069536)
6.18 S15 (NM_001018) Ribosomal
6.19 TUBB2 (NM_006088) NO
6.22 ROM1 (NM_174174) NO
6.29 ✓ - - - X / Nice 3 (BC008306) YES
6.34 L11 (NM_000975) Ribosomal
7.1 ✓ 1
colony
X X X X IK cytokine (BC051295) YES
7.2 Chr17 (AC134407)
7.4 cGMP phosphodiesterase 
(NM 174421)
Mitochondrial
7.5 NADH dehydrogenase (AF493542) Mitochondrial
7.6 Ribosomal protein (NM_182538) Ribosomal
7.9 ATPase (NM 001694); Proteolipid 
(NM 174149)
Mitochondrial
7.12 / /  1
small
colony
X X X X NADH dehydrogenase (NM_005001) Mitochondrial
7.14 - - - X / Mitochondrial genome seq (V00654) Mitochondrial
7.20 X X X X UNC119 (NM 005148); HRG4 
(U40998)
3’UTR
7.23 / ✓1
colony
X X X X C6orf119 -  hypothetical protein 
LOC83640 (NM_031452)
YES
7.24 Mitochondrial seq (V00654) Mitochondrial
8.1
8.3 / X X X X X C6orf119 -  hypothetical protein 
LOC83640 (NM_031452)
YES
8.4 NADH dehydrogenase (NM_005001) Mitochondrial
8.6 / - - - / X NADH dehydrogenase (NM_005001) Mitochondrial
8.10
8.12 Mitotic apparatus (BC013023) -
8.13
8.15 / - - - X / Ubiquitin D (BC012472)
8.17 Mitotic apparatus (BC013023) -
8.21 X X X X L10a (BC070216) Ribosomal
8.26 Hypothetical MGC12972 (BC005064) NO
8.28 •/ X X X X DEAD box family of RNA helicase 
(NM 020865)
-/Ribosomal
8.32 Ribosomal (NM_001011) Ribosomal
8.33 Ribosomal (NM_001011) Ribosomal
8.34
8.35
9.5 Vector (U29899)
9.9
9.13 KIF3A (BC032599r) -
9.14
9.16 SCN2B (Na+ channel) (NM_004588) 3’UTR
9.18
10.14 Ribosomal protein (NM_001011) Ribosomal
10.15 Annexin 3 (rat/mouse)(NM_013470) Mitocondrial
10.23 DEAD box family of RNA helicase 
(NM 004398)
-/Ribosomal
10.25 / X X X / X MAGE-F1 (AF320910) 1 NO
10.28 HLA-B associated transcript 
(BC018875)
10.37 HLA-B associated transcript 
(BC018875)
“
10.41 X X X PFDN 5 (AF520958) -
Appendix 20 Control CO-IP assay
The reliability of the CO-IP/ pull down assay was confirmed using known 
interactors: the SV40 T antigen (pGADT7-T) and p53 (pGBKT7-53) 
(Clontech) (section 2.5.6.2.1).
No bands were seen in the negative controls that incubated the anti-c-Myc 
beads with the ‘No DNA’ lysate or TBS buffer only (Figure A1, lanes 7&8). 
The individual IVT proteins can be seen in lanes 2&3 (denoted with an 
arrowhead) and the ability of the anti-c-Myc coated beads to bind the c-Myc 
tagged p53 protein is seen by the presence of a p53 sized band in lane 4. 
The anti-c-Myc coated beads are unable to bind the HA tagged T protein (no 
band in lane 5), therefore there is no cross-reactivity between the tags. So 
the presence of two bands in lane 6, where the beads have been incubated 
with both p53 and T, proves that the system is able to specifically bind to the 
tag of one protein and then successfully isolated its binding partner from a 
protein mix.
This was further confirmed by exchanging the anti-c-Myc coated beads that 
would bind p53, for anti-HA coated beads that bound T (lane 10). The anti- 
HA coated beads did not independently bind p53 (lane 9) nor any proteins 
from the controls (lanes 12&13). p53 could only be detected when incubated 
with both the anti-HA beads and with T (lane 11).
A further control experiment involving HA tagged MCC2 and c-myc tagged 
harmonin protein, was also undertaken. In the presence of c-Myc tagged
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harmonin, MCC2 could be detected but not when incubated with the anti-c- 
Myc beads alone (data not shown as HA antibody detection was too poor to 
capture on the transilluminator).
Figure A1 Interaction of c-Myc tagged p53 with HA tagged SV40 T- 
antigen by pull down analysis.
The pull down system was checked for specificity using IVT generated p53 (c-myc tagged) 
and the SV40 T antigen (HA tagged) that are known to interact.
Lane 1, Protein size standards. Lane 2&3 isolated p53 and T respectively. Proteins in lanes 
4-8 were pulled out of a reticulosyte lysate mix using anti-c-myc coated beads. Lane 4, p53. 
Lane 5, no HA tagged T detected. Lane 6, p53 and T detected. Lane 7, no protein was 
detected from a ‘No DNA’ IVT lysate control. Lane 8, no protein was detected using TBS 
buffer.
Proteins in lanes 9-13 were pulled out of a reticulosyte lysate mix using anti-HA coated 
beads. Lane 9, no c-Myc tagged p53 detected. Lane 10, T. Lane 11, p53 and T detected. 
Lane 12, no protein was detected from a ‘No DNA’ IVT lysate control. Lane 13, no protein 
was detected using TBS buffer.
332
